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ABSTRACT 
Childhood cancer is the second leading cause of death in Australian children, aged 
1-14y.  As medical advances improve, outcomes for childhood cancer patients also 
improve. For children with cancer, treatment occurs at an important period of growth 
and development, and this can affect their health as adults. In fact chronic disease 
such as obesity and cardiovascular disease are recognised long term problems for 
adult survivors of childhood cancer. With the changing landscape in paediatric 
oncology, the focus of nutritional therapy for paediatric oncology patients may need 
to shift. Decisions on nutritional management during therapy have the potential to 
influence nutritional management in the long term. The broad aim of this thesis was 
to explore the implications for Nutrition and Dietetics care in managing the needs of 
child cancer patients during therapy and following survival. The research was 
grounded in clinical practice, using an in depth case study of a specialist paediatric 
oncology clinic in Sydney, Australia. A number of separate but related investigations 
took place to address specific questions and highlight the way forward for improved 
practice. 
 
The first part of the thesis confirmed the assumption of a nutritional problem in the 
clinic population. Study 1 aimed to assess the dietary intake and habits of young 
survivors of childhood cancer early after treatment completion.  Assessment of 3-
day food diaries found that 54% of young childhood cancer survivors were 
consuming above their estimated energy requirements. Fifty, 32% and 44% of 
children did not meet requirements for folate, calcium, and iron respectively. When 
parents of childhood cancer survivors was questioned about their child’s changing 
dietary habits, the majority of parents found their child’s nutritional intake changed 
dramatically during the active treatment phase. It appears that some of the dietary 
habits established during treatment appeared to carry over once treatment has been 
 
x 
 
completed. Parents reported young survivors of childhood cancer had a poor fruit 
and vegetable intake; increased consumption of "junk food" and large portion sizes. 
These results provided targets for nutritional interventions at the clinic for survivors 
of childhood cancer.  
 
The second part of this thesis aimed to examine feeding practices during and 
following treatment completion. First, a Cochrane systematic review was undertaken 
to assess the effect of nutritional interventions in improving dietary intake to meet 
the dietary guidelines, in childhood cancer survivors. Three studies were found that 
met the inclusion criteria. One study found an improvement in calcium intake and 
calcium supplementation in an intervention in adult survivors of childhood cancer 
aimed at osteoporosis prevention. The second study found that a single group 
intervention improved the self-reported intake of healthy food, though there was no 
improvement in self-reported ‘junk’ food intake.  The review indicated a lack of 
effective interventions for preventing or improving the dietary habits of young 
childhood cancer survivors.  Because enteral feeding is often introduced in the 
treatment phase, study 2 aimed to compare and contrast views among parents, 
patients and healthcare workers on the positive and negative aspects of enteral tube 
feeding (ETF). There appeared to be common perceptions of the purposes and 
impact of ETF among patients, parents and healthcare workers. Both positive (good 
nutrition, weight gain and decreased anxiety) and negative (physical appearance, 
invasive insertion procedure and comfort) aspects of ETF were discussed. There 
were discordant perceptions regarding the timing and type of information provided 
on the use of enteral tube feeding, as well as the decision making process used. 
This study highlighted the need for standardizing and improving the methods used 
for the commencement of ETF on treatment. 
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The third part of the thesis considered possible changes in taste and smell that 
might create problems with feeding after treatment.  First, a literature review was 
conducted on taste and smell disorders resulting from cancer and chemotherapy. 
The review found self-reported taste and smell alterations were prevalent in 
upwards of 86% of cancer patients. In some adult cancer patients, taste and smell 
alterations continued well after their cancer treatment had been completed. Taste 
and smell alterations in patients with cancer appeared to increase their distress, 
reduce appetite and contribute towards a poor nutritional status. There was a lack of 
information on the taste and smell function of survivors of childhood cancer. In light 
of the results from the review of taste and smell issues in cancer survivors, study 3 
aimed to assess smell and taste function in childhood cancer survivors. The study 
found that survivors of childhood cancer did have a greater incidence of taste and 
smell changes, compared to a control sample from the well population. Twenty-
seven percent of survivors of childhood cancer had some form of smell dysfunction. 
This was considerable higher than the 10% of smell dysfunction reported in the 
literature for the general population, using similar methods of assessment. The 
incidence of smell dysfunction was 10% of the cancer survivors studied which again 
is higher than the one to two percent smell dysfunction reported in the general 
population. 
 
In conclusion, as childhood cancer is no longer an acute condition with poor 
outcomes and high morbidity and mortality, it should be treated as a chronic 
condition. Poor dietary habits are manifesting themselves early after treatment in 
paediatric cancer patients. There now needs to be greater awareness of the link 
between the nutrition decisions made during the cancer therapy and how they may 
be affecting the child’s nutritional intake well after cancer therapy is completed. At 
the very least, nutritional interventions to improve the dietary habits of survivors of 
 
xii 
 
childhood cancer need to be initiated soon after treatment completion. Ideally a 
focus on long-term good dietary habits may need to occur during cancer therapy. 
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1 INTRODUCTION AND AIMS 
1.1 Introduction 
 
Nutritional therapy has been a recognised part of the medical management of 
hospital patients since the proverbial “skeleton in the hospital closet” of malnutrition 
was identified in the 1970s (1). The first published paper assessing the efficacy of 
medical nutritional therapy for childhood cancer patients, in the form of parenteral 
nutrition (PN), was published in 1977 (2). This study showed an improvement in 
weight gain with the introduction of parenteral nutrition in 41 patients. The earliest 
review of malnutrition in childhood cancer patients was published in 1979 (3). This 
review assessed the incidence, aetiology and consequences of protein-energy 
malnutrition and the use of medical nutrition therapy. This was the first published 
paper to focus on not just macronutrient deficiencies but micronutrient deficiencies 
in this population (3). 
 
Nutritional therapy in paediatric cancer patients tends to focus on weight and growth 
based outcomes and the maintenance of normal growth and development is the 
primary goal of nutritional interventions (4). Algorithms for initiating nutritional 
supplementation are predominantly based on weight changes (5) and the suggested 
interventions themselves rely on commercial supplements, enteral tube feeding and 
parenteral nutrition (PN) (5). Reviews of nutritional concerns of paediatric cancer 
patients report on the use of medical nutritional therapy but rarely discuss 
recommendations for food intake (4, 6-9). This may be because many paediatric 
cancer patients find eating difficult due to the side effects of intensive chemotherapy 
treatment protocols (10, 11). For those who are able to eat, food choices tend to be 
limited (11) or they have a preference for “junk food”(12). It also appears that 
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parents are not concerned about their child’s overall nutritional intake during their 
child’s cancer therapy (13). The goal of both parents and clinicians working in 
paediatric oncology has been the prevention of weight loss through the use of a high 
energy diet (14). 
 
As medical advances have improved, outcomes for childhood cancer patients have 
also improved. For children with cancer, treatment is occurring during an important 
time of growth and development and treatment at such an early stage in life has the 
potential to affect them when they become adults. Chronic disease such as obesity 
and cardiovascular disease are being recognised as long term issues in adult 
survivors of childhood cancer (15).  Practitioners are beginning to recognise that 
adult survivors of childhood cancer may have poor dietary habits (16, 17), which is 
likely increasing their risk of chronic health conditions such as the metabolic 
syndrome (18).  
 
Interestingly, there is a lack of information regarding the dietary habits of childhood 
cancer survivors during and early after treatment completion. This may be because 
the focus of nutritional interventions during cancer therapy, have been about protein 
and energy and not about overall nutritional intake. Information on the dietary intake 
of young cancer survivors will be needed to inform nutritional interventions to help 
reduce the risk of chronic diseases in adult survivors of childhood cancer.  
 
This thesis focuses on paediatric patients within a single paediatric unit. This is 
important to me as a clinician as it enables me to make changes in clinical practice 
specific to the issues with my clinical population. The results from this thesis have 
the potential to be extrapolated to other paediatric oncology patients, both in 
Australia and overseas. 
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1.2 The position of the researcher 
 
I currently work as the senior paediatric dietitian in the Kids Cancer Centre at 
Sydney Children’s Hospital, Randwick New South Wales (NSW), Australia. The Kids 
Cancer Centre treats children who have both cancer and haematological conditions 
and our catchment includes Sydney metropolitan, rural NSW and the territory of 
Canberra. We treat between 100-120 new patients each year and have a large 
haemapoetic stem cell transplant program. Our transplant unit performs both 
autologous and allogenic transplants (cord blood, bone marrow and stem cell 
transplants) and the centre receives patients for allogenic transplant from the rural 
NSW paediatric oncology unit (John Hunter Hospital in Newcastle) and those from 
the Royal Adelaide Hospital in South Australia. Once patients have completed their 
treatment they can be followed up by the medical teams in outreach clinics around 
NSW and Canberra. Our centre also has a long-term follow-up clinic that reviews 
survivors of childhood cancer who are more than five years from treatment 
completion. This clinic follows these patients into adulthood. 
 
This thesis was born from a need identified while working with paediatric patients 
undergoing their treatment for cancer. Although clinician researchers in the dietetics 
field is not common practice (19),  there is an advantage in being a clinician 
researcher, as I have the potential to directly improve patient outcomes (20, 21). 
The main goal of my position as a clinical dietitian working in paediatric oncology is 
the prevention of treatment related malnutrition. The majority of patients are on 
active treatment and once their cancer therapy is finished and they no longer require 
intensive nutrition support, I did not have the capacity to review these patients long 
term. As will be highlighted chapter two, there is now a greater focus on the 
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survivorship issues of cancer survivors and I found an increase in the number of 
referrals for paediatric patients who were overweight. Many of these patients were 
only a few years off their treatment and had not yet started attending the long term 
follow-up clinic. Interestingly, there was a dearth of literature regarding the dietary 
habits of cancer survivors early off treatment. It has only been since I commenced 
work on my thesis that there has been an exponential increase in the number of 
publications focusing on the nutritional concerns of young survivors of childhood 
cancer. 
 
A number of dietitian students from the University of Wollongong and the University 
of NSW contributed to parts of the research included in this PhD. Their involvement 
included data collection for the research presented in chapters 3, 4, 6, and 8. The 
involvement of the students was approved by the South Eastern Sydney & Illawarra 
Health Service, Human Research Ethics Committee-Northern Hospital Network and 
they were heavily supervised by me (Appendix 3, 7, and 8). 
 
1.3 Research in a clinical setting 
 
Clinical research is any research involving human subjects who volunteer to take 
part in the research (22). It allows the investigator to determine the best methods for 
preventing, diagnosing and treating disease (22). Despite the advantages of 
undertaking research within the clinical setting, there are inherent issues that make 
research in a clinical setting more challenging. Research in a clinical setting focuses 
on a specific population, in the case of this thesis, paediatric cancer patients. This 
automatically narrows the pool of potential participants, lessening the ability to 
achieve adequate statistical power (23).  
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Much of the research presented in this thesis is of cancer survivors, many of whom 
have completed their therapy. A large part of our population are from rural centres 
living an average distance of 240km from the hospital (24). Their ongoing medical 
follow-up occurs in outreach clinics throughout the state. This has made face-to-face 
recruitment difficult, having to rely on postal recruitment. Recruitment using a mail-
out approach may have decreased response rates increasing the potential for 
recruitment bias (25). The advantage of the use of mail-out recruitment is it is likely 
to reduce potential for participants feeling coerced to participate in the study. 
 
1.4 Hypothesis 
 
Much of the research on the nutritional management of childhood cancer patients 
has been done in isolation, with the long-term effect of nutritional decisions during 
treatment not previously considered. Now that childhood cancer is considered a 
chronic disease, a greater focus on how nutritional therapy during cancer treatment 
may affect the long-term outcomes of patients is required. The central hypothesis in 
this thesis is that the nutritional management decisions made during treatment for 
childhood cancer are primarily about the short term goal of promoting an adequate 
energy intake to prevent under nutrition. For clinicians to optimise the nutritional 
management of childhood cancer patients, issues both during and after treatment 
will need to be accounted for.  
  
This thesis is divided into three sections. The sub-hypothesis of each section is: 
1) Poor dietary habits are developing during childhood cancer therapy and 
these are continuing once treatment has been completed. 
2) There are areas of clinical practice that are not accounting for the potential 
long-term impact of nutrition decisions on survivors of childhood cancer, 
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specifically related to actual feeding practices during and following treatment 
completion 
3) Taste and smell dysfunction may be implicated in the problem of developing 
healthy eating habits in childhood cancer survivors 
 
1.5 Aims 
 
This broad aim of the thesis was to explore the implications for nutrition and dietetics 
in managing the needs of child cancer patients during therapy and following survival.  
 
The specific aims of the thesis were: 
1. To identify and articulate the problem of childhood  nutrition in the cancer 
acute care and survival (Section 1) 
2. To examine feeding practices following treatment completion both in terms of 
dietary intakes and parental views of childhood  nutrition (Section 2) 
3. To specifically consider the issue of taste and smell as implicated in the 
problem of developing healthy eating habits in childhood cancer survivors. 
(Section 3) 
1.6 Thesis design and methodology 
 
This thesis is based on research in clinical practice and is a single-site case study. 
An in-depth analysis from data collected from a specialist paediatric service provides 
a useful case study of the problem in situ. The strength of this model is the ability to 
translate research findings into practice and to directly influence patient outcomes 
(20). Eck et al (1998) recommends that research in clinical practice, also known as 
outcomes research, should be routinely integrated into clinical practice (20). 
 
7 
 
Traditionally, clinical dietitians’ continually question and assess their practice. They 
then search the literature to determine the answers to their questions and 
subsequently alter their practice.  In the model proposed by Eck et al, (1998) it is the 
clinician’s role to design and conduct their own studies to determine the answer if 
not available in the literature (20). 
 
As a clinician researcher, I was able to identify the issue of the increasing need for 
dietary advice on chronic disease management in survivors of childhood cancer 
(figure 1.1). A literature review has allowed me to identify gaps in our knowledge. 
This has led me to design studies confirming my hypothesis, assessing clinical 
practice and recommending changes.  
 
 
Figure 1-1 Schema of hierarchy of studies used within the context of research 
in practice 
This thesis has used a mixed methods approach (Table 1-1) to data collection as a 
way of combining both quantitative and qualitative methods (26). The strength of 
using a mixed methods approach is that the qualitative and quantitative methods 
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can compensate for the limitations inherent with each model (26). A mixed methods 
approach also allows the researcher to consider a plethora of viewpoints, and 
perspectives of the cohort being studied (27). Mixed methods is particularly useful 
for health research because it accounts for the complexity of factors surrounding 
health research (28, 29). The thesis also includes both narrative and systematic 
reviews used to inform the quantitative and qualitative studies. Sections 1.7-1.9 
provide a general background on the research methodology used in this thesis. 
Additional background and research methodology are presented and discussed in 
the individual chapters. 
Table 1-1 Common research methods used in mixed methods research  
 
Common quantitative research 
designs  
Common qualitative research 
methods 
 
Randomized controlled trials 
Nonrandomized studies 
-Case-control 
-Cohort study 
-Cross-sectional  
-Nonrandomized controlled trial 
descriptive studies 
-Case series  
-Case report 
-Incidence or prevalence study without 
comparison group 
Case study 
Ethnography 
Grounded theory 
Narrative approaches 
Phenomenology 
Qualitative description 
 
1.7 Quantitative research methods 
Quantitative research is the most common method of research used in both medical 
and nutritional studies. The National Health and Medical Research Council 
(NHMRC) provide a framework for the hierarchy of each quantitative method in 
regards to its methodological strength. It allows an assessment of how likely the 
research method will be to answer the methodological question and the likelihood of 
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bias in the results obtained (30). Chapters 3 and 8 used a cross-sectional study 
design without concurrent controls which is level III evidence (30) 
 
Cross-sectional study design involves the assessment of a specific group of 
participants at one particular point in time (31). They are used to assess prevalence 
and to infer causation (31). It is one of the most common methods used in empirical 
research (32). Data gathered from a cross-sectional study can be used to design 
larger cohort studies or randomised controlled trials (32). As much of the research 
work in this thesis was exploratory, a cross-sectional method allows hypothesis 
generation (30). A cross-sectional research design allows for an estimate of the 
prevalence of the outcome of interest (33) . In the case of this thesis, a cross-
sectional study design was used to assess the prevalence of poor dietary habits and 
to assess chemosensory function in specific cohorts of survivors of childhood 
cancer. There are inherent advantages and disadvantages with this method of 
research (Table 1-2) which were reduced with the concurrent use of qualitative data 
collection with the study of the dietary intake of cancer survivors in a mixed models 
approach (Chapter 4). 
Table 1-2 Advantage and disadvantages of using cross-sectional methodology 
 
Advantages Disadvantages 
 
Inexpensive Provides only one point in time 
Ability to complete over a short time 
period 
High risk of prevalence-incidence bias 
Can assess multiple outcomes and risk 
factors 
Unable to assess causation 
Low risk of ethical issues Cannot differentiate between cause and 
effect 
Quick Inaccurate with rare conditions 
Adapted from Levin, 2006 (33) & Mann, 2003(31) 
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This thesis employed a number of research methods in the cross-sectional studies. 
This included dietary assessment using three-day food diaries, assessment of 
Quality of Life (QoL) and parental feeding behaviours using validated 
questionnaires, and assessment of chemosensory function using validated methods 
of assessment.  
 
1.8 Qualitative research methods 
 
The use of qualitative research in nutrition and dietetic research has been 
increasingly recognised as an important research method (34). Qualitative research 
investigates the how and why of certain behaviours (34) and is often used for 
hypothesis or theory generating (35). Qualitative research is also useful for 
assessing the perceptions about an issue from a group participants (35). 
 
Qualitative methodology has been employed in chapters 4 and 6 using a grounded 
theory approach. Grounded theory provides the researcher with the ability to derive 
their own research questions, rather than using existing theories to structure the 
research (35). This thesis used semi-structured interviews to gather the data from 
participants. Semi-structured interviews allows an exploration of both opinion and 
perceptions of the participants and allows for the interviewee to probe for 
clarification of the answer (36) . Analysis of the interviews allowed to derive 
concepts and themes from the data to construct new theories(36). 
 
Recruitment of participants in qualitative research differs from that of quantitative 
research sampling, with the goal to recruit a representative sample of participants 
(35). Maximum variation sampling was chosen in both qualitative studies in this 
thesis to ensure that a wide range of diagnosis groups, ages and exposure to types 
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of nutrition support were interviewed. Maximum variation sampling ensures that a 
balanced perspective of the issue is obtained (35). 
 
1.9 Systematic and narrative review methods 
 
A literature review allows researchers to synthesise existing research to provide a 
new perspective and framework on the area of interest (37).   If the literature review 
is based on emerging topics then the literature review will provide preliminary 
conceptualisation of the topic. In contrast, a literature review that synthesises a large 
body of existing literature has the potential to reconceptualise previous models (37). 
There are three main types of literature reviews include the traditional quantitative 
and qualitative systematic reviews as well as narrative reviews (38). Systematic 
research reviews are a synthesis of existing literature to inform clinical practice and 
may or may not include a meta-analysis (39). A narrative or integrative review allows 
the inclusion of a range of methods including  experimental and non-experimental 
data (39). The narrative review provides a broad perspective on a topic (38) though 
are at risk of bias if a systematic method of assessment is not used (39). All types of 
literature reviews are retrospective in nature and are at risk of both subjective and 
random error (40). See table 1-3 for a comparison between types of systematic 
reviews. 
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Table 1-3 Comparison of narrative and systematic reviews 
 
 Narrative Review Systematic Review 
 
Question Broad Focused clinical question 
Search strategy Not usually defined Well defined and 
comprehensive 
Selection Not usually defined Well defined and uniformly 
applied 
Appraisal Variable Rigorously performed 
Synthesis Qualitative summary Quantitative summary 
(may include a meta-
analysis) 
Inferences Sometimes evidence-
based 
Usually evidence-based 
Adapted from Cook et al, 1997 (40) 
 
 
Chapter 5 in this thesis uses a quantitative systematic approach to the literature 
review, employing the Cochrane Database of Systematic Reviews methodology 
(41). A Cochrane review has stringent methodology that the review must follow and 
undergoes several layers of peer review prior to publication, thereby reducing its risk 
of bias (42). A systematic review was chosen for this section to synthesise the 
available data in a relatively new area of study. The systematic review will be used 
to inform practice. Contrary to chapter 5, chapter 7 has employed the use of a 
narrative systematic review as a way to provide a broad summary of the topic and to 
identify potential gaps in the literature. The aim of the narrative review was not to 
inform practice. 
1.10 Ethical Approval 
 
The studies presented in chapter 3, 4 and 6 underwent both ethical and scientific 
review at the South Eastern Sydney and Illawarra Health Service, Human Research 
Ethics Committee-Northern Hospital Network prior to commencing. The study 
presented in chapter 8 underwent both ethical and scientific review at the Royal 
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Alexandra Hospital for Children Ethics Committee. All participants were provided 
with written study information and informed consent was obtained prior to data 
collection. All participants were free to withdraw from the research studies at any 
time. 
1.11 Conclusion 
 
Chapter 1 introduced the concepts to be explored in the thesis. It has provided 
information on the context of the researcher and the hypothesis and aims driving the 
thesis. Chapter 2 will provide a comprehensive overview of the available literature 
on the nutritional management of paediatric oncology patients and will further clarify 
the need for the research completed in this thesis.  
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2 NUTRITIONAL MANAGEMENT IN PAEDIATRIC ONCOLOGY 
2.1 Introduction 
 
Childhood cancer is the second leading cause of death in Australian children, aged 
between one to fourteen  years (43).  Despite these figures, childhood cancer 
survival rates have increased since the 1950s.  Eighty-five percent of paediatric 
patients who are diagnosed with a malignancy, are likely to survive past  five years 
(44). With the significant improvement in childhood cancer survival, there is now a 
focus on the long term consequences of treating children with chemotherapy and 
radiotherapy at such a young age.  
 
In a landmark study published in 2006, 10 000 adult survivors of childhood cancer 
were assessed for long term health conditions. Childhood cancer survivors were 
three times more likely to have a chronic condition and eight times more likely to 
have a severe chronic condition compared to sibling controls (15). The results of this 
study has caused a shift in the paradigm of cancer treatment, with childhood cancer 
no longer considered an acute disease with high mortality, but a chronic condition 
associated with ongoing high morbidity. 
 
The nutritional management of paediatric cancer patients is an important aspect of 
their multidisciplinary care plan and medical management. The focus has been on 
the prevention of under nutrition (45). Without nutritional therapy, up to 50% of 
paediatric oncology patients are likely to become malnourished (46). With this 
changing of the landscape of how paediatric oncology is viewed, the focus of the 
nutritional therapy of paediatric oncology patients may also need to be altered. 
Previously where the prevention or treatment of under nutrition has been the focus 
of nutritional therapy, the nutritional management of childhood cancer survivors, 
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from infant until adulthood needs to be considered. Childhood cancer survivors may 
no longer be at risk of under nutrition, but may be at risk of over nutrition or poor 
nutritional intake. Decisions made in regards to their nutritional management during 
their therapy, has the potential to influence their nutritional management in the long 
term. 
 
This chapter will provide a background on the types of childhood cancers, their 
prognosis rates, and treatments, and how these influence the patient’s nutritional 
management goals. The literature review will also focus on the types of nutritional 
therapy currently available to paediatric oncology patients on treatment and a 
discussion on the nutritional management of childhood cancer survivors. This 
information will provide a context to the thesis and allow a clear reasoning for the 
development of the subsequent chapters and research studies. 
 
2.2 Overview of the medical management and outcomes of paediatric cancer 
2.2.1 Types of cancers and prognosis rates 
Approximately 580 children are diagnosed with cancer each year in Australia; a rate 
of 14 in 100 000  children (43). The prevalence of childhood cancer has remained 
stable in Australia in the past 12 years (43). Cure rates for this disease have 
increased over the past four decades.  The most common form of childhood cancer, 
acute lymphoblastic leukaemia (ALL) has a five year survival of 80%, which is up 
from 58% during this time (47). Five-year relative survival for all childhood cancers 
combined, increased from 72.3% for the years 1983-1994 to 79.5% during 1995-
2004 (44). Despite these improvements in survival, childhood cancer remains the 
second most common cause of death among western societies of children between 
the ages of 1-14 years (48), with cancer being attributed  to 17% of all deaths of 
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Australian children aged between one and fourteen years.  Unfortunately other 
common childhood cancers such as brain tumours and central nervous system 
tumours continue to have high mortality, with five year survival around 50% for some 
age groups (44). Table 2-1 outlines the five -year survival rates of common 
childhood cancers. 
Table 2-1 Common paediatric cancers, their incidence, treatment and five year 
survival statistics 
 
Cancer Type Incidence 
 
Treatment 5-year survival 
Acute lymphoblastic 
leukaemia (ALL) 
25%  Chemotherapy  
radiotherapy (CNS +ve) 
HSCT  
90% (<15 years) 
75% (15-19 years) 
Acute myeloid 
leukaemia (AML) 
5%  Chemotherapy 
HSCT  
68% (<15 years) 
57% (15-19 years) 
Non-Hodgkin’s 
lymphoma (NHL) 
7%  Chemotherapy 88% (<15 years) 
77% (15-19 years) 
Hodgkin lymphoma 6%  Chemotherapy 
radiotherapy 
90-95% 
Brain and spinal cord 
tumours 
 Surgery +/- 
radiotherapy +/-
chemotherapy 
70% 
Kidney tumours 
(Wilms’ and germ cell 
tumours) 
7% Surgery +/- 
radiotherapy +/-
chemotherapy 
88% (Wilms’ 
tumour) 
Neuroblastoma  Surgery +/- 
radiotherapy +/-
chemotherapy +/- BMT 
+/- immune therapy 
87% (< 1 year) 
68% (1-4 years) 
52% (5-9 years) 
66% (10-14 years) 
Ewing’s sarcoma  Surgery +/- 
chemotherapy +/- 
radiotherapy 
78% (<15 years) 
60% (15-19 years) 
Osteosarcoma 5% Surgery +/- 
chemotherapy +/- 
radiotherapy 
76% (<15 years) 
66% (15-19 years) 
Rhabdomyosarcoma 3.5% Surgery +/- 
chemotherapy +/- 
radiotherapy 
67% (<15 years) 
51% (15-19 years) 
Adapted from the National Cancer Institute accessed 16/12/2014 
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2.2.2 Medical management of paediatric cancer patients 
The medical treatment of paediatric oncology patients depends on the type of 
cancer, stage of cancer, age of the patient and the patient’s prognosis. For some 
solid tumours, surgery is the only treatment modality recommended. For most 
paediatric oncology patients’, chemotherapy, radiotherapy and haematopoietic stem 
cell transplant (HSCT) are used alone or in combination to treat the cancer. 
Combination therapy is used as a way of improving survival rates (49). Surgery 
and/or radiotherapy is used to control local disease, while chemotherapy is used to 
eradicate the disease (50). The goal of cancer treatment is to maximise the potential 
for cure, while reducing the risk of short and long term detrimental side effects (49). 
 
2.2.3 Chemotherapy 
Chemotherapy is considered the primary treatment for childhood cancers (44). 
Chemotherapy is the umbrella term to describe any drug that is used to treat cancer 
(www.cancer.org, accessed on 06/01/2015). Chemotherapy is a systemic treatment 
and as such, can be affective on all parts of the body. Chemotherapy is mainly 
administered orally or intravenously (49). Other methods of administration include 
subcutaneous or intramuscular injection or intrathecally (injection into the lumbar 
region of the spine) (49).  
 
Chemotherapy targets actively dividing cancer cells (49), though the point of action 
differs for each class of chemotherapy drug (Table 2-2).  Chemotherapy cannot 
distinguish between cancer cells and non- cancer cells that are rapidly dividing and, 
as such, can cause both short term and long term, potentially severe, side effects 
(50).  The non-cancer cells that are more likely to be affected by the chemotherapy 
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agent include hair follicles, blood and bone marrow, gastrointestinal tract and the 
reproductive tract (49). 
Table 2-2  Common chemotherapy agents and their mode of action 
 
Type How they work Examples 
Alkylating agents Damage the cancer cell’s DNA 
preventing reproduction 
Cyclophosphamide 
Busulphan 
Thiotepa 
 
Antimetabolics Interfer with DNA and RNA 
growth of the cancer cells 
6-mecaptopurine  
Cytarabine  
Fludarabine 
Methotrexate 
Anthracyclines Interfer with enzymes involved 
with DNA replication 
Daunorubicin 
Doxorubicin 
Topoisomerase 
inhibitors 
Interfere with the cell’s ability 
to copy DNA 
Etoposide  
Topotecan 
Irinotecan 
Mitotic inhibitors Impair cancer cell reproduction Vincristine 
Vinblastine 
Corticosteroids Kill or slow cancer cell growth Prednisone 
Dexamethasone 
Adapted from Pizzo and Poplack, 2011 (50) 
 
Acute side effects such as nausea vomiting and diarrhoea occur during and shortly 
after the administration of the chemotherapy (50). Nausea and vomiting is one of the 
most common side effects of chemotherapy (51). Nausea and vomiting is classed as 
acute (within 24 hours of administration of chemotherapy), chronic (between 24 
hours and five days of chemotherapy administration) or anticipatory (conditioned 
response before chemotherapy infusion) (51, 52).  
 
Chemotherapy affects the blood and marrow of the patient, causing a short-term 
reduction in white blood cells, red blood cells, platelets (thrombocytopenia) and 
neutrophils (neutropenia) (51). This usually occurs seven to ten days after the start 
of the chemotherapy administration, and places the paediatric cancer patient at 
significant risk of infections and fever during this time (51). Patients are also likely to 
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experience side effects such as mucositis during this period. Mucositis is an 
ulcerative condition of the oral or gastrointestinal tract (51), leading to pain and the 
inability to consume and digest oral intake.  Bone marrow recovery occurs 
approximately 21 days from the start of the chemotherapy cycle. Many of the acute 
side effects, such as nausea, poor appetite and mucositis have reduced by this time. 
Once the patient has recovered from one course of chemotherapy they are given 
another round of drugs and the cycle starts again. The number of cycles of 
chemotherapy varies between chemotherapy regimens. 
 
Long-term side effects of chemotherapy can include secondary cancers, infertility 
and damage to the major organs, such as cardiovascular disease. Information on 
the long term side effects of chemotherapy and other cancer treatments are covered 
in section 2.5. 
 
2.2.4 Radiotherapy 
Radiotherapy is a treatment used to cause cancer cell death by the use of ionising 
radiation (49). Factors such as the age, body size, tumour type and burden, other 
treatment modalities and previous treatment, account for the dosing of radiation 
given to a paediatric cancer patient over the treatment period (49). Treatment is 
given over a period of one week to six weeks. The aim of radiation therapy is to 
target cancer cells only, attempting to minimise damage to healthy cells. This is 
done by data from computer tomography and magnetic resonance scans. Although 
treatment lasts for a short period of time, the patient is required to stay very still 
during the course of the treatment. This can be problematic for young paediatric 
cancer patients, requiring daily sedation using general anaesthetics (51, 53).  
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Side effects from radiation can depend on the targeted area of the radiation. Similar 
to chemotherapy, radiation cannot distinguish between cancer and non-cancer cells 
(51). Patients receiving radiation to the area of the gastrointestinal tract may 
experience diarrhoea, nausea or vomiting, whereas patients receiving radiation to 
the head area may suffer from xerestoma and nausea. Radiation is used for brain 
tumour patients as it is more effective than chemotherapy which is unable to cross 
the blood brain barrier to be carried systemically into the brain area. Side effects 
from radiation to the brain can also include nausea, vomiting and anorexia. 
Approximately 50% of radiation patients experience somnolence (extreme 
tiredness), though this usually resolves within a few weeks (49). Paediatric cancer 
patients who require daily general anaesthetics can also experience additional side 
effects such as nausea and vomiting. Patients who require general anaesthetics are 
required to fast for a portion of each day of treatment resulting in a reduction in food 
intake, leading to weight loss.  
 
Radiation therapy is associated with a neurocognitive dysfunction (54, 55) and 
growth retardation in children (53). Growing and developing tissue is more sensitive 
to the effects of radiation (50) and the younger the child, the more sensitive their 
developing brains are to the effects of the radiation (55). Similar to the use of 
chemotherapy, the use of radiation is a balance between providing adequate 
treatment for curative intent and reducing potential long term serious side effects for 
paediatric cancer patients (54). 
 
2.2.5 Haematopoietic Stem Cell Transplant  
Haematopoietic stem cell transplant (HSCT) is used widely to treat children with 
hereditary and /or haematological disorders of both malignant and non-malignant 
origin (56, 57). Patients are given high dose chemotherapy +/- radiation treatment to 
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completely eradicate a patient’s disease (56). The patient is then rescued with their 
own source of stem cells (autologous transplant) or a donor’s stem cells (allogenic 
transplant) (50). This rescuing of the stem cells allows the patient to receive very 
high doses of anti-cancer therapy. Without the stem cell rescue the patient’s own 
bone marrow would not recover leading to a very high risk of mortality. Patients with 
defective bone marrow, such as those with leukaemia, receive a donor source of 
stem cells (50). This is usually provided from a matched sibling, a matching 
anonymous donor or banked cord blood (56, 58). 
 
As the childhood cancer patient receives very high doses of 
chemotherapy/radiotherapy, they are at risk of morbidity and mortality as a result of 
the treatment. Treatment related mortality can be as a high as 20% (59).  Recovery 
from these acute side effects can take anywhere from two to six weeks. Another 
significant morbidity from a HSCT is graft- versus-host disease (GVHD). This occurs 
when the donor stem cells (specifically the lymphocytes) consider the host’s (the 
patient) body as foreign and starts an immune response against the host (50). 
GVHD can affect many body organs such as the skin, GI tract, eyes and liver 
resulting in severe rash, diarrhoea and liver disease (50). GVHD is classified as 
acute if it occurs within 100 days of the HSCT or chronic if it occurs after 100 days 
post HSCT. Chronic GVHD can be diagnosed up to three years after HSCT (60, 61).   
 
Intensive conditioning regimens resulting in anorexia, nausea, vomiting, diarrhoea or 
mucositis (62-67) limit voluntary nutritional intake during a HSCT. This increases the 
risk of under nutrition (65, 68, 69).  Nutrition support is especially important in the 
paediatric population as long periods of suboptimal nutrition can also affect growth 
velocity (64, 70, 71). The provision of nutrition support has become standard 
practice during a paediatric HSCT (68, 69, 72, 73). 
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The majority of the paediatric HSCT patients are well nourished at the beginning of 
conditioning with a reported incidence of malnutrition between 11-31% (68, 74). For 
most patients the goal of nutrition support during a paediatric HSCT is to maintain 
their nutritional status (66) and therefore to maintain normal growth patterns (64).   
For patients who present to transplant at risk of malnutrition, the goal may actually 
be to improve their nutritional status as sub-optimal pre-transplant muscle reserves 
are associated with a decreased height velocity post-transplant (71). 
 
2.3 Overview of the nutritional concerns in paediatric oncology 
 
2.3.1 Definition and consequences of malnutrition in children 
Nutrition is often seen in terms of a dichotomy; under-nutrition vs. over-nutrition with 
the umbrella term of malnutrition being utilised to define both states. The World 
Health Organisation (75) defines malnutrition as  
 
“…a pathological state resulting from a relative or absolute deficiency or excess of 
one or more essential nutrients….” 
 
Under-nutrition occurs when there is a deficiency of nutrients relating to inadequate 
food consumption.  Over-nutrition occurs when there is excessive food consumption 
leading to excessive calorie intake (75).  Both states can lead to diminished 
functioning in different forms (76). The consequences of over-nutrition includes; 
obesity and  metabolic and endocrine diseases such as heart disease, diabetes and 
stroke (77) whereas under-nutrition can lead to diseases such as Marasmus (75) all 
of which increases a person’s overall mortality risk. Under-nutrition cannot only 
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cause nutrition-related diseases it can have other detrimental consequences on the 
body. These include anaemia, fatigue, apathy, extreme weakness, irritability and 
neurological deficits which can continue to be an ongoing issue even when nutrition 
is re-established (78). 
 
 
Krehl, 1956 (79) described optimal nutrition as 
 
“…..that which provides all dietary nutrients in respect to kind and amount, and in 
proper state of combination or balance so that the organism may always meet the 
varied exogenous and endogenous stresses of life, whether in health or disease, 
with a minimal demand or strain on the body’s natural homeostatic mechanisms”. 
 
In Krehl’s definition he discusses meeting nutritional needs during disease (79). For 
many people certain diseases actually prevent the attainment of optimal nutrition, by 
the prevention of the consumption of adequate nutrients thereby leading to 
malnutrition. In such cases the nutritional issues are caused by the disease itself 
leading a person to be unable to consume or digest adequate nutrients or the 
disease state increasing their nutritional requirements. When optimal nutrition is not 
achieved in the setting of a disease process this can lead to poorer disease 
outcomes, independent of the disease state (80) by increasing morbidity as well as 
overall mortality (81). Clinical implications of poor nutrition include impaired immune 
function, delayed wound healing, and issues with physical functioning and 
decreasing functional status (82) all leading to increased morbidity and possibly 
mortality. 
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Defining malnutrition in children differs to that of adults due to the needs and 
consequences of poor nutrition on a growing child (83). The American Society of 
Parenteral and Enteral nutrition defines paediatric malnutrition as (83): 
 
“An imbalance between nutrient requirement and intake, resulting in cumulative 
deficits of energy, protein or micronutrients that may negatively affect growth, 
development and other relevant outcomes.” 
 
Malnutrition leads to increased morbidity, similar to that of adults, with the additional 
risk of growth stunting as a significant consequence of chronic under nutrition. This 
leads to a reduction in a child’s weight and height velocity (84). Under nutrition in 
children may also cause a reduction in the attainment of appropriate developmental 
milestones (83). 
 
2.3.2 Assessment of nutritional status  
Assessment of malnutrition, both over and under nutrition remains difficult (83), 
especially when comorbidities exist, such as a diagnosis of childhood cancer.  
Traditional methods, such as body mass index (BMI), do provide a useful method to 
screen patients but do not account for issues with fluid retention (83), tumour weight 
(85), changes in body composition and growth failure. Body Mass Index (BMI) 
percentile and z scores are used as a way to standardise children across different 
age groups (83).  A BMI percentile under the 5th indicates under nutrition, while a 
BMI percentile over the 85th percentile indicates a degree of over nutrition. 
Alternatively, a z score less than -2 indicates under nutrition and a z-score over +2 
indicates over weight (86). 
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Percentage of ideal body weight (percentage expected weight for height) is also 
used as a method to define a child’s nutritional status (87) . A child’s ideal weight is 
calculated using standardised growth charts, assuming their ideal weight 
corresponds with the weight percentile. A calculation of current weight/ideal weight x 
100 is used to define their percentage of ideal body weight. The Waterlow factors 
are a method for classifying protein-energy malnutrition in children (87, 88). A 
percentage of ideal body weight greater than 110% indicates over nutrition and a 
percentage of ideal body weight below 90% indicates under nutrition (87).  
 
It is important to note that a patient can remain within a healthy weight range as 
measured by BMI z-scores or the Waterlow factors, but still be considered 
malnourished. Significant reductions in body weight over a short period of time can 
also be a marker of malnutrition. A five percent loss of body weight over a period of 
one month or from pre-illness weight can also be an indicator of malnutrition (89). It 
is also important to consider that markers which rely on weight measurements alone 
to indicate a patient’s nutritional status, do not take into consideration body 
composition (90), tumour burden (85) or fluid status (89). Using these markers of 
nutritional status alone could misdiagnose up to 40% of childhood cancer patients 
who are malnourished (90) as excess fluid or tumour burden could mask a loss of 
fat or skeletal muscle (7). Childhood cancer patients are likely to have a higher fat 
mass and a lower fat free mass compared with their peers, despite assessment of 
weight for height within reference ranges (91). Arm anthropometry (triceps skinfold 
(TSF); mid-arm circumference (MAC)) has been shown to be a reliable method for 
assessment of fat mass (92) but not fat-free mass (90) in paediatric cancer patients. 
 
Other methods of nutrition assessment such as biochemical markers and physical 
examination can be used to provide information on a childhood cancer patient’s 
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nutritional status. The physical examination of a patient’s lower ribs, orbital fat pads, 
triceps skin fold, deltoids and quadriceps by a trained clinician provides a subjective 
assessment of fat and muscle stores (4, 93). The presence of ascites or oedema 
should be noted as these may influence anthropometric measures (93). Information 
on nutrition impact symptoms such as nausea, vomiting, taste and smell changes 
and anorexia can provide information on the likelihood of a poor oral intake and 
provide targets for dietary education and interventions. 
 
The biochemical marker albumin which is a visceral protein had initially been used 
as a marker of nutritional status. The biochemical marker is an acute-phase reactant 
and its production by the liver is influenced by acute and chronic illness. Albumin is 
not considered a good marker of nutritional status in paediatric oncology patients 
(93). Other visceral proteins such as pre-albumin and retinol-binding protein have 
shorter half-lives (4) and may be a better indicator of recent protein stores (93). The 
cost of these tests can be prohibitive (93) leaving clinicians to rely on anthropometric 
measures and physical examination to provide an assessment of nutritional status. 
 
2.3.3 Prevalence of malnutrition 
Childhood cancer patients with solid malignancies, and patients with advanced 
cancer are at risk of under nutrition (94) before treatment has commenced. 
Prevalence may be as high as 25% of all patients diagnosed (94). The prevalence of 
under-nutrition for childhood cancer patients during treatment has been suggested 
to be anywhere  between six to 50% of patients (6), while the incidence of 
malnutrition amongst children with metastatic disease approaching the upper end of 
this range and may be as high as 40% (14).  Much of the literature on prevalence 
rates of malnutrition in paediatric oncology were assessed in the 1980s and 1990s 
using weight based assessments such as BMI z-scores.  Treatment regimens and 
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protocols have changed since then, though there remains very little literature on the 
prevalence rates of malnutrition based on modern day protocols. There also remains 
no uniform definition of malnutrition (46) to enable comparison between prevalence 
studies. A recent systematic review of the literature suggests a prevalence of under 
nutrition for leukaemia patients of between 0-10%, 20-50% for neuroblastoma and 
0-30% for other malignancies (46).  These figures took into account studies that not 
only used weight as a measure of under nutrition, but studies that used other 
measures of under nutrition such as body composition and dietary intake.   
 
Recent studies have looked at the change in body composition of childhood cancer 
patients over the course of cancer therapy based on measurements of weight/BMI 
changes. The majority of these studies focused on patients with ALL, finding 
increasing BMI z-scores over the course of treatment (95, 96). A recent study 
assessed body composition changes over the course of intensive paediatric cancer 
patient’s treatment. Patients with haematological disease and solid tumours did 
have a reduction in BMI and fat free mass (FFM) during the initial phase of their 
treatment.  BMI z-scores and fat mass (FM) appeared to increase over the course of 
the treatment, relating to the use of intensive nutrition support, mainly tube feedings 
(97). 
 
2.3.4 Aetiology of malnutrition 
The primary aetiology of weight loss is the inability of childhood cancer patients to 
consume adequate nutrients to meet their requirements (98). The reason for this is 
multi-factorial, relating to both affects from the disease itself and the treatment of the 
disease. 
 
 
28 
 
2.3.5 Inflammation & cachexia 
Cachexia is a term to describe a state of depletion (99) seen in cancer patients 
(100), characterised by anorexia and weight loss (100). There is a distinct difference 
between weight loss and patients in a cachectic state.  Weight loss, due to 
insufficient intake, is predominantly characterised by a reduction in fat mass and can 
be reversed with an improvement in nutritional intake or adequate nutritional 
support. In contrast, the weight loss seen in patients with cachexia predominantly 
involves a reduction in skeletal muscle mass (101) with or without a loss in fat mass 
(102, 103). These changes are related to an inflammatory response mediated by 
pro-inflammatory cytokines (100) resulting in a difficulty in reversing malnutrition 
using traditional methods of nutritional support (101, 104) leading to  functional 
impairment (103). 
 
2.3.6 Altered substrate metabolism 
Fat, protein and carbohydrate metabolism appears altered in childhood cancer 
patients (6, 98) causing  a loss FFM as well as FM resulting in weight loss and 
under nutrition (Table 2-3) (105). 
Table 2-3 Altered substrate metabolism and the consequences  
 
Substrate Alteration in metabolism Outcome 
Protein  Increase muscle catabolism 
Decreased muscle synthesis 
Increased protein turnover 
Skeletal muscle atrophy 
Hypoalbuminemia 
Fat Increased free fatty acid 
turnover 
Increased lipid breakdown 
Decreased lipogenesis 
Marked wasting  of body fat 
Raised plasma lipid 
Carbohydrate Increased gluconeogenesis 
Increased use of cori cycle 
Abnormal insulin response 
Decreased glucose 
intolerance  
Higher energy cost to 
metabolise glucose 
Adapted from Picton (98), Tisdale (101), Ladas (4), Bauer (7) & Andrassy (6) 
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2.3.7 Altered energy metabolism 
The body’s usual response to starvation is to conserve energy by decreasing energy 
expenditure (6). In adult patients with cancer, energy expenditure has been shown 
to increase, though this appears to be cancer specific and more likely in patients 
with certain solid tumours (106). Measuring energy expenditure in children has 
proven difficult and the studies assessing energy expenditure in young cancer 
patients have been limited (7, 46, 98). A recent systematic review of the literature 
found contradictory results regarding energy expenditure in childhood cancer 
patients (46). There is some suggestion that childhood cancer patients with solid 
tumours had higher energy expenditures at diagnosis (98). This may be related to 
the tumour burden.  
 
2.3.8 Cancer and treatment related side-affects 
Factors such as lethargy, pallor and nausea as a result of the disease process can 
lead to anorexia and weight loss prior to diagnosis (46). These symptoms are often 
used for a differential diagnosis (94).  Poor oral intake is a common among 
paediatric oncology patients once treatment has commenced. As discussed in 
section 2.2.3, cancer therapy such as chemotherapy targets rapidly dividing cells (7) 
resulting in symptoms such as nausea and vomiting (10) and mucositis (107). These 
symptoms lead to prolonged periods of anorexia (108). In a meta-analysis of 
symptoms experienced by paediatric oncology patients, the prevalence of anorexia 
was 40% (107). Taste and smell changes have also been implicated as a factor in 
reducing or changing food intake in paediatric cancer patients (109). 
 
Fatigue is commonly described in paediatric cancer patients (10, 107). Fatigue is 
associated with an increase in sleep as an energy conservation technique, (107) 
indirectly reducing a patient’s food intake. Another consequence of fatigue is a 
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reduction in physical activity, leading to a reduction in FFM (110), contributing to a 
patient’s risk of under nutrition.  
 
2.3.9 Consequences and outcomes of malnutrition in paediatric oncology 
Under nutrition in the paediatric hospital setting has been shown to be associated 
with an increased length of hospital stay as well as a reduced QoL (111). Specific 
consequences of under nutrition for paediatric oncology patients include a reduced 
treatment tolerance and increased treatment side-effects, potentially leading to 
poorer outcomes (6, 14). Recent literature suggests that under nutrition in paediatric 
patients is associated with increased infections and increased mortality (112-114), 
and this is likely independent of disease severity (115). Malnutrition in children 
reduces the absorption of chemotherapy (116) and may be one explanation of 
poorer outcomes in underweight patients (114). Other suggested mechanisms 
include an increased susceptibility to infections from hormonal changes (117). 
 
Acute and chronic under nutrition can also have detrimental effects on a developing 
child as childhood is a significant time of growth and development. Acute under 
nutrition (less than three months in duration) can cause lean body mass depletion 
(83). Chronic under nutrition (greater than three month’s duration) can cause growth 
stunting (84) and cognitive/developmental delay (83). For childhood cancer patients, 
whereby cancer therapy can take between up to two years to complete, their risk of 
extended periods of poor nutrition, in the absence of nutritional support can 
potentially lead to long term issues with growth and development.  
 
Much of the focus on the literature regarding the consequences of poor nutritional 
status has focused on the detrimental effects of under nutrition in the paediatric 
oncology population. New research is showing that being overweight, especially at 
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diagnosis, may also be associated with morbidity and mortality in cancer therapy 
(114, 118). It has also been suggested that overweight patients undergoing a HSTC 
have poorer prognosis than their normal weight peers (119) and higher treatment 
related mortality (120). A recent study of over 400 survivors of childhood 
cancer found that obesity at diagnosis was an independent predictor of 
relapse in child above the age of 10 years (118). This did not appear to be a 
linear relationship as patients who were underweight at diagnosis also have a 
poorer event-free survival than their normal weight peers (114, 118).  
 
Mechanisms for the association between over nutrition and a poor prognosis remain 
unknown. It has been suggested that obesity alters drug deposition decreasing the 
effectiveness of the chemotherapy treatment (119), but the reasoning may be more 
complex. Growth factors and lymphokines which are produced by adipose 
tissue may change the effectiveness of anti-cancer therapy (118). 
 
2.4 Nutritional management in paediatric oncology during therapy 
 
2.4.1 Recommendations for the timing of nutritional interventions 
Nutritional therapy has been established as an integral part of paediatric cancer 
therapy to ensure normal growth and development (4, 8). The three primary 
methods for preventing or reversing under-nutrition include oral nutrition support 
(ONS), enteral nutrition (EN) and parenteral nutrition (PN). Ideally the prevention of 
malnutrition should be the goal of any nutritional intervention (4, 121), yet there 
remain no standardised criteria for initiation of nutrition support (7, 122). Table 2-4 
indicates criteria suggested for nutritional implementation. Algorithms, providing 
criteria for nutritional interventions, have been shown to improve the consistency of 
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the nutritional management of paediatric oncology patients (5, 123), yet they are not 
routinely used. 
Table 2-4 Recommended criteria for initiation of nutrition support  
 
Anthropometric measure 
>5% loss of body weight  
<90% of ideal body weight 
<5th  BMI percentile 
<5th TSF percentile 
A decrease in weight down two percentiles  
Biochemistry 
Serum albumin #3.2 g/dL (in the absence of recent acute metabolic stress within the 
last 14 days). 
Clinical measures 
Anticipated gut dysfunction of > 5 days 
Dietary intake 
<70% of their estimated requirements for oral intake 
Adapted from Rickard et al, 1986 (8) 
 
Certain diagnosis groups and the subsequent treatment protocols used, places 
patients at a higher risk of nutritional depletion. (Table 2-5)  
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Table 2-5 Paediatric oncology diagnosis and their nutritional risk  
 
High nutritional risk disease 
Advanced diseases during initial treatment 
Stage III & IV neuroblastoma 
Pelvic rhabdomyosarcoma  
Ewing’s sarcoma’ 
Some non-Hodgkin’s lymphoma 
High risk leukemia (AML*, VHRALL**, Phi+ ALL***) 
Medulloblastoma 
Multiple relapse leukemia 
HSCT 
Low nutritional risk disease 
Standard risk ALL$ 
Non metastatic solid tumours 
Advanced diseases in remission during maintenance treatment 
Wilm’s tumour 
Adapted from Rickard et al, 1986 (8); Bowman et al, 1998 (5); Bauer et al, 2011 (7)* 
AML: Acute myeloid leukaemia; VHRLL: Very high risk acute lymphoblastic 
leukaemia; Phi+ ALL: Philadelphia positive acute lymphoblastic leukaemia; $ ALL: 
Acute lymphoblastic leukaemia 
 
2.4.2 Oral nutrition support 
Oral nutrition support involves the manipulation of the oral intake to provide the 
patient with additional nutrients by consuming nutrient-dense foods (14).  The use of 
specialty drinks and supplements containing a concentrated source of nutrients that 
 
34 
 
can act as a meal replacement can also be used (14). Oral nutrition support also 
involves counselling on strategies for increasing oral intake when suffering the side-
effects of cancer treatment. The literature suggest that oral nutrition support be 
initiated if patients have lost as little as five percent of their body weight (6, 124). 
 
Oral nutrition support is typically the preferred first step for preventing malnutrition in 
children (4) as it is the least invasive method of nutritional supplementation (125) 
and is therefore preferred by the patient group, However success with the use of this 
form of nutritional supplementation for high risk paediatric oncology patients is 
generally poor (14), and more aggressive nutritional interventions are indicated. 
 
Success with ONS requires the childhood cancer patient to have the ability to ingest 
food in a sufficient enough quantity that by adding additional energy to the food 
already consumed, their overall energy intake will be sufficient enough to meet their 
requirements (12). Oral supplements are also generally not tolerated in this patient 
group. Earlier published work by our centre suggests that fresh milk based 
supplements are preferred to other high energy supplements recommended for this 
patient group (ref).  Side effects associated with cancer therapy such as mucositis, 
nausea (126), taste changes, pain and food aversions (127) preclude patients from 
being able to consume or tolerate adequate oral intake (14) and may also appear to 
change patients food preferences. These food preferences do not appear to be 
standardised across all patients but vary from patient to patient (126). For many 
childhood cancer patients, consuming an adequate oral intake is impossible (126).  
 
Another factor to consider when choosing ONS as a method of nutritional 
supplementation is the longer term consequences of pushing food via the oral route 
when children are undergoing cancer therapy. Food aversions are a common in 
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both children (126) and adult cancer patients (128). Food aversions can occur when 
food is consumed while having negative experience (129). Food aversions are also 
associated with a higher level of parental pressure to eat (130). Recent work at our 
centre on the feeding practices that parents used during their child’s cancer 
treatment revealed negative feeding practices. These included pressuring their child 
to eat, offering nutrient poor food rewards and non-food rewards (131). Many 
childhood cancer patients are at an age where long term feeding patterns and habits 
are being established. Food aversions to certain foods may continue well after the 
child has completed their treatment for cancer and influence their long term food 
preferences. 
 
2.4.3 Enteral nutrition support 
For patients who cannot maintain an adequate nutritional status via the oral route, 
use of EN is recommended (4). EN is the provision of nutrition in a liquid form, via a 
tube into the gastrointestinal (GI) tract, usually the stomach, duodenum or jejunum 
(47). This can be done using a silastic feeding tube which is inserted via the nose 
and fed through the oesophagus to the stomach or duodenum. A gastrostomy can 
also be used to provide EN. This method uses a tube inserted directly into the 
stomach, or jejunum, either surgically or endoscopically.  Childhood cancer patients 
who receive tube feeding use formulated liquid supplements that get infused with a 
pump into the tube. The patient can also be given the feeds during the day via a 
pump or with the use of gravity. 
 
EN has been shown to be effective in promoting weight gain in paediatric oncology 
patients, (132-134) especially when used prophylactically (135, 136). Similar to 
ONS, absorption of nutrients continues through the gastrointestinal tract. Enteral 
nutrition is associated with a reduced risk of bacterial translocation and maintenance 
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of the integrity of the GI tract when compared with use of PN alone. (137). The use 
of tube feeding also allows easier administration of medications and fluids (6).  
 
Many patients also consider the tube a visible sign they are sick and therefore there 
is concern regarding altered body image (137).  Gastrostomy feeding has been 
recommended for use when patients are likely to require long-term feeding during 
their cancer treatment (138). The use of a gastrostomy for paediatric cancer patients 
has been shown to be safe (136). A gastrostomy can also be hidden under the 
patient’s clothes which is seen as an advantage for patients (137). 
 
2.4.4 Parenteral nutrition support 
Parenteral nutrition is an alternate form of nutritional intervention that can be used to 
prevent or reverse malnutrition in the paediatric oncology setting when this cannot 
be achieved using the oral or enteral route (7, 139). PN involves the intravenous 
administration of a solution containing a balanced mix of essential and non-essential 
amino acids, glucose, fatty acids, electrolytes and micronutrients (47). Ideally PN 
infusion should be via the central line to meet the nutrient needs of childhood cancer 
patients (4). Most children undergoing chemotherapy have a central line inserted for 
chemotherapy, making infusion of PN accessible (140).  
  
PN has been used widely in the paediatric oncology setting (122), especially those 
undergoing a HSCT (67, 69, 141). High dose chemotherapy regimens may result in 
gastrointestinal complications such as mucositis, enteritis and typhlitis preventing 
nutrition being tolerated via the enteral route (50). PN is associated with a higher 
risk of infective complications (139) bacterial translocation (137) hyperglycaemia 
and hepatic stenosis  (142). It is not recommended that PN be administered at 
home, resulting in longer hospital stays for patients requiring PN. 
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Issues and concerns with the implementation of enteral and parenteral nutrition  
A survey of nutritional practices in North American paediatric oncology centers, 
found no standardised method of nutritional supplementation to prevent or reverse 
under-nutrition in paediatric oncology patients (143). A recent Cochrane review 
comparing EN with PN in the paediatric oncology setting concluded that there is 
inadequate evidence to allow recommendations for the best form of nutrition 
support. (144). The review concluded that PN may improve nutritional status in well-
nourished paediatric patients compared with EN (144) but these findings are not 
replicated with malnourished patients. Due to a high risk of infective complications 
(139) associated with using PN, the literature suggests that the use of EN should be 
considered before using PN for nutrition support (5, 135, 137).  In reality, these 
recommendations are not always being implemented in a clinical setting (143). 
 
 Reasons for the choice of PN being chosen over EN appear multifactorial. A recent 
study of paediatric oncology patients, and their parents, suggests that the perceived 
discomfort of EN influences patient/parent decision to allow EN to be used (145). 
There is also suggestion that EN is more likely to be initiated in younger patients (< 
6 years) (135). The healthcare team’s recommendations influence the initiation of 
EN (145). In non-oncology settings, such as paediatric patients with developmental 
delay, it appears that timing of the initiation of EN may also be influenced by the 
views and support of the medical teams (146, 147). Literature also suggests that 
parents use EN as a threat to get their child to eat (131), thereby potentially 
exacerbating the negative views of EN with the childhood cancer patients. 
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2.5 Nutritional management in paediatric oncology after therapy completion 
 
 
The majority of the literature focuses on the management (both medical and 
nutritional) of childhood cancer patients during the active phase of their treatment. In 
the last 10 years, there is a shift in focus, and the long term consequences of giving 
cancer therapy to children at a young age have been studied. In a landmark paper 
published in 2006, the health status of 10 000 long term survivors of childhood 
cancer was compared with sibling controls. This study showed that childhood cancer 
survivors have a relative risk of developing a chronic condition of 3.3 and a relative 
risk of a severe or life-threatening condition of 8.2 when compared with their siblings 
(15). Female sex and older age at diagnosis are independent risk factors for 
developing chronic conditions (148). These chronic health conditions include (but 
are not limited to) secondary cancers, endocrine disorders, renal dysfunction and 
severe musculoskeletal problems. However, it may be many years before patients’ 
display these conditions which tend to worsen over time (149). 
 
Specific chronic health conditions of long-term survivors that have the potential to be 
managed by lifestyle factors include osteoporosis, metabolic syndrome, endocrine 
disorders and cardiovascular disease (150). Adult survivors of childhood cancer 
have a greater chance of being diagnosed with the metabolic syndrome than healthy 
controls(151). There prevalence of the metabolic syndrome in childhood cancer 
survivors may be as high as 30% (18). Yet many adult survivors of childhood cancer 
do not meet guidelines for fruit and vegetable intake, consume excessive fat and 
have an inadequate calcium intake (17, 152). Adult, survivors of childhood cancer, 
diagnosed with metabolic syndrome, are 2.2 more likely to have poor diets than 
those without the metabolic syndrome (18). This is independent of disease type and 
treatment. Long-term survivors report barriers to consuming a healthy diet that 
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include taste preferences for higher fat foods and the lack of availability of healthier 
foods (153). They may also be unaware of their risk of chronic disease (150), 
lessening the motivation to change their lifestyle. As childhood cancer survivors are 
already at a higher risk of long-term metabolic complications as a result of their 
cancer therapy, poor nutritional intake may be exacerbating this risk. 
 
2.6 Role of the dietitian in paediatric oncology 
 
 
The role of the dietitian in the clinical management of paediatric oncology patients 
has focused on the prevention and treatment of under nutrition during cancer 
therapy. The goals of nutritional interventions have focused on ensuring adequate 
energy and protein to prevent or reverse under nutrition, potentially at the detriment 
of good nutrition principles. The dietitian must also balance the recommendations 
from the literature regarding the initiation and type of nutrition support recommended 
with the realities’ of working with sick children and their parents.  
 
For many parents, the more aggressive forms of nutrition support, such as enteral 
nutrition, are seen as a last resort and as such parents are tending to force their 
child to consume meals or using the more invasive forms of nutritional 
supplementation as a threat to encourage eating. In turn, clinicians are encouraging 
paediatric oncology patients to “consume whatever they liked,” as a way of 
preventing the child from losing weight. The reality of intensive cancer therapy is 
that most patients with a high nutritional risk diagnosis are unable to maintain their 
nutritional status using food and supplements alone.  
 
Paediatric oncology used to be considered an acute disease with poor short-term 
outcomes. For patients who were “cured” there was no focus on the long term 
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morbidity associated with a cancer diagnosis at such a young age. Since cure rates 
have increased, there has been a shift of thinking to realising that cancer is now a 
chronic disease. The goal of treatment is to provide cure without causing long term 
harm. It appears that nutritional recommendations have been slower to shift the 
paradigm. Childhood cancer survivors are at a greater risk of lifestyle diseases such 
as diabetes, obesity, osteoporosis and metabolic syndrome. The literature also 
shows that adult survivors of childhood cancer are not consuming diets that would 
help to reduce the risk of these diseases, yet there remains a dearth of literature 
regarding the dietary intake and habits of younger cancer survivors. 
 
2.7 Contribution of this thesis 
 
 
The literature review in this chapter provided a context for the placement of this 
thesis. The concepts of malnutrition in childhood cancer and the goals of nutritional 
therapy were introduced. The recent focus by clinician working in paediatric 
oncology on the impact that cancer therapy has on the lives of childhood cancer 
survivors and the concept that clinicians need to maximise cure while minimising 
harm was introduced.  This thesis aims to explore the impact that cancer therapy 
has on the dietary intake of childhood cancer survivors. Contrary to the focus of 
previous work on the nutritional management of childhood cancer patients in which 
protein and energy has been the primary outcome, this thesis will explore childhood 
cancer patients’ nutritional intake based on their diet as a whole.  
 
The studies in this thesis were designed using a cumulative approach, with each 
new study being informed by the results of other studies. The first phase of work in 
this thesis focuses on determining the dietary intake and habits of childhood cancer 
survivors early off treatment. The second phase of the thesis then explores 
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nutritional interventions both on and off treatment. The thesis assesses the 
nutritional interventions that may be available for young cancer survivors and 
specifically determines the reasons for the inadequate use of enteral tube feeding as 
a method of nutritional intervention. The third phase of the thesis explores factors 
that may responsible for the poorer dietary habits of older cancer survivors, 
specifically taste and smell changes.  
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3 DIETARY INTAKE AFTER TREATMENT FOR CHILD CANCER SURVIVORS1 
Chapter 2 provided the background to the medical and nutritional management of 
childhood cancer patients. The majority of research has focused on the nutritional 
management of cancer patients during their cancer therapy. With the improvement 
in survival rates, and an increasing number of adult survivors of childhood cancer, 
childhood cancer therapy can no longer be considered an acute disease. There is 
evidence for poor dietary intake in adult survivors of childhood cancer but there is a 
dearth of information regarding the dietary intake of young cancer patients early 
after treatment completion. Part 1 of this thesis will examine the hypothesis that 
there is significant nutrition related problems in childhood cancer survivors. This 
chapter will report on the findings of a study assessing the dietary intake of young 
cancer survivors early after treatment completion. This study has been published in 
Pediatric Blood and Cancer. 
3.1 Introduction 
 
Childhood cancer survivors have a relative risk of developing a chronic condition of 
3.3 when compared with their siblings (15). These conditions include, but are not 
                                               
1
 This chapter has been published in the following peer reviewed journal: 
Cohen J, Wakefield CE, Fleming CAK, Gawthorne R, Tapsell LC, Cohn RJ. Dietary intake 
after treatment in child cancer survivors. Pediatric Blood and Cancer. 2012;58(3);752-7 
JC designed the study, JC, CF & RG contributed to data collection and analysis and JC, CW, 
RC & LT contributed to the manuscript. 
The key findings have been peer reviewed and presented by JC at the 16
th
 International 
Congress of Dietetics, COSA 37
th
 Annual Scientific Meeting, the Australasian Society for 
Health and Behavioural Medicine ASM & the ANZCHOG Long-term Follow-up Symposium. 
The abstracts included in the following publications: 
Cohen J, Goodenough B, Cohn RJ. Parental attitudes to their child’s nutrition at completion 
of cancer treatment. Pediatric Blood and Cancer. 2009; 53 (5); 853 
 
 
43 
 
limited to, endocrine disorders, metabolic disorders, cardiovascular disease and 
pulmonary disease (154, 155). Specific conditions such as obesity, type II diabetes 
and osteoporosis have the potential to be managed by lifestyle interventions (156). 
Even though behaviours such as consuming a healthy diet and/or maintaining 
adequate physical activity could prevent or lessen the impact of some of these 
chronic diseases (157) health-protecting behaviour prevalence is similar to the 
general population (150, 158, 159). Many adult survivors of childhood cancer 
consume high fat diets, do not meet guidelines for fruit and vegetable intake, and 
have an inadequate calcium intake (16, 17), though their overall energy intake does 
not appear excessive (153). Long-term survivors report barriers to consuming a 
healthy diet that include taste preferences for higher fat foods and the lack of 
availability of healthier foods (153). 
 
The treatment completion period of the cancer trajectory has been described as a 
teachable moment (152). Young patients who have recently completed treatment 
may be the more appropriate target group in whom to intervene and develop 
preventative strategies. This is especially the case as younger age at diagnosis has 
been documented as a risk factor for these chronic conditions, especially obesity 
(160). There is limited information about the dietary intake of childhood cancer 
survivors (CCS) who have recently completed their treatment and almost no data 
examining how this may influence lifelong dietary practices and long-term metabolic 
and endocrine outcomes (161). A small number of studies have assessed the 
dietary intake of childhood cancer patients during treatment with varied findings 
(162-164), though this is unlikely to be generalisible to patients who have completed 
treatment. 
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For dietary intervention plans to be effective in a young population, parental 
involvement is important (150). It is known that parents of children not affected by 
cancer strongly influence their child’s eating patterns, playing a pivotal role in the 
development of their child’s food preferences and energy intake, (165) and playing a 
role in long-term feeding practices (166).  Evidence suggests that parents who 
restrict their child’s dietary intake when they are young may place their child at risk 
of obesity when they are older as they may not develop the skills necessary to 
regulate their own intake (167, 168). This is more likely to occur in parents who are 
highly invested in their child’s health (169). Only one study has specifically 
examined parental influences on child cancer patients’ health behaviours, reporting 
that many parents lessen their control over their child’s eating (and their other 
lifestyle behaviours) during their child’s cancer therapy (13). What is unknown is 
what parenting styles are used at completion of their child’s cancer therapy and 
whether these have the potential to place their child at risk of nutritional issues in the 
future. 
 
The aim of this study was to assess the weight status, dietary intake and associated 
parent feeding practices of a cohort of childhood cancer survivors less than 13 years 
of age and less than 5 years after treatment completion.  
 
3.2 Methods 
 
3.2.1 Study participants 
The participants were parents and/or carers of CCS who were: a) less than 5 years 
post treatment for any type of cancer; b) under 13 years of age; and c) attending the 
Centre Kids Cancer Centre (KCC) at Sydney Children’s Hospital, Australia for follow 
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up.  Eligible participants were identified using KCC records and posted a study 
invitation, a participant information sheet and an opt-in card. Participants were 
excluded if they had insufficient English language skills to complete the 
questionnaire. Participants were recruited between the June 2009 and June 2010. 
The study protocol was approved by the South Eastern Sydney & Illawarra Health 
Service, Human Research Ethics Committee-Northern Hospital Network. Written 
informed consent was received. 
 
3.2.2 Demographics 
CCS-related demographic data including gender, age, cancer diagnosis, and dates 
of diagnosis and completion of treatment were compiled from medical records. 
Historical data on anthropometric measures at diagnosis was also collected. CCS 
weight and height were used to calculate BMI, using the formula: weight in 
kilograms divided by height in meters squared. To allow for comparisons across age 
groups, BMI percentiles were calculated using Epi Info™ (Version 3.5.1, 2008; 
Centres for Disease Control and Prevention, USA). A BMI percentile of <5th 
percentile was classified as underweight, those between the 5th-84th percentile were 
classified as a healthy weight, those between 85-94th percentile were classified 
overweight and >95th percentile were classed as obese (170).  
 
3.2.3 Child Feeding Questionnaire (CFQ) 
The 31-item CFQ (Appendix 4) was used to assess participant beliefs, attitudes and 
practices about their child’s feeding (171). Mean CFQ item scores were calculated 
for each of the seven subscales which fall under 2 categories (Table 3-1) Risk 
factors and concerns; 2) Control in child feeding, attitudes and practices (171). 
Response options are scored on a 5-point likert scale (1=’disagree’ to 5=’agree’). 
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Scores in each of the seven subscales were averaged. Higher mean scores in each 
subscale indicated higher levels of parental concern and control over child feeding. 
The CFQ has been validated for use in parents of children aged two up to the end of 
primary school age (171). 
 
Table 3-1 Child Feeding Questionnaire (CFQ) sub-scales and operational 
definitions 
 
Sub-scale Operational Definition Example 
 
Perceived feeding 
responsibility 
Extent in which parents 
takes responsibility for 
feeding the child 
“How often are you 
responsible for deciding 
what your child’s portion 
sizes are?” 
 
Perceived parent 
overweight 
Parent’s perception of 
their own weight at 
various stages 
“ Perception of weight 
during adolescence” 
 
Perceived child 
overweight 
Parent’s perceptions of 
their child’s weight at 
various stages 
“Perception of their child’s 
weight when they were a 
toddler” 
 
Concerns about child 
overweight 
How concerned the 
parents are that their child 
is overweight 
“How concerned are you 
about your child having to 
diet to maintain a 
desirable weight?” 
Restriction Parent’s attempts to 
control their child’s eating 
by restricting access to 
foods. 
“ I intentionally keep some 
foods out of my child’s 
reach” 
Pressure to eat Parents’ attempts to 
control their child’s eating 
by encouraging the 
amount and type of food 
“If my child says “I’m not 
hungry”, I try and get her 
to eat anyway” 
Monitoring The extent to which a 
parent reports keeping 
track of their child’s 
consumption of energy 
dense foods” 
“How much do you keep 
track of the high fat foods” 
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3.2.4 Dietary intake 
A three-day food diary was used to assess CCS nutrient intake (parent report). 
Participants were given written instructions on how to complete the food diary and 
were asked to complete this over two weekdays and one weekend day. Although 
this method can lead to high respondent burden and is subject to bias (including 
selection of the sample, reporting bias and issues associated with measurement of 
the diet) (172), this prospective method of a three-day food record was utilized as it 
has been shown to be appropriate for measuring individual, short term nutrient 
intake (172). Information on multi-vitamin use was not collected as dietary intake 
from food sources was the focus of this study. 
 
3.2.5 Data analysis 
The three-day food records were analyzed using the Foodworks nutrient analysis 
software program (version 5, 2007; Xyris Software, Brisbane, Australia). For foods 
and beverages not represented in the Foodworks database, nutrient content was 
obtained from nutrition panels. From these dietary data, the CCS mean daily energy 
intakes were calculated and expressed as a percentage of their estimated energy 
requirement (%EER). EER is the mean energy intake predicted to maintain energy 
balance including the needs related to tissue deposition (173). The age-appropriate 
Schofield equation was used to calculate basil metabolic rate (174) and a physical 
activity level of 1.5 (sedentary) was used to calculate EER. Use of a physical activity 
level of 1.5 was based on research of the physical activity levels from previous 
studies of childhood cancer survivors (164, 175). The CCS mean daily nutrient 
intake was calculated and expressed as a percent of their age-appropriate 
estimated average requirement (EAR) (173) to allow comparisons across age 
groups. EAR is used for group assessment of the prevalence of inadequate intake of 
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nutrients in a particular life stage and gender (173). For certain nutrients, EARs have 
not been established and therefore these nutrients were excluded in this analysis. 
 
Remaining data were analyzed using the statistical software package SPSS (version 
17.0, 2009; SPSS Inc, Chicago, IL, USA). Descriptive statistics were calculated for 
demographic and anthropometric, dietary intake and CFQ data. A p-value of <0.05 
was considered statistically significant.  
 
Paired t-tests were used to compare differences between BMI percentiles at each 
assessment time-point. Likewise, paired t-tests were used to determine whether 
there was a significant difference between the three factors in the attitudes and 
practices category of the CFQ and the 4 factors in the risk factors and concerns sub-
scale. As the data were normally distributed, Pearson’s correlation coefficients were 
used to assess correlations between the subject’s %EER, BMI percentiles, CFQ 
factors, gender, age and time since completion of treatment. A backwards linear 
regression model was used to determine the degree of the relationship between 
each of the CFQ subscales and the patient’s BMI percentile. Time since treatment 
completion was included as a covariate. 
 
3.3 Results 
 
3.3.1 Patient demographics 
A total of 139 participants were invited to participate in the study and 50 volunteered 
to take part, yielding a response rate of 36%.  Reasons for refusal to participate 
could not be determined. The CCS mean age at diagnosis (SD) was 3.47 (2.41) 
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years and the mean age at the time of their parent’s study participation was 7.12 
(2.59) years. See Table 3-2 for further demographic details. 
Table 3-2 Demographic and medical characteristics of child cancer survivors 
 
Characteristic N (%)  
Sex  (male:female) 60:40 
Cancer diagnosis, %   
        ALL 25 (50) 
        ALL - relapsed 2 (4) 
        AML 2 (4) 
        Neuroblastoma 5 (10) 
        Wilms Tumour 6 (12) 
        Rhabdomyosarcoma 2 (4) 
        Lymphoma 2 (4) 
        Medulloblastoma 2 (4) 
        Other 4 (8) 
Age at cancer diagnosis, years   
        Mean (SD) 3.47 (2.41) 
        Range 0.7-8.8 
Age at assessment, years   
        Mean (SD) 7.12 (2.59) 
        Range 3.1-12.3 
Time since treatment completed, years   
        Mean (SD) 2.29 (1.56) 
        Range 1.0-4.8 
 
3.3.2 Dietary intake 
Results from the three-day food diaries revealed that 54% of the CCS was 
consuming more than 110% of their %EER, while 50, 32 and 44% of children did not 
meet their requirements for folate, calcium and iron respectively (Table 3-3). Only 
6% percent of the CCS was consuming less than 75% of their %EER. There was no 
significant difference in %EER between those treated for Acute Lymphoblastic 
Leukemia (ALL) and other diagnoses (110% vs. 121% respectively, t= -1.164 
p=0.26). 
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Table 3-3  Mean nutrient intake 
 Mean (SD)             
(%) 
Range                 
(%) 
Percent not 
meeting 
requirements 
Normative 
data*.  
Percent of estimated energy requirement (EER) 
 
 115.6 (34.0) 59-235 54% (>110% 
EER) 
 
Nutrient intake 
 
Protein 359.5 (158.5) 124-955 
 
0% 0% 
Thiamin 267.0 (177.3) 75-1180 2% 0% 
Riboflavin 307.9 (150.5) 74-834 2% 0% 
Niacin 
Equivalents 
392.3 (167.9) 158-1068 0% 0% 
Vitamin C 314.8 (202.2) 72-917 4% 2% 
Folate 119.7 (85.0) 43-630 50% 2% 
Vitamin A 203.9 (106.7) 73-549 8% 2.3% 
Magnesium 214.2 (142.9) 62-860 4% 2% 
Calcium 126.5 (56.6) 39-323 32% 31.5% 
Phosphorus 226.1 (91.4) 56-504 4% 4% 
Iron 111.1 (49.8) 49-370 44% 1% 
Zinc 232.4 (112.9) 75-780 2% 0% 
 
* Australian National Children’s Nutrition and Physical Activity Survey- Main 
Findings. In: Department of Health and Ageing, editor. Australian Government; 
2007. Based on ages 2-13 years. 
 
Table 3-4 presents the distributions of mean BMI percentiles as measured at 
diagnosis (T1), end of treatment (T2) and at the time of parent’s study participation 
(T3).  Data for BMI percentiles of CCS under the age of two cannot be calculated 
and were therefore not included in the analysis. Historical anthropometric data was 
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not available for four CCS (T3). Paired t-tests showed a statistically significant 
increase in BMI percentiles from T1 to T3 (56.29 vs. 67.17 t= -2.758, p=0.01). 
 
Table 3-4  Mean body mass index (BMI) percentiles for subjects over the age 
of 2 years  
 n Mean (SD) Range p-value 
Diagnosis (T1) 30 56.3 (29.4) 0.14-99.3 0.06 (T1-T2) 
End treatment (T2) 37 65.4 (31.0) 0.1-97 0.28 (T2-T3) 
Time of study (T3) 46 67.1 (24.9) 0.75-99.9 0.10 (T1-T3)* 
* Value is significant at p<0.05 
 
 The majority of children were within the healthy weight range at the three 
assessment points with 10% of children overweight and 10% obese at T3 (Figure 3-
1). There was no difference in BMI percentiles between those treated for ALL and 
those treatment for another diagnosis (65.88 vs. 67.10; t=-0.167, p=0.87). 
 
 
 
Figure 3-1 Percentage of children in each weight category over three 
assessment time points 
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3.3.3 Child feeding practices 
From the risk factors and concerns subscale of the CFQ,  parents appeared to have 
had a high perceived responsibility in regards to their child’s intake and were the 
least concerned about their child’s risk of being overweight (t=8.249, p=0.001) 
(Table 3-5). In the control of child feeding, attitudes and practices subscales parents 
had significantly higher scores for monitoring their child’s intake (t=-6.621, p=0.001) 
and using a restrictive form of parenting (t= 3.822, p=0.001) compared with 
pressuring their children to eat.  
Table 3-5  Mean scores for the 7 subscales of the child feeding questionnaire  
 
Categories Sub-scales Mean ±SD* Range 
 
Risk factors and 
concerns 
Perceived responsibility 4.18 ± 0.48 3-5 
Perceived parent weight 3.10 ± 0.40 2-4 
Perceived child weight 2.91 ± 0.41 2-4.3 
Concerns about child 
weight 
2.52 ± 1.28 1-5 
Control in child feeding, 
attitudes and practices 
Restriction 3.43 ± 0.80 1.5-4.75 
Pressure to eat 2.77 ± 0.99 1-5 
Monitoring 3.99 ± 0.71 2-5 
* Possible values: 1=low levels of concern or control; 5=high levels of concern  
 
The full additive regression model with 8 independent variables (CFQ sub-scales 
and time since end of treatment) explained 38.4% of the variance in BMI z-scores 
(F= 2.803; p= 0.016). The final model with only 3 variables (parental perception that 
their child was overweight, parental concern about their child being overweight and 
time since treatment completion) explained 36% of the variance in BMI z-scores (F= 
7.672, p=0.001), a loss of only 2%.  
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3.4 Discussion 
Assessment of the dietary intake of childhood cancer survivors is essential to allow 
the development of appropriate nutritional interventions. Yet there is a paucity of 
literature in this area, especially relating to young childhood cancer survivors. This 
study assessed childhood cancer survivor’s dietary intake less than five years from 
completion of treatment to determine overall nutritional adequacy, as well as to 
describe parental attitudes and beliefs about their child’s feeding practice. 
 
Obesity is associated with CCS both less than 18 years of age (176) and adult 
survivors of childhood cancer, especially those treated for ALL and with cranial 
irradiation (177, 178). The present study found that 10% of the CCS was overweight 
and 10% were obese at the time of the study using BMI percentiles as a marker of 
obesity. It has been suggested that BMI is not an accurate marker of abdominal 
obesity, (156), (179) potentially underestimating obesity rates in this cohort. 
However there was a statistically significant increase in BMI percentiles from the 
start of treatment (T1) to the time of assessment (T3). Although this has the 
potential of being more a reflection of the catabolic state associated with diagnosis 
resulting in lower BMI percentiles, recent literature suggests that malnutrition rates 
at diagnosis in this population may only be around 9% (180) . 
 
This study found that a large proportion of the CCS (54%) were consuming above 
their estimated energy requirement. This finding is important because energy 
imbalances as small as 1-2%, sustained over a period of time, are likely to promote 
weight gain in this population (181). This may, in part, explain the increasing BMI 
percentiles of our cohort, though this will need to be confirmed with future studies. 
This is clinically important as it provides a potential target for dietary intervention 
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programs, namely  to decrease energy intake in this population, which may go some 
way towards preventing obesity and associated endocrine and metabolic 
complications in young childhood cancer survivors (16). Additionally, obesity 
prevention in these patients is more likely to be successful than treatment of obesity 
in long term survivors (182, 183). 
 
It is  noted that the energy intake of this cohort of paediatric cancer survivors 
appears similar to that of the general Australian population (184). Although it was 
not assessed in this study, it may be that paediatric cancer survivors need to 
consume less than their peers to prevent long-term weight gain due to the fact that 
childhood cancer survivors may  have lower total energy expenditure than the 
general population (caused by reduced physical activity levels rather than reduced 
resting energy expenditure) (164, 185). Issues such as motivation, fear and pain 
(186, 187) have been reported as reasons for adult cancer patients having 
sedentary lifestyles and lower physical fitness levels (188) both during and after 
cancer treatment (189). Targets for energy intake for CCS may therefore need to be 
set at lower ranges or an increase in physical activity will need to be encouraged so 
as to prevent long-term weight gain.  
 
Our findings regarding micronutrient intake indicate that inadequate calcium intake 
may be an important concern soon after the treatment period (with 32% of our 
population not meeting daily requirements). Inadequate calcium intake also appears 
to be a concern for older CCS, with the literature reporting up to 68% of CCS were 
not meeting guidelines for calcium intake(16). Although this trend is similar to the 
general Australian population this is more concerning for survivors of childhood 
cancer, particularly those treated for ALL, as they are at higher risk of osteopenia 
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(190). Altered bone metabolism during treatment may interfere with the attainment 
of peak bone mass, predisposing survivors of childhood cancer to premature onset 
and complications related to osteopenia and osteoporosis (191). While treatment 
greatly affects bone mineral density (BMD), BMD is multi-factorial and lifestyle 
factors including nutritional status, adequate calcium intake (particularly dairy 
calcium) and weight-bearing exercise are important modifiable factors in the 
prevention of osteoporosis (190, 192). Survivors of childhood cancer must ensure 
they have a positive calcium balance to build bone and attain peak bone mass to 
prevent these problems (190).  
 
The finding that 50% of the CCS failed to meet their folate EAR is also of concern, 
as current epidemiological research suggests a link between decreased folic acid 
intake and increased homocysteine levels (193). Increased homocysteine levels are 
associated with endothelial dysfunction, decreased nitric oxide bioavailability, 
decreased vasodilatation and increased low-density lipoprotein deposition in arterial 
walls, resulting in atherosclerosis and ultimately increased risk for cardiovascular 
disease (193). Good food sources of folate include green leafy vegetables and citrus 
fruit (194).  Studies of adult cancer survivors have found inadequate vegetable 
intake (17) which has the potential to lead to inadequate folate intake. These habits 
may be manifesting early in the off treatment period, leading to inadequate folate 
intake, however this needs to be confirmed in future studies. It also appears that an 
inadequate folate intake is unique to the childhood cancer population compared with 
children unaffected by cancer (Table III). 
 
Although studies assessing parental influences, (including beliefs, attitudes and 
practices), on child’s eating patterns and weight status could not be found for the 
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paediatric oncology population, research in children not affected by cancer has 
demonstrated that parent feeding methods are linked to child weight status (171). 
Parent child feeding behaviours of monitoring, pressure and restriction are highly 
correlated with an increased energy intake and BMI in children (167) . This study 
failed to find any relationship between CCS BMI percentiles and %EER between all 
7-domains of the CFQ. It is possible this was due to a floor effect, given that only 
20% percent of children were classified as overweight/obese. The parents in this 
study were more likely to endorse behaviours such as monitoring and restrictive 
style of parenting and felt responsible for their child’s intake which has the potential 
to lead to increasing weight and risk of obesity over time. These results provide 
possible targets for interventions in the future.   
 
3.4.1 Limitations 
This single centre study was limited by a low response rate, which increased the 
chance of bias and reduces generalisability to the broader paediatric oncology 
survivor population. The high participant burden associated with completing 3-day 
food diaries (172) may have reduced participation rates. Recruitment via a letter 
invitation instead of face-to-face recruitment may also be a factor in the poor 
response rate. The lower representation of overweight children may also have 
introduced bias into the study whereby only parents of CCS within a healthy weight 
were willing to participate in this study out of concern for being judged for their child 
feeding practices. It is also important to note that using BMI percentiles may not be 
a sensitive marker of obesity in this population, as the measure may not reflect 
changes in body fat (179). Waist circumference may be more predictive of 
cardiovascular risk in the CCS (156). Another limitation of this study was the lack of 
a control group. Although it is recommended that future studies utilise a control 
group, these studies need to be consider that the control children may also not be 
 
57 
 
meeting the dietary guidelines. It is recommended that future studies compare the 
dietary intake of childhood cancer patients with both control groups and age-
appropriate dietary guidelines. 
3.4.2 Conclusion 
This study has provided preliminary data regarding the dietary intake of childhood 
cancer survivors less than 13 years of age, within five years of completing cancer 
therapy. It provides potential targets for nutritional interventions that may be 
implemented to prevent some of the deleterious long-term effects associated with 
cancer therapy. It appears that a large proportion of the CCS are consuming more 
than their recommended energy requirements, and if this continues, their intake may 
place this group at increased risk of obesity and other associated endocrine and 
metabolic disorders. Large proportions are also consuming inadequate calcium, 
folate and iron, which could increase the risk of late-effects associated with cancer 
therapy. Parents used both monitoring and restriction to regulate their child’s intake, 
which may also contribute to poor dietary habits by decreasing their child’s self-
regulation of intake. This is especially of concern considering they do not appear to 
be concerned about their child’s risk of being overweight. It is imperative that 
interventions are established soon after treatment completion, targeting parents to 
enable us to improve the long-term dietary habits of this population. 
 
3.4.3 Implications 
The findings from this chapter provide a quantitative assessment of the nutritional 
intake of a cohort of child cancer survivors. This study is the first to provide evidence 
that the poor dietary intake seen in adult survivors of childhood cancer is 
manifesting itself recently off treatment. Although we hypothesised that the poor 
nutrient intake seen in this population may be related to an inadequate fruit and 
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vegetable intake or an intake of high energy foods, this cannot be confirmed with the 
results from this current study alone. The next chapter will provide further insight into 
the dietary habits of the cancer survivors. 
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4 EXPLORING THE VIEWS OF PARENTS REGARDING THE DIETARY HABITS 
OF THEIR YOUNG CANCER-SURVIVING CHILDREN2 
Chapter 3 provided information on the nutrient intake of young survivors of 
childhood cancer early after their cancer therapy has finished. This chapter will 
provide further insight into the dietary habits of the childhood cancer survivors and 
how these habits have change over their cancer trajectory. It will provide clinicians 
with the information on the dietary habits that could be targeted when developing 
appropriate nutritional interventions. The findings of this chapter have been 
published in Supportive Care in Cancer. 
4.1 Introduction 
 
Poor dietary intake during childhood cancer treatment is well documented. 
Treatment side-effects such as nausea, vomiting, diarrhoea, mucositis and anorexia 
                                               
2
 This chapter has been published in the following peer reviewed journal: 
Cohen J, Wakefield CE, Fleming CAK, Tapsell LC, Walton K, Cohn RJ. Exploring the views 
of parents regarding the dietary habits of their young cancer-surviving children. Supportive 
Care in Cancer. 2015;23(3);463-471 
JC designed the study, JC & CF contributed to data collection and analysis and JC, CW, RC, 
KW & LT contributed to the manuscript. 
The key findings have been peer reviewed and presented by JC at the 16
th
 International 
Congress of Dietetics, COSA 37
th
 Annual Scientific Meeting, the Australasian Society for 
Health and Behavioural Medicine ASM & the ANZCHOG Long-term Follow-up Symposium 
with the abstracts included in the following publications: 
Cohen J, Wakefield C.E, Fleming CAK, Cohn RJ. A qualitative study of parent attitudes to 
nutrition after completion of their child’s cancer treatment. Asia-Pacific Journal of Clinical 
Oncology. 2010; 6(3): 205. 
Cohen J, Wakefield, CE, Fleming CAK, Cohn RJ. Consequences of treatment on food 
preferences and dietary habits of childhood cancer survivors. Pediatric Blood and Cancer. 
2011; 57(5); 827 
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lead to poor oral intake and, in some cases, malnutrition (14, 195, 196) Childhood 
cancer patients’ dietary habits appear to be altered during cancer treatment. 
Preferences for sweeter or sour tasting foods and significant challenges with food 
refusal of previously tolerated foods have been reported. (127) 
 
Child feeding behaviours can be strongly influenced by positive and negative 
associations when young. (197) Dietary habits that are established when a child is 
young are also more likely to continue into their adult life. (198-201) Adult survivors 
of childhood cancer also have a poor dietary intake, with an inadequate intake of 
fruit and vegetables, consumption of high fat diets and an inadequate calcium 
intake. (17, 153) These dietary habits are manifesting themselves early after the 
treatment period, with child cancer survivors (CCS) recently off treatment displaying 
an excessive energy intake and an inadequate calcium and folate intake. (202)  The 
concern is that the dietary habits and food preferences that are established during 
childhood cancer therapy are persisting once treatment has been completed. 
 
There remains a dearth of literature regarding the dietary habits of CCS at treatment 
completion. The determination of parental views about their child’s nutritional habits 
is important, as parents can influence child dietary behaviours.(200)    Dietary 
interventions for younger children will also need to be parent focused. The more 
concerned a parent is about their child’s intake the more likely they may take steps 
to intervene. (203)  The study aimed to compare parental views of CCSs’ current 
dietary habits with their habits prior to their cancer diagnosis, during their treatment, 
and with those of children in the general population. In doing so, this study aimed to 
contribute to the evidence-base regarding the dietary habits and patterns of young 
child cancer patients.  
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4.2 Methods 
 
4.2.1 Study participants 
Participants were parents and/or carers of CCS who were: a) less than 5 years post 
treatment for any type of cancer; b) not attending a long-term follow-up clinic; c) 
under 13 years of age; and d) attending the Kids Cancer Centre (KCC) at Sydney 
Children’s Hospital, Australia for follow up. Eligible participants were identified using 
KCC records and were posted a study invitation, a participant information sheet and 
an opt-in card. Participants initially participated in a study assessing their child’s 
dietary intake after cancer treatment using a questionnaire and three-day food 
diaries. (202) Participants who participated in this study were able to indicate 
whether they would participate in the follow-up qualitative study. All participants of 
the dietary intake study agreed to participate in this follow-up qualitative study 
(n=51). A cohort of parents/carers of child cancer survivors who had participated in 
the dietary intake study (202)  were selected to participate in semi-structured 
telephone interviews. Participants were purposefully sampled to build on the insights 
gained thus far.  Maximum variation sampling was implemented to allow a range of 
diagnosis groups and ages of parents of childhood cancer patients to be 
interviewed. Incentives for participation were not used in the dietary intake study or 
the qualitative study.  
 
4.2.2 Controls 
Control participants were recruited via advertising in the hospital and through 
community organisations. Control participants were well children who were not 
patients of the hospital and were age-matched. Parents of multiple children were 
asked to focus on the dietary habits of one child only. Parents of age and sex 
 
62 
 
matched children without cancer or another disease that could affect their dietary 
intake or required food restrictions were interviewed regarding their child’s current 
intake. Excluded diseases included, but were not limited to,: food allergies or 
intolerance, diabetes, coeliac disease, crohn’s and ulcerative colitis, cystic fibrosis, 
renal failure, metabolic conditions and failure to thrive. Children were also excluded 
from the control arm of the study if they required supplemental nutrition via a 
nasogastric tube or gastrostomy. The parent/carer who was interviewed for both the 
cancer and control groups was the main carer responsible for food purchasing and 
meal preparation. The study protocol was approved by the South Eastern Sydney 
and Illawarra Health Service, Human Research Ethics Committee-Northern Hospital 
Network. Informed, written consent was obtained from each participant. 
 
4.2.3 Procedure 
Interviews for both the CCS and the control group were conducted via the 
telephone. This method of interviewing was chosen to ensure participation by a 
geographically diverse group, specifically those living in rural and remote regions, to 
reduce the bias associated with studying a group in the same geographic region. 
Telephone interviews have been shown to be as effective in eliciting reliable 
information as face-to-face interviews (25).  Telephone interviews may also have 
some advantage due to the anonymity that telephone interviews provide, favouring a 
more in-depth response (25).  
 
The interview schedule was prepared by a multidisciplinary team (dietitian, 
psychologist and oncologist) and used a semi-structured approach. The interviews 
further explored previous insights gained from our previous study regarding their 
dietary intake.(202) The interviews for the parents of the young child cancer 
survivors were separated into their current intake, intake during treatment and intake 
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prior to the cancer diagnosis. The interviews focused on determining parental views 
regarding their child’s eating habits, food volumes, food types and weight at each 
stage of their cancer journey. There was also a focus on self-reported parent 
feeding practices. The parents of controls were asked similar questions; however 
the focus was on their current intake (Table 4-1). As prescribed by Miles and 
Huberman (204), results from early interviews were used to suggest additional lines 
of questioning in subsequent interviews and all interviews were conducted by one 
researcher. Interviews were conducted until thematic saturation was reached.  
Thematic saturation was determined when there was a continual repetition of 
themes and when no new themes were mentioned in subsequent interviews. In 
accordance with gold-standard guidelines (204), participant’s responses were 
recorded and transcribed verbatim.  
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Table: 4-1 Questions used during the telephone interview to parents of young 
child cancer survivors and healthy controls 
 
Young child cancer survivors Healthy controls 
 
Nutrition prior to treatment 
Could you tell me how you viewed 
your child’s eating habits before they 
were diagnosed? 
Compared to other children their age 
how did you feel about the amount 
your child ate? 
Did you use any strategies to help 
your child to eat? 
How did you feel about their weight 
compared to other children before 
they got sick? 
 
 
Nutrition during treatment 
How did you feel about your child’s 
eating during their cancer therapy? 
How did you feel about the types of 
foods you child was eating? 
Did your child need any other forms of 
nutrition? 
Did you use any strategies to get your 
child to eat? 
How did you feel about your child’s 
weight during treatment? 
 
Current nutrition 
How do you view your child’s intake 
and diet? 
How do you view your child’s portion 
sizes? 
What are your thoughts about the 
types of foods your child eats? 
Do you use any strategies to help 
your child to eat? 
How do you feel about your child’s 
weight? 
Current nutrition 
How do you view your child’s intake 
and diet? 
How do you view your child’s portion 
sizes? 
What are your thoughts about the 
types of foods your child eats? 
Do you use any strategies to help 
your child to eat? 
How do you feel about your child’s 
weight? 
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4.2.4 Qualitative data analysis 
Transcripts were coded line-by-line and analysis was facilitated by the qualitative 
data analysis software NVivo, 2008, Version 8 (QSR International, Victoria, 
Australia) which allows the researcher to store, code and retrieve raw data as well 
as to collate secondary information such as researcher observations/ideas. To 
ensure accuracy with regards to the coding and analysis and to meet gold-
standards(205),  a multi-level consensus coding methodology was used. (206, 207)  
Fifteen percent of interviews from the CCS (n=3) and the control group (n=3) were 
coded independently by two investigators, who met to review the coding and 
address any disagreements (204).  The final coding was analyzed and emerging 
themes were categorized and enumerated (204). 
 
All coding was done by an Accredited Practising Dietitian. Any mention of individual 
foods by the participants were classified into food groups based on the Australian 
Guide to Healthy Eating (208). Accredited Practising Dietitians, are skilled in food 
composition, to be able to conduct this categorisation. Terminology used by parents 
such as “junk food” and “unhealthy foods” were coded separately and counts were 
done on the number of times these words were mentioned. “Junk foods” and 
“unhealthy foods” were classified as such, if they were energy dense, nutrient poor 
foods that were providing a large number of calories for relatively few nutrients. 
 
4.3 Results 
 
4.3.1 Demographics 
Eighteen parents/carers of CCS and 18 controls participated in the semi-structured 
interviews. The CCS represented a range of ages and diagnosis groups (Table 4-2). 
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There was no significant difference between the CCS and control group in regards 
to age or gender.  The control group all resided within metropolitan Sydney. Fifty-
five percent (n=10) of the parents worked full time and 39% worked part time (n=7). 
One parent was a full time career. 
 
Table 4-2 Demographic characteristics of parents, young child cancer 
survivors and healthy controls  
 
 Young child cancer 
patients 
(n=18) 
Healthy control  
(n=18) 
Child demographic 
Sex (M:F) 11:9 11:7 
Age (SD) years 8.50 (2.71) 8.5 (2.90) 
Diagnosis (number) 
     ALL a 
     Neuroblastoma 
     Wilm’s Tumour 
     Rhabdomyosarcoma 
     Lymphoma 
     Brain Tumour 
 
8 
3 
3 
1 
2 
1 
 
Age at diagnosis (yrs 
(SD)) 
3.47 (2.41) 
Time since treatment 
completion (yrs(SD)) 
2.29 (1.56) 
Nutrition intervention 
during treatment 
(number) 
     Nutrition education 
     Enteral nutrition 
     Oral supplements 
     PN b 
 
 
6 
5 
2 
2 
Parent demographics 
Sex (M:F) 0:18 1:17 
Area of residence 
(urban:rural) 
8:10 18:0 
Employment                          
(full:part:unemployed) 
 7:8:3 
a ALL-acute lymphoblastic leukaemia; bPN=total parenteral nutrition 
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4.3.2 Remembered dietary habits prior to diagnosis of CCS  
The majority of the parents described their child as a “healthy eater” prior to their 
cancer diagnosis (Table 4-3). Most parents appeared satisfied with the amount of 
food their child was consuming. Four parents described their child as consuming 
inadequate volumes of food and one parent considered their child to be consuming 
an excessive volume of food.  Parents did not appear to be experiencing concerns 
about their child’s weight prior to their diagnosis. A small number of parents believed 
their child was underweight and two considered their child to be overweight. Parents 
appeared to use a variety of strategies to encourage their child to eat, though none 
of the parents recalled providing “unhealthy” foods as an alternative to their normal 
foods as a way of ensuring that their child had an adequate intake. 
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Table 4-3 Summary of themes from parents of young child cancer survivors of 
their child’s remembered dietary habits prior to their cancer diagnosis 
 
 Number of 
respondents  
( n=18) 
Quote 
Dietary habits 
Healthy eater 16  “….was a very healthy little eater, you 
know fruits, vegetables - look [he] 
love[d] his lollies and chocolates like 
any other kid but …just pretty normal 
eating…” (male;12 yrs; Wilms’)”   
 
“Yeah, she was a good eater….I can’t 
really remember exactly what she was 
like but there was no problems with 
what she ate and she ate very healthy 
foods” (female; 5yrs, ALL a) 
 
 
Volumes of food 
Adequate 13  “I wasn’t worried about the amount 
either.  I didn’t have to watch it.  It was 
fine” (male; 10yrs, ALL) 
 
 
Weight perception 
Healthy weight range 13 “(Her weight ) you know like a chubbed 
up baby, a good weight, healthy” 
(female; 5yrs, ALL) 
 
Parent feeding practices 
Restricting foods 
 
 
Pressuring to eat 
 
 
Bribery 
 
 
Positive encouragement 
 
 
 
 
5 
 
 
5 
 
 
3 
 
 
3 
 
 
 
 
“I do everything in moderation….I don’t, 
I never stock junk food at home” 
(female; 8yrs, ALL) 
 
“our strategy was, if you don’t eat your 
vegies, you don’t get dessert, it’s that 
simple” (male, 11yrs, Lymphoma) 
 
“It always used to be if you eat all of 
your dinner you get yoghurt for dessert. 
It was never bribe him with lollies or 
anything like that”  (male; 10yrs, 
lymphoma) 
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Monitoring 
 
2 “(I) always tell them that like for 
example she didn’t like carrot and I said 
“carrot has good colour, so if you eat 
carrot it gives you good colour for your 
skin” (female; 8yrs, ALL) 
 
“ I mean sometimes he’d have to pull 
back on the chips” (male; 13yrs, ALL) 
 
 
a ALL: Acute Lymphoblastic Leukaemia 
 
4.3.3 Remembered dietary habits during treatment of CCS  
 
Parents reported a significant change in CCSs’ eating habits while their children 
were receiving their anti-cancer treatment (Table 4-4). The main themes that 
emerged from the parent report regarding their child’s eating habits during their 
cancer therapy included: 1) A decreased preference for fruits and vegetables; 2) An 
increase in preferences for carbohydrate-based foods such as bread, pasta or 
savoury biscuits;  3) An increased desire for foods they considered “junk food”. It 
also appeared that savoury foods were chosen by the CCS in preference for sweet 
foods. Parents also considered the foods eaten by CCS during treatment to be 
“unhealthy”.  
 
Parents’ views regarding the volume of foods appeared to be evenly split. Half of the 
parents were concerned that their child was not eating adequate volumes of food 
while the majority of the remaining parents described their child as overeating at 
certain phases of treatment.  
 
Parental concern about their child’s weight also appeared to change when their child 
was on treatment. A larger number of parents were concerned that their child was 
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underweight or overweight. Parent feeding practices also changed on treatment. 
Parents appeared to allow CCS to eat “whatever they liked” during treatment and 
several pushed their child to eat. None of the parents interviewed restricted their 
child’s food intake or type of foods eating during treatment.  
 
Table 4-4  Summary of themes from parents of young child cancer survivors 
of their child’s remembered dietary habits during their child’s cancer 
treatment. 
 
 Number of 
respondents  
( n=18) 
Quote 
Dietary habits 
Decreased fruit and 
vegetable intake 
13 “She was not interested in fruit, vegies, 
anything like that which…. it was 
certainly something I noticed because 
my toddler had always been a really 
good fruit and vegie eater…” (female;6 
years; neuroblastoma). 
 
Increased preference for 
carbohydrate-based 
foods 
11 “you know he would eat lots of crackers 
probably more than anything … maybe 
that was like the salt content” (4) 
 
Increased desire for “junk 
foods” 
18 “….definitely with the treatment of 
chemo, more carbs, more sugar, more 
salt.” (female; 11 yrs; ALL a). 
Increased preference for 
savoury foods 
18 “As long as it was savoury and it was 
crap, she would eat it…” (female;8yrs; 
Wilms’). 
Volumes of food 
Excess 
 
 
 
 
 
Inadequate 
8 
 
 
 
 
 
9 
“…[the patient] was put on to steroids. I 
couldn’t feed him enough.  He just 
wanted to eat anything and 
everything…  He would have a full meal; 
he would eat more than me and then 
say, “Can I have a pie now please?” 
(male; 13yrs;ALL). 
 
“I would say lack of eating, (the patient) 
couldn’t really stomach food” (male; 
12yrs; Wilm’s) 
Weight perception 
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Underweight 
 
 
 
Overweight 
11 
 
 
 
3 
“my husband was taking him down to 
the shower, and just looking at him from 
behind it was like, oh my God, he had 
no bum, no legs, there was nothing 
(male; 13yrs, ALL) 
 
“She ate a lot. Puffed up obviously with 
the steroids and gained a bit of weight” 
(female; 11yrs, ALL)  
Parent feeding practices 
Encourage any types of 
foods 
 
 
 
 
 
No food restrictions 
 
 
 
 
 
Forcing their child to eat 
18 
 
 
 
 
 
18 
 
 
 
 
 
5 
“We didn’t care as long as he ate. It 
didn’t matter if he wanted a cupcake for 
breakfast … and we would go and get 
him McDonalds, he wanted garlic bread 
one time when he woke up from an 
anaesthetic so we went and got him 
garlic bread” (male;10 yrs; lymphoma). 
 
“I mean as a mum it goes against 
everything that I would normally do for 
my child. As I say, I was pretty pedantic 
about what they ate and how I prepared 
their food and then all of a sudden I’m 
begging this child to eat absolutely 
anything just to be able to get 
something into him….” (male; 11 
yrs;Lymphoma). 
 
“I did not reward him but I actually 
begged him (to eat)”(male; 8yrs, 
neuroblastoma) 
a ALL: Acute Lymphoblsatic Leukemia 
 
4.3.4 Current dietary habits of CCS and controls  
4.3.4.1 Young child cancer patients 
When parents were questioned about their observations on CCSs’ nutritional habits 
after treatment compared with prior to the cancer diagnosis, three main themes 
emerged (Table 4-5): 1) Decreased fruit and vegetable intake; 2) Increased 
consumption of “junk food”; 3) Increased portion sizes. However, not every parent 
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interviewed reported concerns about their child’s excessive dietary intake, with 
some reporting that they were concerned that their child did not consume adequate 
portions of food. 
 There appeared to be a shift toward increased parental concern about their child’s 
weight, with parents reporting their child was gaining too much weight after 
treatment had been completed. The strategies parents used to encourage CCS to 
eat appeared to change once the cancer treatment had been completed. Many 
parents started restricting their child’s food intake and two parents continued to 
provide their child with unhealthy foods to ensure adequate intake. Parents also 
tended to use a larger variety of methods to encourage their child to eat than they 
did during cancer treatment.  
 
4.3.4.2 Controls 
A small number of parents of healthy children considered their child to be a fussy 
eater. The majority of parents believed that their child ate a sufficient amount of 
foods, while only a small number of parents expressed concerns that their child 
consumed excessive volumes of food. A smaller number of parents of healthy 
children compared with parents of CCS did report that their child did not consume 
adequate vegetables, though even these children appeared to eat some vegetables 
or salads.  The majority of parents of healthy children considered their child to be a 
healthy weight for their age and height.  
 
The feeding practices of parents of healthy children appeared to differ to those of 
CCS after treatment.  A smaller number of parents of healthy children felt the need 
to restrict food. The most common parenting practices used in this group to 
encourage their children to eat was providing education to their children on healthy 
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eating. None of the parents of the control children felt the need to provide 
“unhealthy” food as a way of ensuring that their child “ate something”. 
Table 4-5 Summary of themes from parents of young child cancer survivors 
compared with parents of healthy children regarding their child’s current 
dietary habits. 
 
 Young child cancer patients Healthy controls 
 
 Number of 
respondent
s  ( n=18) 
Quote Number of 
respondent
s           ( 
n=18) 
Quote 
Dietary habits   
Inadequate 
fruit and 
vegetable 
intake 
 
 
 
High intake of 
“junk foods” 
 
 
16 
 
 
 
 
 
18 
 
 
 
 
“….[he] won’t eat 
vegetables and fruit 
since coming off 
treatment 
…”(male;4 yrs; 
neuroblastoma). 
 
“she'd eat more junk 
food now if I allowed 
it, whereas before 
she would eat 
carrots and apples 
over lollies.” 
(female; 8 
yrs;Wilms’).    
 
6 
 
 
 
 
 
13 
“he is fussy 
with his 
vegetables...th
e main vegies 
he eats is 
carrots, bok 
choy and 
broccoli...” 
(male;6yrs). 
 
“[he} loves 
lollies; loves 
chips; loves 
cake and all 
that sort of 
stuff but we 
don’t not let 
him have it” 
(male; 11yrs) 
Volume of food 
Excessive 
 
 
 
 
 
 
Inadequate 
11 
 
 
 
 
 
 
5 
“there are days 
when she overeats, 
like she might go to 
someone’s house 
and they say, ‘God 
she eats a lot’.” 
(female;4yrs;ALL a). 
 
“Only eats salty carb 
foods so [her] 
mother has her on 
multi vitamins... she 
2 
 
 
 
 
 
 
2 
“I think he eats 
more than 
other kids his 
age” (male; 
11yrs) 
 
 
 
 
“She goes 
through 
phases.  Some 
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still doesn’t put on 
any weight.” 
(female;4 
yrs;Wilm’s). 
days she 
barely eats at 
all” (female; 
4yrs) 
Weight perception   
Underweight 
 
 
 
 
 
Overweight 
3 
 
 
 
 
 
7 
“…she’s quite tiny, 
she’s quite thin…I 
always look at her 
and think she’s 
small” (female; 5yrs, 
ALL) 
 
”we’ve spent half his 
life, most of his life, 
concerned with him 
not putting weight 
on and not eating 
and now we have 
gone the other way 
and he is actually a 
bit overweight for 
his age and size” 
(male;9 yrs; 
rhabdomyosarcoma
). 
0 
 
 
 
 
 
2 
 
 
 
 
 
 
“ …I think he’s 
too heavy and 
it’s all around 
his tummy” 
(male; 11yrs) 
Parent feeding practices   
Food 
restriction 
 
 
 
 
 
 
 
 
 
Bribery 
 
 
 
 
Pressuring  
their child to 
eat 
 
 
14 
 
 
 
 
 
 
 
 
 
6 
 
 
 
 
5 
 
 
 
 
 
I am probably quite 
strict because a lot 
of parents would 
think that that’s too 
controlling but I 
think I see the 
difference after 
treatment and it’s in 
order to help her  
(female; 11 yrs; 
ALL) 
 
‘If you eat it then I’ll 
let you watch TV.’ 
(male; 8yrs; 
neuroblastoma) 
 
 
“you know we sit 
there and make her 
eat one piece …. 
6 
 
 
 
 
 
 
 
 
 
5 
 
 
 
 
4 
 
 
 
 
 
“I think that 
one of the 
secrets is that 
you can't have 
too much junk 
in the house, 
because if it is 
in there, if 
you're not in 
the kitchen, 
then they are 
easily sneaking 
it you know...” 
(male;10 yrs)   
 
 
“We’ve bribed 
him; we’ve 
paid him; 
we’ve hidden 
them 
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Food as 
reward 
 
 
 
 
 
Concealing 
vegetables 
 
 
 
 
 
 
 
 
Positive 
encouragemen
t 
 
 
5 
 
 
 
 
 
5 
 
 
 
 
 
 
 
 
 
4 
that’s about the only 
way I can get her to 
do that (eat)” 
(female; 5yrs, 
Wilms’) 
 
 
“.. (we) try and bribe 
her so if she eats 
that she can have 
something else” 
(female; 5yrs, 
Wilms’) 
 
 
“…with spaghetti 
bolognaise I’ll put a 
lot of vegies in the 
bolognaise sauce … 
I’ll grate the zucchini 
and the carrot in 
there” (male; 5yrs, 
ALL) 
 
 
 
 
“..I acknowledge 
that I’m losing a 
degree of control, 
I’m trying to educate 
him about healthy 
foods … and 
making healthy 
choices himself” 
(male; 10yrs, ALL) 
 
 
 
1 
 
 
 
 
 
2 
 
 
 
 
 
 
 
 
 
7 
[vegetables]” 
(male; 11 yrs) 
 
“He doesn’t eat 
a great deal of 
fruit during the 
day, … at 
home I have to 
cut it up and 
put it in front of 
him and tell 
him to eat it to 
get fruit into 
him.” (male; 13 
yrs) 
 
“Before he can 
have dessert 
… he has got 
to eat his 
dinner” (male; 
10yrs) 
 
 
“Because she 
doesn’t try a lot 
of other 
vegetables … I 
put about six to 
seven 
vegetables in a 
very, very 
powerful food 
process, and I 
cook it in the 
mince and she 
won’t see it 
and she’ll eat 
it.” (female; 
4yrs) 
 
“We talk about 
what's good for 
you and what's 
not good for 
you and what's 
going to help 
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you grow and 
be strong and 
have energy.” 
(female; 4yrs) 
a ALL: Acute Lymphoblsatic Leukaemia 
4.4 Discussion 
 
This study revealed a parent-reported change in CCS dietary habits across the 
cancer journey. CCS may not return to their pre-diagnosis dietary habits once their 
treatment is completed, instead developing new eating habits. The three main 
themes that emerged from parental report of their CCS’s current eating habits were; 
1) Decreased fruit and vegetable intake; 2) Increased consumption of “junk food”; 3) 
Increased portion sizes. The majority of parents appeared less concerned with their 
child’s weight, dietary intake or dietary habits prior to the cancer diagnosis, but 
developed concerns about excess weight gain and poor eating habits after 
treatment completion. These results were in contrast to the control group, in which 
the majority of parents viewed their child to be a healthy weight, consuming 
reasonable volumes of food. Although one-third of control parents reported that they 
were not satisfied with their child’s vegetable consumption, this proportion was lower 
than the number of parents of CCS who were concerned about their child’s 
inadequate intake of vegetables.  
 
Reasons for this change in CCS dietary habits and intake are likely multi-factorial. 
Previous studies of cancer patients (both child and adult) suggest a role of learned 
food aversions influencing dietary habits (127, 209-211). Cancer patients experience 
significant side-effects such as nausea, vomiting, mucositis and diarrhoea (195, 
196) that can lead to anorexia, weight loss and malnutrition (14, 195, 196). There is 
an emphasis on preventing treatment-related weight loss during cancer therapy, 
especially in children, to maintain adequate growth and development (105, 122). 
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Parents of CCS reported changing their parenting styles regarding food during their 
child’s cancer treatment and allowed their child to eat “whatever they wanted”. One 
third of parents also reported pushing their child to eat as a way of preventing weight 
loss.  It may be that this emphasis on food and eating during the intensive cancer 
treatment may be a contributing factor to learned food aversions and a subsequent 
change in their dietary habits long term.  
 
Many parents appeared to allow and encourage the intake of “unhealthy” foods 
during their child’s treatment and reported that their child continues to consume 
these foods once treatment has been completed. Healthcare workers may also 
encourage parents to allow their child “eat whatever they want” during treatment, as 
a way of preventing weight  loss. Dietary habits, food preferences and oral skills are 
established at a young age and these habits, once established, are likely to be 
carried into adulthood (198-201). Young children also have an innate preference for 
energy dense foods and constant exposure to these types of foods at a young age 
can increase the desire for these foods through associative learning (200). Although 
parental reports indicated eating habits did improve after treatment, there was a 
consistent parental theme regarding their child’s strong, and ongoing, preference for 
“Junk food” and larger portions of these foods. As these patients are being treated at 
such an important time in the establishment of long term eating habits, not only the 
cancer therapy, but the foods they are exposed to during this time, may strongly 
influence their dietary habits at treatment completion.  
 
Repeated exposure to certain foods during childhood is also needed for long-term 
acceptance of foods. (198) Parental reports of the dietary habits of their children 
suggest a significant reduction in the preference for vegetables and other “healthy” 
foods. The majority of parents in this study allowed the consumption of unhealthy 
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foods during the cancer treatment as a way of getting their child to eat. If CCS has a 
reduced exposure to other (healthier) foods during their cancer treatment, this may 
influence their acceptance of these foods once treatment had been completed. 
 
4.4.1 Limitations and conclusions 
Although the study numbers were small, this qualitative study provides insight into 
parent-reported change in dietary habits of child cancer patients across the cancer 
journey. It appears that child cancer survivors may not re-establish pre-cancer 
dietary habits, once their cancer treatment has been completed. Limitations of this 
study include the control group not being matched for socio-economic status and the 
reliance on parent memory and recall.  This study does provide insight that the 
dietary habits of CCS may differ from that of the age-matched, non-oncology 
population.  This study provides evidence that future studies, to longitudinally 
explore childhood cancer patients’ dietary habits and food intake during and after 
cancer treatment are justified.  This study suggests that not attending to the 
development of health dietary habits during cancer therapy may have adverse long-
term effects. This may be more so for some diagnostic groups, such as ALL, for 
whom weight loss is not as common. Information about healthy dietary habits may 
need to be provided during cancer therapy, in particular during maintenance phase 
therapies, rather than waiting until treatment completion or long term follow-up. 
Information on the predictors, such as diagnosis, treatment type and use of nutrition 
support on the dietary habits of child cancer patients and survivors, is also needed 
to allow the development of appropriate dietary interventions. Future research may 
need to assess the influence of medical treatments on the dietary habits of children 
with other chronic diseases. 
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4.4.2 Implications 
This chapter provides evidence that the dietary habits of childhood cancer survivors 
are changing throughout the cancer journey. This chapter also shows that young 
childhood cancer survivors are not returning to the dietary habits that they had prior 
to their cancer diagnosis. Part 2 of the thesis will be exploring the hypothesis 
regarding the areas of concern for clinical practice, specifically related to actual 
feeding practices during and following treatment completion. In light of the evidence 
from both this thesis and the literature, regarding the poor dietary habits of survivors 
of childhood, it is important to determine whether nutritional interventions have been 
able to improve their nutritional intake. The next chapter is a systematic review of 
the literature, assessing the availability and efficacy of nutritional interventions in 
cancer survivors. 
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5 SYSTEMATIC REVIEW OF NUTITIONAL INTERVENTION IN CHILDHOOD 
CANCER SURVIVORS3 
Chapters 3 and 4 provided evidence that young cancer patients have a poor dietary 
intake and habits early after their cancer therapy is complete. The literature review 
(chapter 2) also revealed that the predominant studies on the nutritional 
management of childhood cancer patients focuses on the prevention of under 
nutrition. This chapter is a systematic review of the literature assessing the number 
and effectiveness of nutritional interventions for survivors of childhood cancer. This 
chapter has been accepted for publication as a Cochrane Review in the Cochrane 
Collaboration of Systematic Reviews. 
                                               
3
 This protocol for this systematic review has been published in the following peer review 
journal: 
Cohen J, Wakefield CE, Bartle J, Cohn RJ. Nutritional interventions in childhood cancer 
survivors. Cochrane Database of Systematic Reviews (Protocol). 2012. 
This chapter has been peer reviewed and accepted for publication in the following peer 
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Background 
5.1.1 Description of the condition 
In the last thirty years, detection and treatment methods for childhood cancer have 
improved to such an extent that up to 80% of paediatric patients now survive their 
cancer (48, 212). This has resulted in a growing number of child cancer survivors 
and an increased clinical and research interest in the survivorship issues as a 
consequence of treatment, in particular treatment-related morbidity and quality of life 
(212). Childhood cancer survivors have a relative risk of developing a chronic 
condition of 3.3 and a relative risk of a severe or life-threatening condition of 8.2 
when compared with their siblings (15). Female sex and older age at diagnosis are 
independent risk factors for developing chronic conditions (148). These chronic 
health conditions include (but are not limited to) secondary cancers, endocrine 
disorders, renal dysfunction and severe musculoskeletal problems (15, 154, 155, 
213). However, it may be many years before patient’s display these conditions 
which tend to worsen over time (15). 
 
There is now much focus in the literature on the importance of long-term monitoring 
of these patients (160, 214, 215) and increasing recognition of the need for both 
secondary and tertiary interventions that may lessen the burden of these chronic 
conditions (15, 216, 217). It may be possible to reduce the incidence of these 
chronic conditions with focused prevention strategies (15, 150) aiming for quality of 
life similar to peers (218). Specific chronic health conditions of long-term survivors 
that have the potential to be managed by lifestyle factors include osteoporosis, 
metabolic syndrome, endocrine disorders and cardiovascular disease (150). An 
individual's risk of these conditions varies depending on factors such as disease and 
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treatment type, age and sex. For example, survivors of acute lymphoblastic 
leukemia (ALL) who were treated with radiotherapy are at a greater risk of obesity, 
whereas those who received treatment for brain tumours are at risk of inadequate 
growth hormone (160). Those who received chemotherapy agents such as 
anthracycline are at risk of cardiovascular disease (219). 
 
5.1.2 Description of the intervention 
Despite the fact that health-promoting behaviour, such as consuming a healthy diet 
or maintaining adequate physical activity, could lessen the impact of these chronic 
issues (157), the prevalence of health-protecting behaviour in adults who have 
survived childhood cancer is similar to that of the general population (150, 158). 
There is a strong association in the general population between inadequate physical 
activity combined with a diet high in saturated fat and sugar and low in fruit and 
vegetable intake, and symptoms associated with the metabolic syndrome (220). 
This is of concern since many adult survivors of childhood cancer do not meet 
guidelines for fruit and vegetable intake, consume excessive fat and have an 
inadequate calcium intake (16, 17). These poor eating habits appear to be 
manifesting themselves early after treatment completion. Long-term survivors report 
barriers to consuming a healthy diet that include taste preferences for higher fat 
foods and the lack of availability of healthier foods (153). They may also be unaware 
of their risk of chronic disease (150), lessening the motivation to change their 
lifestyle. As childhood cancer survivors are already at a higher risk of long-term 
metabolic complications as a result of their cancer therapy, poor nutritional intake 
may be exacerbating this risk. 
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Interventions may need to be age-specific and differ between the older and younger 
childhood cancer survivor cohorts. Interventions may also need to target specific 
conditions and high risk groups or may target the general paediatric population. For 
example, childhood cancer survivors treated for ALL using cranial irradiation are at a 
higher risk for obesity and subsequently metabolic syndrome (221) and, therefore, 
they could be targeted with specific nutritional interventions to reduce obesity rates. 
In contrast, patients treated with anthracycline are at risk of cardiovascular sequelae 
(221) and, therefore, interventions may target not only weight reduction but also aim 
to reduce cardiovascular risk (222). Strategies to manage these chronic conditions 
may involve prevention interventions for younger cancer survivors or treatment 
interventions for older cancer survivors. Due to these variations in risk, a “one-size 
fits all” approach may not be indicated. 
 
5.1.3 How the intervention might work 
There is clear evidence that lifestyle changes, including improved diet and physical 
activity, are effective in the prevention or reduction of metabolic and cardiovascular 
risk factors in the general adult population (223). A range of nutritional interventions 
have been reported to be effective in preventing or reducing risk factors associated 
with the metabolic syndrome. These include: low glycaemic index/high protein diets, 
increased fruit, vegetable and fibre intake, reduced salt diets and a Mediterranean-
style diet (224, 225). A recent Cochrane review assessing nutritional interventions 
for reducing or preventing cardiovascular risk found that interventions were more 
likely to be effective in participants who were told of their higher risk of disease 
(225). 
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In the general paediatric population, little research has focused on the prevention of 
metabolic syndrome. Rather, there is a focus on prevention and treatment of 
childhood obesity. The literature suggests that family-targeted behavioural lifestyle 
interventions using a combination of nutrition, physical activity and behavioural 
components are effective for bringing about change in overweight children (226). 
There does not appear to be research focusing on the efficacy of specific types of 
nutritional interventions. As the mechanisms for the increased incidence of these 
chronic diseases may be different in the general population to the oncology 
population, the results and recommendations from these studies may not be able to 
be extrapolated to childhood cancer survivors. Interventions focusing on older and 
adult survivors of childhood cancer may not be appropriate for the younger 
survivors. 
 
5.1.4 Why is it important to do this review? 
As this is a new area of study, there are minimal data in the literature with regard to 
the most effective nutritional interventions available to reduce the incidence of 
chronic disease after childhood cancer, despite the ongoing focus on long-term 
follow-up of these patients. The purpose of this Cochrane review was to assess the 
literature regarding nutritional interventions developed for childhood cancer 
survivors, to facilitate the production of best-evidence management guidelines. 
 
5.1.5 Objectives 
To assess the efficacy of a range of interventions designed to improve the dietary 
intake of children who have completed treatment for cancer, as compared to a 
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control group of childhood cancer patients off treatment who did not receive the 
intervention. 
 
5.2 Criteria for considering studies for this review  
 
5.2.1 Types of studies  
All randomized controlled trials were included in this review. There was no limit to 
length of the intervention, type of intervention and length of follow-up. 
 
5.2.2 Types of participants  
Studies that involved childhood cancer survivors of any age, who were diagnosed 
with any type of cancer type when less than 18 years of age were eligible for the 
review. Participating childhood cancer survivors had completed their treatment with 
curative intent prior to the intervention. Studies including parents and/or carers of 
this participant group were also included if the parents/caregivers were involved in 
the intervention or reported on the participant outcomes. Treatment included 
chemotherapy and/or radiotherapy. Studies which included participants with a co-
morbidity that may have affected eating such as autism (227), developmental delay 
(228) and Down’s syndrome (229) were excluded. 
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5.2.3 Types of interventions  
5.2.3.1 Strategies  
Interventions that included educational and counselling strategies, health promotion 
or behavioural interventions with either individual or family-based interventions were 
included in this review. 
 
5.2.3.2 Topics 
Nutritional interventions involving cancer survivors with or without their family 
members were captured. Physical activity interventions for cancer survivors (230) 
and nutritional interventions for childhood cancer patients receiving active treatment 
(231) were excluded as these have been targeted by an alternate Cochrane 
reviews. 
 
5.2.3.3 Settings   
There was no restriction on the settings for the interventions. Settings may have 
included community, home-based or hospital-based interventions. 
 
5.2.3.4 Delivery  
All methods of delivery of the intervention were eligible, including face-to-face, 
telephone and online interventions. There were no restrictions regarding the 
interventionist. That is, eligible interventions were those that were delivered by 
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specialist and non-specialist medical and allied health professionals, as well as by 
other non-health professionals. 
 
5.2.3.5 Types of comparison 
We included studies which compared nutrition interventions to a non-intervention 
control group that received usual care or another intervention. 
 
5.2.4 Types of outcome measures  
We included studies that reported one or more of the following primary outcomes 
listed below. These outcomes needed to be assessed at baseline and at a minimum 
of one follow-up time point. 
 
5.2.4.1 Primary outcomes  
A change in nutritional intake which was measured by one or more of the following: 
1. Weighed food diaries; 
2. Self-reported food diaries; 
3. Single or multiple 24 hour recalls; 
4. Food frequency questionnaires. 
The nutrients may include but are not limited to: 
1. Energy; 
2. Protein; 
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3. Fat; 
4. Carbohydrate; 
5. Calcium; 
6. Iron; 
7. Folate; 
8. Vitamin(s); 
9. Mineral(s). 
 
5.2.4.2 Secondary outcomes  
1. Metabolic risk factors, i.e. glucose and insulin metabolism; 
2. Cardiovascular risk factors, i.e. resting blood pressure, blood lipids, and 
cholesterol; 
3. Measures of weight and body fat distribution, i.e. body mass index (BMI), 
Dual-energy X-ray Absorptiometry (DEXA) and weight/height percentiles; 
4. Behavioural change, i.e. changes in nutritional intake; 
5. Changes in knowledge regarding disease risk and nutritional intake; 
6. Participant views of the intervention; 
7. Measures of health-status and quality of life; 
8. Measures of harm associated with the process or outcomes of 
the intervention; 
9. Cost effectiveness of the intervention; 
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5.2.5 Search methods for identification of studies  
5.2.5.1 Electronic searches  
We searched the following electronic databases: the Cochrane Central Register of 
Controlled Trials (CENTRAL) (The Cochrane Library, Issue 3, 2013), 
MEDLINE/PubMed (from 1945 to April 6th, 2013) and EMBASE/Ovid (from 1980 to 
April 6th, 2013). The search strategies for the different electronic databases (using a 
combination of controlled vocabulary and text words) are shown in the appendices 
(Appendix 2, Appendix 3, Appendix 4). 
 
5.2.6 Searching other resources  
We located information about trials not registered in CENTRAL, MEDLINE/PubMED, 
EMBASE/OVID, either published or unpublished, by searching the reference lists of 
relevant articles and review articles. We hand searched the conference proceedings 
of the International Society for Paediatric Oncology (SIOP) (from 2008 to 2012) and 
The International Conference on Long-Term Complications of Treatment of Children 
and Adolescents for Cancer (2008-2012). We scanned the ISRCTN register and the 
register of the National Institute of Health (NIH) (http://www.controlled-trials.com) for 
ongoing trials at the first half of 2013. We did not impose language restrictions on 
the search. 
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5.2.7 Data collection and analysis  
5.2.7.1 Selection of studies  
Two review authors (JC, CW), worked independently, screening all the titles and 
abstracts resulting from the searches and excluded articles that were clearly 
irrelevant. Full text copies of all relevant articles were retrieved. Using the defined 
eligibility criteria, the two review authors determined their eligibility for inclusion. We 
resolved any disagreement between review authors on classification of an article 
between the review authors. Third party arbitration was not necessary. There was a 
need for clarification of detail of one trial. One of the review authors (JC) contacted 
the study authors from Rai 2008 (232), to obtain clarification for a complete 
assessment of the trial’s relevance for the review. The reasons for exclusion of any 
study considered for review are summarised in Table 5-1. 
Table 5-1 Characteristics of excluded studies 
 
Excluded study Reason for exclusion 
Hudson 1999 (233) This study described the study protocol 
and participant baseline data only. 
Hudson 2002 (234) The nutrition component of this study 
was described in another publication 
which has been included for assessment 
in this review. 
Mays 2012 (235) This was a validation study and did not 
include an intervention. 
Moyer-Mileur 2009 (236) 
 
The study included participants on 
maintenance therapy 
Nathan 2009 (150) This study contains a review of the 
literature and only reported on a smoking 
cessation intervention in childhood 
cancer survivors. 
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5.2.7.2 Data extraction and management  
Two review authors (JC and CW) independently extracted data, using a 
standardised form, from each article. For each trial, the following data was 
extracted: 
1. Characteristics of the studies including the study sponsors and the authors’ 
affiliations, study design, risk of bias items, duration of study, loss to follow-
up and compliance;  
2. Characteristics of study population including country where participants 
enrolled, inclusion and exclusion criteria, number randomised in each arm, 
information on the control group, demographic characteristics, type of 
cancer, age at diagnosis, cancer treatment, time since diagnosis, time 
beyond active treatment;  
3. Characteristics of the intervention including type of nutritional intervention, 
details of the intervention, frequency, duration, intensity, number of sessions, 
intervention format (i.e. individual or group, professionally led or not, home- 
or facility-based), description of control intervention, adherence and 
contaminations as well as co-interventions (i.e. physical activity, medication 
use);  
4. Characteristics of the outcomes as stated previously. 
We entered and combined the trial data using Review Manager 5.2. One review 
author entered the data into RevMan 5.2 (JC), and another review author worked 
independently to verify the data entry (CW). We resolved any disagreement 
between review authors on classification of an article between the review authors. 
Third party arbitration was not necessary. 
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5.2.7.3 Assessment of risk of bias in included studies  
Two independent reviewers (JC, CW) assessed the validity of each study using the 
risk of bias items. We reported the following criteria for each trial: adequate 
sequence generation and allocation concealment (selection bias), masking or 
blinding of personnel, participants and outcome assessors (performance or 
detection bias), incorporate incomplete data (attrition bias) and selective outcome 
reporting (reporting bias). Baseline imbalance (gender, ethnicity, diagnosis, age and 
health behaviour or nutritional intake) and differential diagnostic activity were also 
assessed as other potential sources of bias. 
 
We assessed and graded each trial’s risk of bias parameter as “adequate”, 
“inadequate”, or “unclear”. Trials with one or more unclear or inadequate risk of bias 
components were be considered to have a high risk of bias. We resolved any 
disagreement between review authors on classification of an article between the 
review authors. Third party arbitration was not necessary. 
 
The Grades of Recommendation, Assessment, Development and Evaluation 
(GRADE) system was used to rate the overall quality of evidence for each outcome 
by two independent reviewers (237, 238). The GRADE approach defines the quality 
of a body of evidence as “High”, “Moderate”, “Low” or “Very Low” (239). Factors that 
may have resulted in a decrease in the quality of evidence included: 1) risk of bias; 
2) inconsistency; 3) indirectness; 4) imprecision; and 5) publication bias. 
 
93 
 
5.2.7.4 Measures of treatment effect  
For continuous outcomes, the mean difference between groups was assessed. For 
dichotomous outcomes, a relative risk was assessed. 
 
5.2.7.5 Unit of analysis issues  
We aimed to include cluster-randomised, cross-over and repeated measures trials in 
this analysis, though none of the eligible studies used these methodologies. 
 
5.2.7.6 Dealing with missing data  
It was necessary to contact the authors of the Rai 2008 study (232), to gather further 
detail on the nutrition intervention. 
Intention-to-treat analysis was performed for all studies. 
 
5.2.7.7 Assessment of heterogeneity  
As none of the data was able to be pooled due to the different outcome measures 
and interventions between the trials, assessment of heterogeneity using the I2 
analysis was unable to be performed. 
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5.2.7.8 Assessment of reporting biases  
We had planned to assess reporting bias by constructing funnel plots. As there were 
less than 10 studies included in this review, the power of the tests was too low to 
distinguish chance from real asymmetry (239) so this was not able to be completed. 
 
5.2.8 Data synthesis  
The data of the included studies were entered into Review Manager 5.3 software. 
Data analysis was performed according to the Cochrane Handbook for Systematic 
Reviews of Interventions (239). As the data was not able to be combined in a meta-
analysis, we provided a narrative summary of the trial findings according to the 
review objectives. For data that was provided as medians and ranges, the mean 
difference was converted to mean and SD based on the methodology of Hozo 2005 
(240).  
 
5.2.9 Subgroup analysis and investigation of heterogeneity  
We had planned to perform subgroup analysis based on the following categories: 1) 
age at intervention (< 13 years; 13 to 18 years; > 18 years); 2) forms of intervention 
(face-to-face; phone etc.); 3) duration of intervention; 4) childhood cancer type; and 
5) type of treatment received. Due to insufficient trials, this was unable to occur. Due 
to lack of data in the included studies subgroup analyses were not possible 
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5.2.10 Sensitivity analysis  
As pooling of the results was not possible, we were unable to use sensitivity 
analyses to explore the impact of the inclusion of studies with a high risk of bias and 
studies with an unclear risk of bias.   
 
5.3 Results 
 
5.3.1 Results of the search  
A total of 3607 studies were identified from running the search through three 
electronic databases CENTRAL, MEDLINE/PubMED, EMBASE/OVID. An additional 
study was identified from searching the ongoing trial registries. No studies were 
identified upon screening reference lists of relevant articles and reviews. No studies 
were identified from the conference proceedings from The International Pediatric 
Oncology Society and The International Conference on Long-Term Complications of 
Treatment of Children and Adolescents for cancer. Initial screening of the title and 
abstracts of each study allowed the exclusion of 3599 publications. We obtained the 
full text articles of nine studies, of which three met the inclusion criteria. Five studies 
did not meet the inclusion criteria and one of the studies was classified as ongoing 
(Figure 5-1). 
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Figure 5-1 Study flow diagram 
5.3.2 Included studies  
Three studies were included in this review. All three studies were RCTs. For further 
details on the studies see Table 5-2 
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Table 5-2 Characteristics of included studies 
 
 Cox 2005 Mays 2011 
 
Rai 2008 
Methods Design: Parallel RCT 
Setting: Single-site paediatric 
oncology unit, USA 
 
Design: Parallel RCT 
Setting: Two site, Pediatric oncology 
units, USA 
Design: Parallel RCT 
Setting: Single site, paediatric 
oncology unit, USA 
Participants Number  
Intervention: n=131 (4 lost to follow-
up) 
Control: n=135 (1 lost to follow-up) 
Age at study entry 
Group:12-18 years 
Intervention (mean ± SD): 15.09 ± 
1.90 years 
Control (mean ± SD): 14.96 ± 1.97 
years 
Sex 
Number  
Intervention:38 
Control: 37 
No information on attrition was 
available. 
Age at study entry 
Group:11-21 years 
Intervention (mean ± SD): 14.2 ± 2.0 
years 
Control (mean ± SD): 14.2 ± 2.8 years 
Sex 
Number  
Intervention: n=141 (45 dropouts) 
Control: n=134 (49 dropouts) 
Age at study entry  
Intervention (mean; range): 16.6 
(9.4 35.3) years 
Control (mean; range): 17.2 (9.4 
33.5) years 
Sex 
Intervention: 78 males: 63 females 
Control: 78 males: 56 females 
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Intervention: 57 males: 74 females 
Control: 61 males: 74 females 
Diagnosis 
Leukaemia/Lymphoma 
Intervention: 73 
Control: 72 
Solid Tumour: 
Intervention: 58 
Control: 63 
Treatment 
Information not available 
Age at diagnosis 
Information not available 
Time since diagnosis 
Intervention (mean ± SD): 15.09(1.90) 
years 
Intervention: 17 males: 21 females 
Control: 19 males: 18 females 
Diagnosis 
Intervention: 21 Leukaemia: 17 others 
Control: 18 Leukaemia: 19 others 
Treatment 
Information not available 
Age at diagnosis 
Information not available 
Time since treatment completion 
Information not available 
Inclusion criteria 
1. Previously treated for any form 
of oncologic malignancy 
2. One or more years off treatment 
3. One or more years cancer-free 
4. Able to comprehend and speak 
English 
Diagnosis 
ALL 
Treatment 
Radiation  
Intervention:53 
Control:34 
Chemotherapy 
Intervention: 141 
Control:134 
Age at diagnosis 
Intervention (mean; range): 4.7 
(0.7; 17.4) years 
Control (mean: range): 4.6 (1.0; 
16.39) years 
Time since treatment completion 
Intervention (mean ; range): 7.1 
(5.0 18.2) years 
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Control (mean ± SD): 10.31 (2.94) 
Inclusion criteria 
1. 12-18 years 
2. In remission 2+ years from 
completion of therapy 
3. Adequate cognitive functioning 
4. English as a primary language 
Exclusion criteria 
1. Not U.S. residents 
2. English not their primary 
language 
 
Exclusion criteria 
1. Suffering from renal 
insufficiency or end stage renal 
disease 
2. Currently taking a thiazide 
diuretic 
3. Suffering from a pervasive 
developmental or other major 
psychiatric disorder precluding 
valid informed consent 
Control (mean ; range): 7.2 (4.6 
19.1) years 
Inclusion criteria 
1. Treated on St Judes 
Children's Research 
Hospitals total XI, XII or XIII 
treatment protocol 
2. At least five years from 
completion of cancer 
therapy 
3. In first remission 
Exclusion criteria 
1. Active disease 
2. Pregnant or lactating 
females 
3. Inability to chew or swallow 
pills 
4. Currently consuming more 
than 800mg of 
supplemental calcium or 
800IU of Vitamin D 
5. Anaemia 
Interventions Intervention 
The intervention consisted of standard 
Intervention 
The intervention consisted of a single 
Intervention 
This study was a 24 month nutrition 
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care plus a single multi-behavioural 
intervention provided by a clinical 
physician or nurse practitioner during 
a routine visit to the long-term follow-
up clinic. The multi-behavioural 
intervention consisted of: 
1. Discussion of after therapy 
clinical summary 
2. Health behaviour training of 
health goal 
3. Health goal commitment to 
practice 
Telephone reinforcement of the 
education was provided at 3 and 6 
months after their initial clinic visit 
Co-interventions: 
Other health behavior practices were 
targeted during the intervention. 
These included; smoking cessation, 
sun protection and exercise. 
Contraindications: 
None 
 
half-day, group workshop in addition to 
standard care. The workshop was given 
by a registered dietitian. The workshop 
included an interactive behavioural 
session and focused on risk reducing 
health promotion behaviours. The 
workshop had a focus on bone health. 
Co-interventions: 
None 
Contraindications: 
None 
Control group 
The control group received standard 
care and were offered the intervention 
at the conclusion of the study. 
and supplementation intervention. 
The intervention group received 
nutrition education sessions every 
6 months. At baseline and 12 
months these were given face-to-
face by a registered dietitian, and 
at 6 months and 18 months these 
were given in the form of mailed 
information. The education 
included information such as: 
1. Number of serves of dairy 
products 
2. Serve sizes of dairy foods 
3. Healthy diet 
The intervention group was also be 
given 24 months of calcium and 
vitamin D supplementation which 
were taken daily 
Co-interventions: 
None 
Contraindications: 
None 
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Control Group 
Standard care consists of: 
1. Breast or testicular self-
examination 
2. Targeted late-effects screening 
3. Clinical assessment 
4. Late effects risk counselling 
 
Control group 
The control group received 
education sessions identical to the 
intervention group. They also 
received placebo tablets instead of 
calcium and vitamin D 
supplements. 
Outcomes The outcomes were measured at 
baseline and 12 months post-
intervention for both the intervention 
and control groups. 
Outcome measure: Behavioural 
change 
1) Frequency of nutrition as a health 
protective behaviour 
2) Frequency of junk food 
consumption as a health risk 
behaviour 
 
The outcomes were measured at 
baseline and 1month post-intervention 
for both the intervention and control 
groups. These outcomes were: 
Outcome measure: Change in 
nutritional intake: 
1) Dietary calcium intake measured 
with 24-h recall 
Outcome measure: Behavior change: 
1) milk consumption frequency 
2) Use of calcium supplementation 
The outcomes were measured at 
baseline, 12 months, 24 months 
and 36 months post-intervention for 
both the intervention and control 
groups. 
Outcome measure: Body 
composition 
1) Bone mineral density 
Notes Study Sponsors 
Oncology Nursing Society Foundation 
Study Sponsors 
Study Sponsors 
National Institutes of Health; Grant 
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(2003-2005) 
American Lebanese Syrian 
Associated Charities (ALSAC) 
 
American Cancer Society 
Lance Armstrong Foundation 
National Cancer Institute (CA091831) 
number: P30 CA-21765 
Centre of Excellence grant from the 
State of Tennessee 
Le Bonheur Foundation (Memphis 
TN) 
American Lebanese Syrian 
Associated Charities (ALSAC) 
NIH; Grant numbers: R21 
HD059292; GM 92666 Grant 
sponsor 
Gabrielle’s Angel Foundation 
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5.3.3 Participants 
A total of 616 participants from the three studies were included in the analysis. One 
of the studies included participants who had been treated for ALL (232). Cox 2005 
and Mays 2011 included participants with all forms of paediatric cancer (212, 241). 
The number of participants in each study varied. The smallest study included a total 
of 38 participants in the intervention and 37 in the control group (241). It was unclear 
whether any participants were lost to follow-up. Cox 2005 study included a total of 
266 participants (131 in the intervention and 135 in the control group) (212). Four 
and one participants respectively were lost to follow-up. The largest study included a 
total of 275 participants (141 in the intervention and 134 in the control group) (232). 
Ninety-four participants (45 in the intervention and 49 in the control group) did not 
complete the study. 
 
The ages of the participants varied among the three studies. Two studies recruited 
adolescent childhood cancer survivors [ages 11-21 years (241) and 12-18 years 
(212)]. The third study included childhood cancer survivors of all ages up to 18 years 
(232). None of the included studies had participants older than 21 years at study 
entry. 
 
5.3.4 Intervention 
The timing of the interventions after the childhood cancer therapy varied among the 
studies. Cox 2005 and Mays 2012 included participants within two years of 
diagnosis (212, 241) and Rai 2008 included participants who were more than five 
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years since therapy completion (232). The intervention and timing also varied 
among the three studies included in this analysis. Two of the studies included 
interventions that consisted of an initial, single, face-to-face health education 
session focusing on health behaviour change (212, 241). One of these studies 
focused on general health behaviours such as reducing junk food intake(212). The 
individual education session was provided by a clinician or nurse practitioner during 
a routine visit to the hospital. These participants were giving education 
reinforcement, via the telephone, at three and six months after the intervention. The 
other intervention focused on bone health, calcium and dairy intake and the final 
assessment was done one month after the intervention (241). The education 
session was provided in a group setting by a registered Dietitian. 
 
The final study (Rai 2008) (232) had a 36 month follow-up, with the focus of the 
intervention being on bone health. The intervention consisted of calcium and vitamin 
D supplementation. Nutrition education was provided at baseline and every 6 
months for 24 months. At baseline and 12 months post baseline, the education was 
given face-to-face by a registered dietitian. At 6 months and 18 months the nutrition 
education was in the form of mailed information. For further information on these 
studies, see Table 5-2. 
 
The study of Cox 2005 also included a co-intervention of changing the health 
behaviour practices of smoking cessation, sun protection and exercise (212). This 
study did not have any contraindications. The studies of Mays 2011 and Rai 2008 
(232) did not include any co-interventions or contraindications (232, 241). 
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5.3.5 Control 
Of the three studies included in this review, the control groups of two of those 
studies received standard care (212, 241). The standard care between these groups 
did vary. The standard care of the control group for the study of Cox 2005 included 
late-effects screening and education on their risk factors which was provided during 
routine clinic visits (212). The standard care of the control group for  Mays 2011 was 
no education on nutrition related risk factors (241). The control group of the final 
study received an identical nutrition education component as the intervention group 
in combination with placebo tablets (232).  
 
5.3.6 Outcomes 
The primary outcomes of the studies in this review were dietary/nutrient intake. The 
secondary outcomes measured by the included studies were body composition 
(BMD) and health behaviours. The control group measurements were assessed at 
the same time points as the intervention groups for all three of the studies. The time 
points for the outcome measures, differed between the studies. The study of Mays 
2011 measured their outcomes (milk consumption frequency, calcium 
supplementation, dietary calcium intake) at baseline and one-month post 
intervention (241). The study of Cox 2005 measured their outcomes (frequency of 
nutrition as a health protective behaviour; frequency of junk food consumption as a 
health risk behaviour) at baseline and 12 months post-intervention (212). The final 
study of Rai 2008 measured their outcomes (bone mineral density) at baseline, 12 
months, 24 months and 36 months post intervention (232). 
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The other secondary outcomes were not addressed in any of the three included 
studies. These secondary outcomes were: metabolic risk factors, cardiovascular risk 
factors, changes in knowledge, participant views of the intervention, health status 
and QoL, measures of harm or cost effectiveness of the intervention. All three 
studies had different methodology and different outcomes being measured and for 
this reason the data was unable to be pooled.  
 
5.3.7 Excluded studies  
The full text publications of five studies were analysed but were subsequently 
excluded. Three of the studies (Hudson 1999; Hudson 2002; Mays 2012) described 
the study protocol and provided results from other components of the study. The 
study data relating to the aims for this review were reported in other articles which 
were included in this review (212, 241). The fourth study (Nathan 2009) contained a 
review of the literature and the results of a smoking cessation intervention and was 
subsequently excluded from the review. The final study (Moyer-Mileur 2009) 
included participants on maintenance therapy and had not completed their cancer 
therapy. For information on the excluded studies see Table 5-1. 
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5.3.8 Risk of bias in included studies  
See Table 5-3 and Figure 5-2 and Figure 5-3 for detailed information on the risk of bias assessment. 
Table 5-3 Risk of bias in included studies 
 
 Cox 2005 Mays 2011 
 
Rai 2008 
 Risk Reason for judgement Risk Reason for judgement Risk Reason for judgement 
Random sequence 
generation 
(selection bias) 
 
Low risk Quote: "The randomisation 
was stratified by gender and 
age because of the clinical 
impression that risk 
perception could carry by 
gender or age". 
 
Unclear 
risk 
Comment: The paper 
states that the 
participants were 
randomly allocated but 
no further information 
on the methodology 
was provided. 
Low risk 
Comment: The 
participants were 
stratified when 
randomised into sex, 
race, age and BMD z-
score. 
Allocation 
concealment 
(selection bias) 
Unclear 
risk 
Comment: Although 
randomisation was 
performed using the 
procedure as set out by 
Zelen 1974,(242) it was 
unclear which actual 
randomisation technique 
Unclear 
risk 
Comment: There was 
no information 
provided on participant 
attrition. 
Low risk Quote: "Only the St 
Jude pharmacy had 
access to the 
randomisation system, 
which is maintained by 
the Department of 
Biostatistics at St Jude". 
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was used. 
 
Incomplete 
outcome data 
(attrition bias) 
Unclear 
risk 
Comment: The study 
reported that five 
participants (four in the 
intervention group and one 
in the control group) were 
lost to follow-up. There was 
no discussion on how this 
data was handled. We were 
unable to assess how this 
would influence the outcome 
or whether this would have a 
clinically relevant effect. 
 
Unclear 
risk 
Comment: This study 
reported data at 
baseline and follow-up 
on all outcomes cited 
in the protocol or 
methodology section 
Unclear 
risk 
Comment: There were 
a large number of 
dropouts in both the 
intervention (n=45) and 
control groups (n=49). It 
is unclear how this data 
was treated. 
Selective reporting 
(reporting bias) 
High risk Comment: This study 
presented a secondary 
analysis of data. This 
analysis was not in the 
original publication of the 
results. 
 
Low risk Comment: 
Minimal baseline 
imbalance: At 
baseline, there was no 
significant difference 
between the 
intervention and the 
control group for 
demographic and 
other reported 
characteristics. 
High risk 
Comment: This study 
did not publish all 
outcomes that were 
reported on the clinical 
trials registry 
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No differential 
diagnostic activity: All 
assessments were 
performed at baseline 
and follow-up for both 
the intervention and 
the control group. 
Other bias Low risk Comment: 
Minimal baseline imbalance: 
At baseline, there was no 
significant difference 
between the intervention 
and the control group for 
demographic and other 
reported characteristics. 
No differential diagnostic 
activity: All assessments 
were performed at baseline 
and follow-up for both the 
intervention and the control 
group. 
 
Low  risk 
Comments: This study 
does not discuss 
whether participants or 
personnel were 
blinded. Due to the 
nature of the study 
and the form of the 
intervention, it would 
be impossible for the 
participants and 
personnel to be 
blinded. 
Low risk 
Minimal baseline 
imbalance: At baseline, 
there was no significant 
difference between the 
intervention and the 
control group for 
demographic and other 
reported characteristics. 
No differential 
diagnostic activity: All 
assessments were 
performed at baseline 
and follow-up for both 
the intervention and the 
control group. 
Blinding of 
participants and 
personnel 
(performance bias) 
High risk Comment: This study does 
not discuss whether 
participants or personnel 
were blinded. Due to the 
nature of the study and the 
High risk Quote: "All telephone 
interviews were 
administered by a 
trained research 
assistant who was 
Low risk 
Comment: Both the 
participants and the 
research personnel 
were blinded. 
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form of the intervention, it 
would be impossible for the 
participants and personnel 
to be blinded. 
 
masked to the trial 
condition". 
Blinding of outcome 
assessment 
(detection bias) 
High risk Comment: The outcome is 
subjective (a self-reported 
outcome) and the 
participants are not blinded. 
 
Low risk Comment: The paper 
states that the 
participants were 
randomly allocated but 
no further information 
on the methodology 
was provided. 
Low  risk 
Comment: Both the 
participants and the 
research personnel 
were blinded. 
 
111 
 
 
Figure 5-2 Risk of bias summary: review authors' judgements about each risk 
of bias item for each included study 
 
 
Figure 5-3 Risk of bias graph: review authors' judgements about each risk of 
bias item presented as percentages across all included studies 
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5.3.9 Allocation (selection bias)  
Two of the studies (Cox 2005; Rai 2008) described an adequate random sequence 
generation and were assessed as low risk (212, 232). In the study by Rai 2008, the 
randomisation was completed by the pharmacy after participants had been stratified 
into sex, race, age and BMD (232). The study of Cox 2005 used a randomisation 
procedure that was stratified by gender and age (212). The final study was 
assessed as “unclear” in the use of random sequence generation (241). Mays 2011 
reported that the participants were randomised, but no further information was 
provided on the procedure (241). Two of the studies were assessed as having an 
unclear allocation concealment as there was no mention of the procedures used in 
the study methodologies (212, 241). The study of Cox 2005 referred to the 
methodology used by another author, though the methods used were still not clear 
(212). The study of Rai 2008 used a well described randomisation procedure and 
was assessed as having a low risk of allocation concealment (232). 
 
5.3.10 Performance bias  
Due to the nature of the interventions, blinding of the personnel or the participants 
was impossible with two of the three studies (Cox 2005; Mays 2011) assessed as 
having a high risk of performance bias (212, 241). In the final study (Rai 2008), the 
participants and the personnel were blinded to the intervention as participants were 
given a vitamin supplement or a placebo (232). This study was assessed at having a 
low risk of performance bias. 
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5.3.11 Detection Bias 
Although personnel cannot be blinded when delivering nutrition interventions such 
as these, it is possible for detection bias to be minimized by blinding the outcome 
assessment. One study (Cox 2005) did not provide any information regarding 
blinding of the outcome assessment but the outcome was subjective (a self-reported 
outcome) and therefore the blinding of the outcome assessment was assessed as 
high risk (212). In the remaining two studies (Cox 2005; Rai 2008), detection bias 
was assessed as low risk because the assessors were blinded to the study groups 
(212, 232). 
 
5.3.12 Incomplete outcome data (attrition bias)  
Two of the three studies reported drop-outs during the study (Cox 2005; Rai 2008) 
(212, 232). No further information was provided on how the missing data was 
handled and the studies were assessed as having an unclear risk of attrition bias. 
Although the fourth study had a short follow-up time of one month and was less 
likely to have drop-outs, no information was provided on study attrition. This study 
was assessed as having an unclear risk. 
 
5.3.13 Selective reporting (reporting bias)  
The study of Mays, 2011 was the only study to be assessed as having a low risk of 
reporting bias (241). This study reported data at baseline and follow-up on all 
outcomes cited in the protocol or methodology section. Cox 2005 presented the 
results of a secondary analysis, not mentioned in the original protocol. Hudson 2002 
and Rai 2008 did not publish all outcomes that were reported on the clinical trials 
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registry (232, 234). These two studies were assessed to be at high risk of reporting 
bias. 
 
5.3.14 Other potential sources of bias  
All studies were assessed for baseline imbalances and differential diagnostic activity 
as other potential sources of bias. In regards to baseline imbalances, there was no 
significant difference between the baseline data between the intervention and the 
control group for all studies (212, 232, 241). All three studies were assessed at 
being low risk.  
 
All three studies were classified as a low risk of differential diagnostic activity 
because the studies performed the same assessments in the intervention and the 
control group at all time-points (212, 232, 241). 
 
5.3.15 Effects of interventions  
The three studies included in this review focused on different outcomes. We were 
unable to pool the data and the findings reported were from individual studies only. 
 
5.3.16 Change in nutritional intake 
Calcium intake was the only nutrient that was assessed across any of the studies 
(241). Use of a single, group-based behaviour change intervention showed no 
statistically significant difference in the calcium intake (as measured by a 24-hour 
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recall) between the intervention (n= 38) and control group (n=37) at the one month 
follow-up (MD 111.60; 95% CI -258.97 to 482.17; P value = 0.56) (Figure 5-4) (241). 
As analysed by Mays 2011, after regression analysis, adjusting for baseline calcium 
intake and changes in knowledge and self- efficacy, there was a significantly greater 
calcium intake for the intervention as compared with the control group at the one 
month follow-up (Beta coefficient= 4.92; 95% CI 0.33 to 9.52; P value = 0.04) (241). 
 
Figure 5-4 Forest plot of change in nutritional intake (calcium)  
5.3.17 Body Composition  
Body composition was used as an outcome measure in one study (Rai 2008) (232). 
The data was provided as medians and ranges. This data was converted to mean 
and SD based on the methodology of Hozo 2005 (240). There was no statistically 
significant difference in bone mineral density (measured with a DEXA scan) at the 
36 month follow-up (MD -0.05; 95% CI -0.26 to 0.16; P value = 0.64) (Rai 2008) 
(Figure 5-5) between those who received the calcium and vitamin D 
supplementation in conjunction with nutrition education (n=141) and those 
participants who received nutrition education alone (n=134) (232). There was no 
statistically significant difference in bone mineral density between the intervention 
and the control group at the 12 month (median difference -0.17: P value 0.99) and 
24 month follow up (median difference -0.04: P value 0.54). 
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Figure 5-5  Forest plot of change in body composition (bone mineral density) 
 
5.3.18 Behavioural Change  
The behaviour change outcome was assessed in two studies. In the first study, 
health behaviour change was measured using single questions on a four-point Likert 
scale (212). The participants were asked how often they practiced health practicing 
behaviours and rated this from 1=never to 4=always. A single, face-to-face, multi-
component health behaviour change intervention with two telephone follow-ups 
brought about no statistically significant difference in the use of nutrition as a health 
protective behaviour (n=131) compared with those who received standard care (n= 
135) (MD -0.05; 95% CI -0.24 to 0.14; P value = 0.60) (Figure 5-6) (212).  
 
Figure 5-6 Forest plot of behaviour change (nutrition) 
The same intervention brought about a statistically significant reduction in self-
reported junk food intake (measured on a four-point likert scale: 1= never to 4= 
always) in the intervention (n=131) compared with the control group (n= 135) (MD -
0.17; 95% CI 0.33 to -0.01; P value= 0.04) (Figure 5-7). 
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Figure 5-7 Forest plot of behaviour change (junk food) 
A single, face-to-face, group health behaviour session focusing on bone health 
brought about a statistically significant increase in the intervention group’s self-
reported milk consumption (measured in number of days) (MD 0.43; 95% CI 0.07 to 
0.79; P value = 0.02) (Figure 5-8) as compared with those who received standard 
care (241).  
 
Figure 5-8  Forest plot of behaviour change (milk consumption) 
The intervention was also effective in increasing the participants days on calcium 
supplementation (MD 11.42; 95% CI 7.11 to 15.73; P value <0.00001) (Figure 5.9) 
(241).  
 
Figure 5-9 Forest plot of behaviour change (days on calcium supplementation) 
There was a statistically significant increase in calcium supplementation in the group 
that received the education sessions compared with those who received standard 
care (RR 3.35; 95% CI 1.86 to 6.04; P value < 0.0001) (Figure 5-10). A total of 31 
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participants took some form of calcium supplementation after the intervention and 
nine participants took some form of calcium supplementation in the standard care 
group. 
 
Figure 5-10 Forest plot of behaviour change (any calcium supplementation) 
 
5.4 Discussion 
 
5.4.1 Summary of main results  
Childhood cancer survivors are at higher risk of health conditions such as 
osteoporosis, metabolic syndrome, endocrine disorders and cardiovascular disease 
than their peers (150). Targeted nutritional interventions may prevent (216, 217) or 
reduce (15, 150) the incidence of these chronic diseases. This systematic review 
included three studies (212, 232, 241) that have studied the efficacy of a nutritional 
intervention, in a randomised manner, in childhood cancer survivors. These studies 
utilised differing methodologies, and as a consequence, pooling of the results did 
not occur. 
 
The interventions that appeared to bring about a significant positive change were 
those that focused on health behaviour change. A single, group health behaviour 
education session significantly increased self-reported milk intake (MD 0.43; 95% CI 
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0.07 to 0.79; P value = 0.02), use of calcium supplementation (RR 3.35; 95% CI 
1.86 to 6.04; P value < 0.0001) and the number of days on calcium supplementation 
(MD 11.42; 95% CI 7.11 to 15.73; P value <0.00001) as compared with standard 
care (241). The intervention did not improve calcium intake (MD 111.60; 95% CI -
258.97 to 482.17; P value = 0.56), though a regression analysis, adjusting for 
baseline calcium intake and changes in knowledge and self- efficacy, found a 
significantly greater calcium intake for the intervention as compared with the control 
group at the one month follow-up (Beta coefficient= 4.92; 95% CI 0.33 to 9.52; P 
value = 0.04).This study had a short follow-up time of one month and the effect of 
the intervention long term was not assessed. 
 
A face-to-face, multi-component health behaviour session with two telephone follow-
ups with education reinforcement, over a 12 month period, reduced self-reported 
junk food intake (MD -0.17; 95% CI -0.33 to -0.01; P value= 0.04) but did not 
improve childhood cancer survivors’ use of nutrition as a health-protecting behaviour 
(MD -0.05; 95% CI -0.24 to 0.14; P value = 0.60) (Cox 2005) as compared with 
standard care. 
 
The study of Rai 2008 was the only study to assess the efficacy of nutritional 
supplementation on childhood cancer survivors’ body composition. This study was a 
randomised, double-blind RCT of calcium and vitamin D supplementation versus 
placebo. Both the intervention and control group received nutrition education by a 
registered Dietitian. There was no statistically significant difference on bone mineral 
density as measured by DEXA between the intervention and the control group at the 
36 month follow-up (MD -0.05; 95% CI -0.26 to 0.16; P value = 0.64). There was 
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also no statistically significant difference in bone mineral density between the 
intervention and the control group at the 12 month (median difference -0.17: P value 
0.99) and 24 month follow up (median difference -0.04: P value 0.54). 
5.4.2 Overall completeness and applicability of evidence  
This review does not provide evidence that the nutritional interventions used in 
these studies improved dietary intake or body composition in childhood cancer 
survivors. The study of Mays 2011, was the only included study that assessed the 
primary outcome of a change in nutritional intake (241). Mays 2011 found no 
statistically significant improvement in calcium intake with a single, group, education 
session (241). A regression analysis, adjusting for baseline calcium intake and 
changes in knowledge and self- efficacy, found a significantly greater calcium intake 
for the intervention as compared with the control group at the one month follow-up 
(241). The study had a short follow-up time of one month and long-term compliance 
with the nutritional changes were not assessed. There was a modest, positive effect 
for health behaviour change interventions on improving self-reported health 
behaviours such as junk food consumption (212), and milk intake (241). Although no 
statistically significant differences were found for many of the outcomes this could 
be the result of low power in the studies. It should be noted that no evidence of 
effect is not the same as evidence of no effect. 
 
The following outcomes were not assessed in any of the included studies: metabolic 
and cardiovascular markers, changes in knowledge, and participant views of the 
intervention, health status and QoL, measures of harm or the cost effectiveness of 
the intervention. 
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The two studies that did show a positive change in health behaviours may not be 
applicable in all settings. The intervention required an initial face-to-face information 
session. This type of intervention may not be possible for survivors of childhood 
cancer who come from geographically diverse regions who may not travel to the 
primary care centre for long-term follow-up. An efficacy of interventions utilising 
computer and other technologies may need to be assessed.  
 
Many of this systematic review’s predetermined outcomes (e.g. metabolic risk 
factors, cardiovascular risk factors, changes in knowledge, and measures of harm) 
were not assessed in the included studies. Only one of the studies assessed the 
primary outcome of dietary intake. Although two of the interventions found a 
significant positive change in health behaviours, there is no evidence to suggest that 
this translates to the prevention of risk factors such as cardiovascular disease, 
metabolic syndrome or obesity. Future interventions should consider assessing 
outcomes such as body composition and blood lipids in combination with dietary 
intake and changes in health behaviours. 
 
All three of the captured studies were from paediatric oncology units in the USA. 
The findings therefore may not be generalisable to childhood cancer survivors from 
other countries, especially low income countries. 
 
5.4.3 Quality of the evidence  
By applying the GRADE criteria (237, 238), the quality of findings varied between 
moderate (bone mineral density) and low (all other outcomes). All outcomes were 
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downgraded one level for imprecision. Due to a lack of blinding of participants, 
personnel and outcome assessors, the quality of evidence for the outcomes “.self-
reported nutrition) and “junk food” was further downgraded. Due to lack of details 
regarding the randomisation procedure and lack of blinding of participants and 
personnel, the outcomes “calcium intake”, “milk consumption” and “calcium 
consumption” were downgraded to low quality. The study of Cox 2005  had a high 
risk of reporting bias (results were from a secondary analysis) and performance bias 
(inadequate blinding of the personnel) (212). The study of Cox 2005 had an unclear 
selection bias, attrition bias and detection bias and results from this study therefore 
need to be interpreted with caution (212). 
 
The study of Rai 2008 was the only study to be assessed as having a low risk of 
performance bias as both the participants and personnel were blinded (232); Mays 
2011 had a high risk of performance bias (241). Although it is difficult to blind 
participants to the intervention due to the nature of many nutritional trials, two 
studies blinded the assessors (232, 241). Adequate allocation concealment would 
be possible for all nutritional intervention trials, though the study of Rai 2008 was the 
only study to be assessed as a low risk of selection bias (232); Mays 2011 had an 
unclear risk (241). The studies of Mays 2011 and Rai 2008 had a low risk of 
reporting bias (232, 241). All three studies were assessed as unclear in their attrition 
bias. All three studies were assessed as having a low risk of other bias (212, 232, 
241). The studies had minimal baseline imbalance and no differential diagnostic 
activity. 
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5.4.4 Potential biases in the review process  
The search strategies for the electronic databases (CENTRAl, MEDLINE/PubMED, 
EMBASE/OVID) were developed in collaboration with the Cochrane Childhood 
Cancer Group. Additional searching was done of clinical trials databases, reference 
lists and proceedings from conferences. Although it is always possible to miss 
studies, an earlier published review did not identify any different additional 
interventions prior to 2010 (217). 
 
5.4.5 Agreements and disagreements with other studies or reviews  
Only one other review paper was identified in the literature systematically reviewing 
diet (and exercise) in childhood cancer survivors (217). This review included studies 
that focused on diet in childhood cancer survivors, though the majority of these were 
observational studies and unable to be included in the current review. They 
identified one nutritional intervention in childhood cancer survivors which was also 
included in our review (212) but did not identify any other type of interventional 
studies. Stolley  2010 concluded that the literature on the dietary intake of childhood 
cancer survivors is methodologically weak (217). There were very limited 
intervention studies and use of control groups in the observational studies was rare. 
Stolley  2010, highlights the minimal use of validated methods of dietary assessment 
(217). Since the paper by Stolley  2010 was published, there are an increased 
number of intervention trials (three) which were included in this review though the 
use of validated dietary methods remains poor (217). 
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5.5 Authors' conclusions  
 
5.5.1 Implications for practice  
Due to the heterogeneity of the studies included in this review, the authors are 
unable to draw conclusions regarding the effectiveness of nutritional interventions 
for childhood cancer survivors. Although there is weak evidence for the 
improvement in health-behaviours using health behaviour change interventions, 
there remains no evidence as to whether this translates into an improvement in 
dietary intake. It is important to note that ‘no evidence of effect’ is not the same as 
‘evidence of no effect’. Many outcomes were not assessed in the included studies. 
There remains no evidence that there is a subsequent reduction in the risk of 
cardiovascular and metabolic disorders in childhood cancer survivors from the 
interventions. 
 
5.5.2 Acknowledgements  
The authors would like to thank the Cochrane Childhood Cancer Group for their 
support with the development of this protocol, in particular Edith Leclercq for help 
with development of the search strategy and running of the search strategies in the 
different databases. The authors would also like to thank Susan Kaste for providing 
additional data for the study of Rai 2008 and Jodie Bartle for input into the initial 
protocol. The editorial base of the Cochrane Childhood Cancer Group is funded by 
Stichting Kinderen Kankervrij (KiKa). 
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5.5.3 Implications   
This review highlights the need for further intervention trials to be implemented in 
survivors of childhood cancer. Chapters 2 and 3 found that poor dietary habits are 
manifesting early after treatment completion. Nutritional interventions are more likely 
to be effective if they are implemented early after treatment completion. The use of a 
randomised design with a blinding of personnel to the outcome measures is possible 
with this type of nutritional intervention and is recommended in future studies. It is 
also suggested that future studies utilise validated measures of dietary intake. 
Objective measures of body composition, cardiovascular and metabolic risk should 
also be included as outcome measures in these studies. The next chapter will focus 
on the nutritional management of paediatric cancer patients during cancer therapy. 
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6 ENTERAL NUTRITION IN PAEDIATRIC ONCOLOGY: A MULTIPERSPECTIVE 
STUDY4 
Chapters 3 and chapter 4 provided evidence that poor dietary intake seen in adult 
survivors of childhood cancer, is manifesting itself early after treatment completion. 
It also appears that these dietary habits are occurring during the treatment. Section 
2.4.2. of the literature review discussed recent work at our center regarding the 
feeding practices used by parents to encourage a child to eat during cancer therapy. 
These practices were predominantly negative. The literature review also indicated 
that the threat of tube feeding was also used as a method of coercion to eat. 
Negative feeding practices during cancer therapy may be contributing to the long 
term poor dietary habits seen in survivors of childhood cancer. This chapter focuses 
on the views of parents, patients and healthcare workers surrounding the use of 
tube feeding as a method of nutritional supplementation.  
 
 
                                               
4
 This chapter has been submitted for publication in the following peer review journal: 
Cohen J, Wakefield CE, Tapsell LC, Walton K, Cohn R. Enteral nutrition in paediatric 
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contributed to data analysis and manuscript preparation. 
The key findings have been peer reviewed and presented at the 16
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 International Congress 
of Dietetics and The 43rd Congress of the International Society of Pediatric Oncology with 
the abstract included in the following publications: 
Cohen J, Wakefield CE, Fleming CAK, Cohn RJ. What do parents of childhood cancer 
patients actually think about enteral nutrition. Pediatric Blood and Cancer. 2011;57(5); 835 
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6.1 Introduction 
 
Nutritional therapy is an important part of the management of childhood cancer 
patients to ensure adequate growth and development (4). Oral intake can be 
reduced due to the presence of oral mucositis, nausea and vomiting (14, 51) or taste 
and smell changes (243). Child cancer patients’ nutritional status may also be 
compromised due to intestinal malabsorption (14) and inflammation (46). Without 
nutritional therapy, the prevalence of under-nutrition during treatment for childhood 
cancer may be as high as 50% of patients in developed countries (46). Maintenance 
of a good nutritional status during cancer therapy can also improve a childhood 
cancer patient’s tolerance to chemotherapy, reduce their risk of infection and 
improve quality of life (8, 244). Enteral tube feeding (ETF) is an important part of 
nutritional therapy in paediatric cancer patients. It is used when oral nutritional 
therapy is no longer effective (4).   Evidence shows that ETF promotes weight gain 
in paediatric oncology patients (133, 134, 245, 246), especially when used 
prophylactically (135).  Despite the evidence for its effectiveness as a method of 
nutritional intervention, the criteria for the use of ETF for paediatric oncology 
patients are inconsistent (122). 
 
 
The prevention of hospital malnutrition has become a focus in the clinical setting 
(247). Prompt nutritional interventions are considered a key to prevention (248). To 
achieve appropriate and timely nutritional interventions, multidisciplinary 
collaboration is considered paramount (248). Although the healthcare team’s 
recommendations influence the initiation of ETF in the paediatric setting, 
recommendations for the utilization of ETF can differ between healthcare 
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practitioners (122), leading to inconsistencies in ETF initiation.  A cohesive team 
management of nutritional therapy will likely enhance appropriate utilisation of ETF. 
 
 
Patient centered decision making is also important when initiating ETF (249). 
Parents and patients have a strong influence over the initiation of nutrition support, 
with many refusing the use of ETF for their children. A recent study of paediatric 
oncology patients, and their parents, suggested that the perceived discomfort of 
ETF influences patient/parent decisions to allow ETF to be initiated (145). Parents 
also use the threat of the use of ETF as a way to coerce their child to eat (131). 
There is also suggestion that ETF is more likely to be initiated in younger patients (< 
6 years) (135), than in older patients.  
 
 
To ensure that the appropriate initiation of ETF is optimized, collating the views of 
paediatric oncology clinicians, parents and patients on ETF in a paediatric oncology 
setting would be beneficial. This would enable the development of psycho-
educational interventions for families and staff. The aim of this study was therefore 
to compare and contrast views among parents, patients and healthcare workers on 
the positive and negative aspects of ETF, the ways in which information was 
provided on ETF; and, how the decision making process was conducted for the 
initiation of ETF. 
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6.2 Methods 
 
6.2.1 Study participants 
Two groups of participants were recruited at the Kids Cancer Centre (KCC), Sydney 
Children’s Hospital, Australia, for this study: 1) Paediatric cancer patients <18 years 
of age,  who were currently on treatment or who had undergone treatment at the 
KCC in the previous three years; and 2) Healthcare professionals. There is no 
literature determining the minimum age in which a child can participate in qualitative 
research (250). For our study, for participants under the age of 12 years, the parents 
were interviewed. The healthcare professionals included medical, nursing and allied 
health staff. Potential participants were mailed a study invitation letter, a participant 
information sheet and an opt-in card. Participants were also invited, in person, 
through the outpatient clinic of the KCC. Participants were excluded if they were 
unable to speak English.  This study was conducted according to the guidelines laid 
down in the Declaration of Helsinki and all procedures involving human 
subjects/patients were approved by the South Eastern Sydney and Illawarra Health 
Service, Human Research Ethics Committee-Northern Hospital Network. Informed, 
written consent was obtained from each participant. 
 
6.2.2 Procedure 
Interviews were conducted via the telephone by a research assistant. She was not 
associated with, or known by, the participants and had extensive training and 
experience with semi-structured interviews. Telephone interviews were offered as 
many participants lived in rural or remote areas (24), and did not attend hospital on 
a regular basis.  Telephone interviews are considered to be as effective as face-to-
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face interviews for eliciting reliable qualitative data (25). All interviews were 
recorded.  
 
Semi-structured interviews were used to elicit information from the participants 
(Table 6-1). After an extensive literature review, the initial core discussion guide was 
developed. The interview focused on: 1) Attitude and impact of ETF; 2) Information 
and support regarding ETF; and 3) Clinical management of ETF.  The discussion 
points were based on themes elicited in previous research on attitudes towards 
enteral feeding in a general pediatric setting (146, 251). Once the initial discussion 
guide had been developed, a multidisciplinary team (dietitian, psychologist and 
oncologist) who have extensive experience in conducting qualitative research and 
understood many of the challenges faced by families in this situation reviewed the 
discussion guide. Results from the early interviews were also used to determine 
additional lines of questioning for subsequent interviews (204).  The health 
professional discussion guide was based on the same domains as the parent/patient 
discussion guide. There was also a focus on the criteria they used to initiate EN.
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Table 6-1  Discussion guide for semi-structured interviews for 
parents/patients and healthcare workers 
 
Parents/Patients 
 
Views  prior to use of enteral tube feeding 
 What information were you given about enteral tube feeding at the beginning 
of your/your child’s treatment? 
 Who gave this information to you?  
 What did you think about the use of enteral tube feeding at the beginning of 
your/your child’s treatment? 
Views during and after use of enteral nutrition 
 Can you describe whether there were any positives of you/your child receiving 
enteral tube feeding? 
 Can you describe any negatives of you/your child receiving enteral tube 
feeding? 
 Did your feelings about enteral tube feeding change after you/your child 
received it? 
 Did you/your child experience any complications with receiving enteral tube 
feeding? If so, what? 
 Could you tell me how you felt when you/your child received the nasogastric 
tube or gastrostomy? 
 Do you think enteral tube feeding affected your life in any way? For example, 
your social life, your family relationships, how you/your child coped with your 
cancer treatment.  
 Did you have any issues or concerns with the enteral feeding process?  
 Do you have any advice or recommendations about enteral tube feeding for 
other patients/parents?  
 How about for doctors or other healthcare workers? 
 
Healthcare workers 
 
 What are the first two things that come to mind when you think about enteral 
tube feeding in the pediatric oncology setting? 
 What are the positive aspects of enteral tube feeding? 
 What are the negative aspects of enteral tube feeding? 
 What are your thoughts about how enteral tube feeding is managed on the 
ward? 
 What criteria do you use to decide whether or not you should initiate enteral 
tube feeding? 
 What materials and resources do you use to make this decision? 
 How do you think enteral tube feeding impacts on the patients and their 
families? 
 Can you comment on how you would approach a family about initiating enteral 
tube feeding in their child? 
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 Can you comment on the support given to health professionals to initiate 
enteral tube feeding in oncology patients? 
 Do you have any other advice or recommendations regarding the use of 
enteral tube feeding in the paediatric oncology setting? 
 
 
6.2.3 Data analysis 
All participant responses were transcribed verbatim by an independent, trained 
transcriber. This methodology was performed in accordance with gold-standard 
guidelines (204). Transcripts were coded line-by-line, and analysis was facilitated by 
the qualitative data analysis software NVivo, 2008, Version 8 (QSR International, 
Victoria, Australia). To ensure accuracy with regards to the coding and analysis, 
fifteen percent of the interviews were coded independently by two investigators, and 
their coding was compared for consistency (204, 205). The final coding was 
analyzed and key themes were categorized and enumerated  (204). 
 
 
6.3 Results 
 
Interviews were conducted with 30 families (Table 6-2), representing a response 
rate of 24.5%. Twenty parents (2 fathers, 18 mothers) were interviewed as their 
child was under 12 years of age. Ten interviews were conducted with the childhood 
cancer patients. Interviews were conducted with 18 healthcare workers, yielding a 
response rate of 33%. Responses from participants were divided into three main 
themes: 1) Attitude and impact of ETF; 2) Information and support regarding ETF; 
and 3) Clinical management of ETF. Responses from the patient participants and 
the healthcare workers were compared. 
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Table 6-2  Demographics of participants and healthcare workers  
 
Patient (n=30) 
 
Age (mean ± SD) years 9.54 ± 5.16 
Sex (M:F) 13:17 
Stage of treatment (n) 
     On treatment  
     Receiving maintenance therapy 
     Post treatment  
 
10 
5 
15 
 
Diagnosis 
     ALL* 
     AML† 
     Wilms’ Tumour 
     Brain Tumour 
     Neuroblastoma 
     Other 
 
9 
3 
3 
8 
2 
5 
Healthcare Workers (n= 18) 
 
 Position    
     Consultant 
     Fellow 
     Clinical Nurse Consultant 
     Clinical Nurse Educator 
     Registered Nurse 
     Allied Health 
 
5 
2 
2 
1 
6 
2 
* ALL, Acute Lymphoblastic Leukaemia; †AML, Acute Myeloid Leukaemia 
 
6.3.1 Attitudes toward, and impact of, enteral nutrition  
Participants were asked to recall their views regarding ETF prior to and after use. 
The emerging themes and representative comments are displayed in Table 6-3. 
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Table 6-3 Views of enteral tube feeding from patients, parents and healthcare 
workers 
 
Themes n Representative Patient 
Comments (n=30) 
n Representative 
Healthcare worker 
comments (n=18) 
 
Prior to enteral nutrition 
 
Positive     
Ensure good     
nutrition 
9 “It would just give you 
piece of mind that they are 
getting the nutrition that 
they need” (Mother: 
female, CNS tumour, 8 
yrs). 
 
4 “Positives in terms of 
delivery of essential 
nutrients, vitamins” 
(Fellow). 
 
 
Less pressure 
on the child to 
eat/less conflict 
7 “When I found out about it 
I felt a huge amount of 
relief that I wouldn’t have 
to struggle with trying to 
eat” (Patient: male, 
Biphenotypic Leukaemia, 
17 yrs). 
 
4 “Enteral feeding is often a 
way of diffusing conflict 
....the last thing you need 
is to have the [patient] 
fighting with the mother 
and father about what they 
can and can’t get in” 
(Consultant).  
 
Weight gain 7 “When a child is sick and 
thin its body can't fight as 
well as it can if it is healthy 
and nourished so if she 
had dropped enough 
weight we would have 
definitely have done it” 
(Mother: female, ALL*, 2 
yrs). 
 
1 “It means that they are 
going to either hopefully 
maintain their weight or 
not lose significant weight, 
so to try to minimise 
toxicity of regimens” 
(Fellow). 
 
 
Easier to give 
medication 
2 “NG† tube might be really 
easy because of the 
medication...It needs to 
get in and...with NG tube 
at least you have that 
option to just give it even if 
[the patient] like[s] it or 
not. (Mother, male, ALL, 5 
4 “It is often also a good 
way to give medications” 
(Fellow). 
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yrs). 
 
Less time in 
hospital 
0  1 “[EN‡] usually means 
getting out of hospital 
[and] having some control 
and having some time at 
home” (Consultant). 
 
Negative     
How it 
looks/makes 
them look sick 
8 “I didn't want him to have 
[ETF], maybe it was just 
admitting that he was 
really sick then just to look 
it” (Mother: male, 
medulloblastoma, 11 yrs). 
 
 
16 “..the patients are quite 
reluctant...because of ... 
the body image, and you 
can see it and it makes 
them look sick .... it 
certainly separates them 
from normal teenagers” 
(Clinical Nurse 
Consultant). 
 
Invasive 7 “I never, ever wanted to 
have a tube down my 
nose the central line ... 
just seems to be … less 
intrusive in a way but 
down the nose and down 
my throat that always 
appeared horrible to me 
and I wasn’t very happy 
with it” (Patient: male, 
MDS, 13 yrs). 
1 “I think parents view things 
like NG tubes as invasive” 
(Fellow). 
 
 
Uncomfortable 7 “I have noticed just from 
being in hospital was that 
the children who had it 
...find it incredibly 
uncomfortable and they 
couldn't understand why 
they had to have it and so 
they were constantly 
pulling it out” (Mother; 
female, ALL, 5 yrs). 
 
 
4 “I think parents view NG 
tubes as .... uncomfortable 
in the children...when they 
have not experienced it 
firsthand ..... probably the 
only time they witness NG 
tubes in other kids on the 
ward is when they watch 
them go in .... that is  a 
little bit traumatic, but 
once it is in, it is not a 
major issue” (Fellow). 
 
Insertion 
procedure 
0  4 “We have to pass the NG 
tube and so i think that .... 
frowned upon by the 
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parents, they try and avoid 
the tube feeding for as 
long as possible because 
they don't want that tube 
inserted” (Registered 
Nurse). 
 
Worried about 
how the patient 
will cope 
3 “You are sort of anxious 
about it, how [the patient] 
would cope with it” 
(Mother; female, NHL§, 8 
yrs). 
 
0  
Failure by 
parents 
2 “I think is some of [the 
parents] feel that they are 
not succeeding as 
parents” (Mother: male 
Wilms’ Tumour, 2 yrs). 
2 “Some parents see it as a 
failure on their part and so 
they are reticent to admit 
defeat” (Consultant). 
 
Having to use 
formula 
2 “I was still breastfeeding 
[and] I felt a little bit funny 
because I hadn't 
particularly wanted her to 
have formula at all.  I was 
expecting her to go from 
breastfeeding to solids 
and then just cut out the 
breastfeeding and purely 
solids” (Mother; female, 
AML, 2 yrs). 
 
0  
Extra work at 
home 
1 “You have the other 
machines at home and 
you have to put it all in at 
night and you know it's 
kind of another add on 
thing” (Mother: male, ALL, 
5 yrs). 
 
0  
Unnatural 1 “It are just my own gut 
feeling that there must be 
a reason why when we 
are sick we don't want to 
eat.  ... but, wouldn't it 
make sense that if our 
body doesn't want to eat 
that we don't need food?” 
(Mother: female, AML, 4 
0  
 
137 
 
yrs). 
 
Concerns about 
reaction to the 
tape used 
1 “I would have had no 
problem with it, only that 
she seriously sensitive 
skin and it has got to get 
tapped to her face” 
(Mother: female, 
neuroblastoma, 6 
months). 
 
0  
After enteral nutrition 
 
Positive     
Weight gain 10 “I really hate it to be 
honest but I do know that 
right now, it’s the only way 
I can really gain weight” 
(Patient: male, MDS, 13 
yrs). 
 
 
8 “The main positives is 
maintaining weight, 
maintaining nutrition and 
that's getting the calories 
in and having them 
healthier” (Consultant). 
 
 
Better nutrition 9 “You felt reassured that 
[the patient] was getting 
the nutrition in because 
even when she was 
eating, it was just like 
crappy stuff so there was 
nothing good or nutritious 
about it” (Mother: female, 
NHL, 8 yrs). 
 
9 “I do think the relief of 
knowing that your child is 
getting their nutritional 
requirements can remove 
some stress.  Especially if 
you're a family where food 
is a big part of your life 
and nutrition” (Social 
worker). 
 
Less 
stress/anxiety 
8 “Once we said okay and 
he got [ETF] we sort of 
[felt] relieved, like this 
pressure just lifted off our 
shoulders and we didn't 
have to fight with him” 
(Mother; male, 
medulloblastoma, 7 yrs). 
 
 
9 “I think a big plus with it, is 
that it does relieve a lot of 
the eating stress at the 
home, so [the parents] can 
chill out and have good 
times instead of constantly 
fighting about, [food]” 
(Consultant). 
 
Patient got 
used to the 
tube 
7 “Every time [the patient] 
cried, [when] they tried to 
put in [the tube], but after 
1 “One of the big 
advantages is once you 
get the tube in it is well 
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that she was fine again” 
(Mother: female, Wilms’ 
Tumour, 8 yrs). 
 
 
tolerated, once you get 
past the first couple of 
days and it is not 
uncomfortable anymore” 
(Consultant). 
 
Less pressure 
to eat 
6 “We didn't have to be 
stressed any more about 
making [the patient] eat all 
the time which is a real 
constant battle between 
him and I” (Mother: male, 
medulloblastoma, 11 yrs). 
 
3 “[ETF] is a lot easier on 
the patient as well when 
they are not getting forced 
to eat a whole bunch of 
stuff that they just can’t 
tolerate” (Registered 
Nurse). 
 
Easier for 
medications 
4 “All the medicines [the 
patient] didn't like to take 
and the pills ... we could 
throw straight down the 
tube that was an 
advantage” (Mother: male, 
neuroblastoma, 11 yrs). 
 
2 “[ETF] makes medications 
easier” (Registered 
Nurse). 
 
 
Could feed 
while child was 
asleep 
2 “It gave me a bit of piece 
of mind that if she didn't 
eat during the day at least 
she was getting some 
nutrition 
overnight” (Mother: 
female, AML, 2 yrs). 
 
1 “[ETF] makes the feeding 
easier; the parents can do 
it at night time” 
(Registered Nurse). 
 
 
Less time in 
hospital 
1 “I don't have that 
stress that if I don't eat I 
am going to end up back 
in hospital” (Patient: 
female, medulloblastoma, 
17 yrs). 
 
 
 
4 “[ETF] as opposed to 
TPN, is very helpful, and 
... you can do it as an 
outpatient so it increases 
[the “[Patient’s] discharge 
capability too, because in 
the past the children might 
have needed to stay in 
hospital because they 
can't eat” (Fellow). 
 
Negative     
How it looks 12 “I didn’t particularly like 
the way that it identifies 
you as a sick person” 
(Patient: male, 17 yrs, 
0  
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Biphenotypic Leukaemia). 
Insertion 
procedure 
11 “The negatives, when they 
had to put it down, I really 
was quite insistent that 
they put it down when she 
was under general 
anaesthetic because she 
had them pretty much 
every week.” (Mother: 
female, AML, 2 yrs). 
9 “NG tubes are very 
traumatic putting them 
down is horrendous it 
doesn't really matter about 
the age of the child” 
(Registered Nurse). 
 
 
Vomiting up the 
tube 
7 “There was always that 
part of me that didn't like it 
because I felt like it was 
causing [the patient] so 
much discomfort with the 
vomiting and also with the 
tube itself.” (Mother: 
female, AML, 4 yrs). 
 
10 If it’s [ETF] not successful, 
and the tube keeps getting 
thrown up or the child 
keeps throwing up, then.... 
it’s just too hard” (Clinical 
Nurse Consultant). 
 
 
Uncomfortable 6 “ [The patient]  kept saying 
that it felt really funny on 
her neck, an 
uncomfortable feeling 
having that thing going 
down your neck” (Mother: 
female, NHL, 8 yrs). 
 
 
3 “It [ETF] feels 
uncomfortable and they 
[the patient] often say that 
discourages them from 
feeling like they want to 
eat at other times because 
it sits at the back of their 
throat and it hurts a bit to 
swallow” (Clinical Nurse 
Consultant). 
 
Makes patient 
feel sick 
5 “I’ve always felt sick and 
I’ve always felt worse 
having the feeds 
continuous” (Patient: 
male, MDS, 17 yrs). 
0  
Issues with 
tape on the 
face 
5 “The tape and stuff was a 
bit irritating, ... I thought it 
would get a bit inflamed, 
[on the face]” (Mother: 
male, neuroblastoma, 11 
yrs). 
 
 
1 “You have got the tape on 
the cheek; there was one 
child who has a bad fungal 
infection underneath that 
so that is again a rare 
downside” (Consultant). 
 
Sleep 
deprivation 
2 “During the night the 
machines always turning 
6 “I imagine if you lived in 
the house, you would find 
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and it constantly makes 
noise and when it runs out 
it beeps and everyone has 
to get up and fix it” 
(Patient, female, 
medulloblastoma, 17 yrs). 
 
they have got a fair bit of 
sleep deprivation around 
it” (Consultant). 
 
 
Type of formula 2 “The nutritionist was fairly 
hesitant to switch from the 
ordinary milk to the pre-
digested stuff and once he 
was on the pre-digested 
stuff he really settled 
down” (Mother: male, ALL, 
5 yrs). 
 
0  
Impact on 
family 
2 “I was opening my 
baggage all the time 
because I would be 
carting different tins, with 
the food” (Mother: male, 
neuroblastoma, 11 yrs). 
 
 
5 “It [ETF] limits what you 
can do.  In terms of where 
you want to go or if you go 
on holiday, you have to 
bring pump” (Clinical 
Nurse Consultant). 
 
Impact on long 
term feeding 
1 “I was concerned that 
because she was being 
tube fed for most of it, it 
would affect her [eating] 
long-term” (Mother: 
female, AML, 2 yrs). 
 
 
1 “Once they [the patient] 
have been out from 
transplant for many 
months and still on 
nasogastric feeds, then 
certainly there can be 
some anxiety about the 
return of normal appetite 
and normal feeding habits” 
(Fellow). 
 
Risk of 
aspiration 
0  3 “I have been involved in 
where there has been a 
concern about aspiration 
on a chronic basis which 
might have been 
exacerbated by having a 
nasogastric tube in” 
(Consultant). 
 
Cost 0  2 “It can be an ongoing cost 
issue trying to get feed.” 
(Clinical Nurse 
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Consultant). 
 
Diarrhoea 1 “At one stage he did 17 
diarrhoeas a day” (Mother: 
male, ALL, 5 yrs). 
 
1 “Negatives for nasogastric 
enteral feeding is 
diarrhoea” (Fellow). 
 
Tube blocking 0  4 “Problems occur if the 
tubes then blocks and we 
have to take it out and put 
a new one in; you get 
some frustration and 
aggression as to why did 
the tube block” (Fellow). 
 
* ALL, Acute Lymphoblastic Leukaemia; † EN, Enteral Nutrition; ‡ NG, Nasogastric; 
§NHL, Non-Hodgkin’s Lymphoma 
 
6.3.1.1 Prior to use of enteral nutrition 
The main positive aspects expressed by the participants regarding ETF prior to its 
use were: 1) Ensuring good nutrition (n=9); 2) Less pressure on the patient and 
family to get the child to eat (n=7); and 3) To promote weight gain (n=7). The 
healthcare workers described similar positives which included: 1) Better nutrition 
(n=4); and 2) Less conflict between parents and patients relating to oral intake 
(n=4). Healthcare workers also described a positive of ETF as being ‘easier to give 
medications’ 
 
“When I found out about it I felt a huge amount of relief that I wouldn’t have to 
struggle with trying to eat” (Patient: male, Biphenotypic Leukaemia, 17 yrs). 
 
The main concerns expressed by participants prior to its use included: 1) The 
physical appearance on the child’s face (n=8); 2) Their concern it was invasive 
(n=7); 3) The degree of discomfort from the enteral feeding tube once inserted 
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(n=7).  The same negative aspects were expressed by healthcare workers. The 
healthcare workers confirmed that the most common reason for concern from 
parents and patients was the physical appearance after insertion of the tube (n=16). 
They also suggested that concerns about discomfort from the tube would be a 
challenge for patients (n=4).  
 
“I think parents view nasogastric (NG) tubes  as .... uncomfortable in the 
children...when they have not experienced it firsthand..... probably the only time they 
witness NG tubes in other kids on the ward is when they watch them go in .... that 
is  a little bit traumatic, but once it is in, it is not a major issue” (Oncology Fellow). 
 
6.3.1.2 After use of enteral nutrition 
Once ETF had been initiated, the positives described by both the patients and 
parents appeared to match their views prior to insertion. The key positives included: 
1) Weight gain (n=10); 3) Better nutrition (n=9); 3) Less worry (n=8); and 4) Less 
pressure to eat (n=6). A proportion of this group also commented that their child “did 
get used” to the tube (n=7). The positive views of the healthcare workers also 
remained the same and were similar to the views of the parents and patients. 
 
“Once we said okay and he got [ETF] we sort of [felt] relieved, like this pressure just 
lifted off our shoulders and we didn't have to fight with him” (Mother; male, 
medulloblastoma, 7 yrs). 
 
Parent and patient negative views regarding ETF, however appeared to change 
once the tube had been inserted, with the primary concern expressed relating to the 
insertion procedure. This did not appear to have been a focus prior the initiation of 
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ETF. Participants also commented that the constant emesis of the tube was a 
problem. The other negatives of ETF after the insertion, described by the 
participants, related to feeling awkward in public with the tube as it was so visible.  
 
“There was always that part of me that didn't like it because I felt like it was causing 
[the patient] so much discomfort with the emesis and also with the tube itself.” 
(Mother: female, AML, 4 yrs). 
 
 
The healthcare workers’ views regarding the negative perceptions surrounding ETF 
once it had been utilised, appeared to agree with that of the parents and the 
patients. The healthcare workers were aware of the concerns with the tube insertion 
process and emesis of the tube. Healthcare workers also viewed sleep deprivation, 
as a result of use of the feeding pump at home, as a potential difficulty for parents 
and patients. None of the parents or patients interviewed spontaneously described 
this as a concern. Healthcare workers did not spontaneously discuss the possibility 
that the physical appearance of the tube would continue to be a challenge for 
families after insertion 
 
“I imagine if you lived in the house, you would find they have got a fair bit of sleep 
deprivation around it” (Physician). 
 
6.3.2 Information about enteral nutrition 
Parents reported first receiving information about ETF from various sources. These 
included: doctors (n=13), the dietitian (n=11) and nursing staff (n=3). One parent 
reported that they sought information regarding ETF from other families. For parents 
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of children who did not receive ETF during their treatment (n=8), many reported that 
tube feeding was not mentioned as a possibility during their child’s treatment (n=5). 
Some parents reported that they may have found out information on ETF when their 
child was first diagnosed, but were unable to confirm this. They reported that they 
received a lot of information at diagnosis and were unable to focus on all the 
information provided due to the stress of their child’s cancer diagnosis (n= 6).  
 
“It is all a bit of a blur, there may have been information in amongst everything but 
until it was actually, like you say, crunch time, we didn't really think about it” (Mother: 
female, AML, 4 yrs). 
 
Half of the patients interviewed did not recall receiving any information on the use of 
ETF (5/10) during their treatment.  
 
“I wasn’t given any information.  It was just “You’re going to get a NG [nasogastric] 
tube put in” (Patient: female, AML, 17 yrs) 
Three of the seven physicians reported that they raised the possibility of the use of 
ETF at the initial diagnosis. One physician stated they did not mention it at 
diagnosis. 
“The amount of detail you go into can vary from family to family and you wouldn't 
talk about it at the very beginning of diagnosis generally because they are still 
getting over the shock of the new diagnosis and the treatment plan so it wouldn't 
feature in those discussions but at a later stage it definitely does.” (Pediatric 
oncology fellow)   
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It appears that ETF is mentioned as a possibility to patients and their parents when 
there is a concern about weight loss or poor feeding.  The majority of healthcare 
workers reported that the dietitian was the one to discuss the use of ETF with 
parents and patients (n = 9). 
 
“Our greatest resource is our dietitian .  We are very much guided by that in terms of 
whether there are concerns about calories.... a large proportion of [ETF] is guided by 
a combination of looking at the weight and clinical assessment and then getting 
guidance from the dietitian as to what is appropriate.” (Paediatric oncology fellow)   
 
6.3.2.1 Decision process 
The decision process and criteria for the use of ETF appeared to vary, with no 
standardized criteria. Half of the healthcare workers (n=9) reported that weight loss 
was the main criteria used for ETF initiation, though the amount of weight loss 
varied from five percent to 15% loss of body weight. Many healthcare workers relied 
on the dietitian to provide advice as to when ETF needed to be initiated (n=6). It 
appeared that some healthcare workers and parents would have preferred there to 
be a more specific criteria for initiation. 
 
“I think there is a lot of um-ing and ah-ing  and from a decision about whether we 
enteral feed or not..... We still don't have a line in the sand.... kids need a line of 
sand” (Clinical Nurse Consultant). 
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6.3.3 Clinical management of enteral nutrition 
6.3.3.1 Insertion procedure 
There appeared to be similar views regarding the insertion procedure between the 
parents, the patients and the healthcare workers. Of the parents and patients 
interviewed, eight (40%) and three (30%) respectively, reported that the insertion 
procedure was a negative experience due to the pain and discomfort with the 
procedure. 
 
“I found that really quite traumatic for her and for me” (Mother: female, AML, 2 yrs). 
 
A similar percentage of healthcare workers (50%; n=9) considered the insertion 
procedure a negative experience for patients.  
 
6.3.3.2 Use of sedation for insertion 
A small number of parents (n=4) and patients (n=2) reported that the use of 
midazolam, improved the insertion procedure.  The parents reported that each 
nasogastric tube insertion was different and that the methods used varied. 
 
“It is much more comfortable for him to have the Midaz[olam]. It just takes the edge 
off, just relaxes him I think a little bit more than, you know he knows what's coming” 
(Mother: male, medulloblastoma, 7 yrs). 
 
A number of healthcare workers (n=8) reported that using Midazolam, for the 
insertion procedure, improved the experience of tube insertion.  
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“A lot of the time we use Midazolam and it tends to be a bit ad hoc.  There's been 
one occasion where I've tried to get the pain team to do some nitrous [oxide] 
but they refused.” (Physician). 
6.3.4 Recommendation to other parents 
Despite the large number of problems with the ETF insertion procedure, blockage of 
tubes, and emesis, a large number of parents (n=12) would still recommend the use 
of ETF to other families. Many parents (n=13) also felt that their perception of ETF 
changed to a more positive view after use. 
 
“I'd be surprised if rational parents didn't see the positive... I don't see how overall 
you can't see it as a net positive.  It is another thing to have to manage and it's 
another thing protruding out of the patient’s body and all that stuff but it's a means to 
an end.  I certainly wouldn't have it any other way because what's the 
alternative?)” (Father: female, Brain tumour, 3 yrs). 
 
 
6.4 Discussion  
 
Nutrition interventions, in the form of ETF, play a key role in the management and 
treatment of pediatric oncology patients. Recent literature has shown that proactive 
ETF is achievable (135). This study showed that parents/patients and healthcare 
workers could all see  positive and negative aspects of ETF, as well as the 
management of ETF, in a similar way. Discordant views between the 
patients/parents and healthcare workers appeared around the decision making 
process and when information was provided on the use of ETF. 
 
148 
 
 
Decision making of patients (and their parents) in the healthcare setting is complex.  
Information provision alone may not be adequate enough to enable quality decisions 
to be made (252). Physician understanding of the patient’s experience in 
combination with the provision of information on evidence for the use of the medical 
intervention (253) is more likely to encourage compliance with the recommended 
treatment. This study demonstrated that healthcare workers appeared to understand 
patients’ and parents’ challenges surrounding ETF. Therefore effective information 
provision and decision support may be the missing link in the process for initiating 
ETF use. Differences in perceptions between parents and physicians regarding the 
sufficiency of information surrounding ETF has been shown to be a difficulty  with 
parents of non-oncology children (146). This difference in perceptions between the 
parents/patients and the healthcare workers also appeared in the pediatric oncology 
setting. A focus on the form and timing of the information provision may be needed 
to ensure that uptake of ETF in an appropriate timeframe if achieved.  
 
 
The physicians varied in regards to whether they provide information on ETF at 
diagnosis or at other points during treatment. The parents did acknowledge that 
even if this information had been provided at diagnosis, they may not have been 
able to recall this information due to the stress receiving a cancer diagnosis for their 
child. The literature has shown that parents feel overwhelmed by the information 
given at their child’s cancer diagnosis (254, 255). This may lead to a poor recall of 
all of the information provided to them (256).  It may be that providing information on 
ETF at diagnosis is not appropriate at such a stressful time. Physicians may need to 
ensure information on ETF is given to parents and patients separate to diagnosis 
but before nutrition becomes a concern for the patient and parents. This information 
 
149 
 
may also need to be standardized across all the medical teams. Further work is 
needed to determine the appropriate timing of information provision to families 
regarding the use of ETF during cancer treatment. 
 
Shared decision making is a process in which patient treatment decisions are made 
in collaboration with the patient (257). The clinician provides information on the 
benefits and harms for all treatment options and a joint decision is made regarding 
the treatment plan (257). Shared decision making is not always used in the clinical 
setting but is encouraged to improve patient outcomes, including patient satisfaction 
(258). Shared decision making may allow the discordant views between patients 
and clinicians regarding the use of ETF  to be improved (257). Use of decision aids 
may be one way of standardizing and improving the provision of information on ETF 
to pediatric oncology patients and their families, especially when facing a decision 
that involves competing values (such as balancing appearance and comfort with 
better nutrition) (259). Decision aids provide unbiased, balanced, and non-directive 
information about a procedure. They differ from standard education materials as 
they provide options to the patient (260) and allow them to participate in the decision 
making process (261). Decision aids have been shown to have a positive influence 
in patient-physician decision making (261). The use of decision aids has been 
suggested as a way to improve the quality of decision making for use of ETF for 
parents of children with neurological disabilities (147) and carers of adults with 
severe dementia (262). Incorporating decision aids into the pediatric oncology 
setting may be one way to improve uptake of this form of nutritional intervention. 
Use of a decision aid with standardised information may also address challenges 
around the differing criteria for use of ETF between clinicians. Development of the 
decision aid in consultation with clinicians may allow agreement to be reached on 
the criteria for initiation of ETF based on published literature. 
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Peer knowledge sharing has also been discussed as a factor for improving decision 
making in the healthcare setting (260). Few parents and patients in this study sought 
information from their peers. The majority of information on ETF came from 
healthcare workers, such as their physician, dietitian and nursing staff. Many 
parents stated they would recommend the use of ETF to other parents if asked. 
Peer knowledge sharing could be utilized as a standard practice to improve the 
information provision and subsequently improve the decision making process. 
 
After ETF was commenced, the concerns from parents and patients, centered on 
the practical aspects of the tube. These negatives included the invasive nature of 
the insertion procedure, emesis of the nasogastric tube, and discomfort in using the 
nasogastric tube and how visible the nasogastric tube was in public. Interestingly, 
none of the parents or patients who participated in the study mentioned the tube 
insertion procedure as an area of concern prior to the tube being inserted. Although 
it is not possible to alter some of the negative aspects discussed above, such as the 
physical appearance of the tube, introduction of  psychological preparation (4), 
cognitive-behavioural techniques (263) and utilization of play therapists may lessen 
the distressing nature of the procedure. 
 
6.4.1 Limitations 
This study provides insight into potential reasons for a reluctance to use ETF for 
many patients and parents, though there are several limitations of this study that 
need to be addressed. For the majority of participants, this study relied on 
retrospective recall of their views of ETF and could have subsequently introduced 
 
151 
 
recollection bias. Future studies should assess patient and parental views on ETF 
prior to and after initiation. A participation rate of 24% could suggest that the results 
from this study were not representative of all childhood cancer patients and their 
parents.  We did, however, continue interviewing until information saturation was 
achieved.  A recent review of qualitative study sample sizes revealed that our 
sample size is similar to many other qualitative studies that also achieved saturation 
(264).   
 
 
6.5 Conclusion 
 
Parents, patients and healthcare workers perceived the positive and negative 
aspects of ETF in a similar way. There appears to be discordance between 
patients/parents and the healthcare workers in relation to the information provided to 
them on the use of ETF. This uncertainty in the methods and timing of information 
provision on the use of ETF may be contributing to a less than optimal use of this 
method of nutrition support. By standardizing and improving the methods used for 
the information provision of ETF, the concerns surrounding the use of ETF with 
pediatric oncology patients may be reduced. Introduction of tools such as decision 
aids and peer knowledge sharing may help to optimize the use of ETF in pediatric 
oncology patients.  
 
6.5.1 Implications 
This chapter provides information on the decision making process for the initiation of 
enteral tube feeding. The uncertainty in the methods and timing of information 
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provision on the use of tube feeding may be contributing to a less than optimal use 
of this method of nutrition support. This may also be a reason for parents using 
enteral tube feeding as a way of coercing their child to eat. Improving the methods 
of information provision around, not only enteral tube feeding, but all methods of 
nutrition support may not only improve uptake of the appropriate nutritional 
interventions but improve the feeding practices of parents during their child’s cancer 
therapy. This may have implications on long-term dietary intake of survivors of 
childhood cancer. The third section in this thesis examines the hypothesis that taste 
and smell dysfunction may be implicated in the problem of developing healthy eating 
habits in childhood cancer survivors. The next chapter is a review of the prevalence 
of taste and smell dysfunction in cancer patients, both during and after treatment. 
The review also assesses the relationship between taste and smell dysfunction and 
oral intake 
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7 REVIEW OF TASTE AND SMELL DISORDERS RESULTING FROM CANCER 
AND CHEMOTHERAPY5 
 
Chapters 3 and 4 found young survivors of childhood cancer are not meeting 
recommended nutritional guidelines. It also appears that young survivors of 
childhood cancer are not returning to the dietary habits they had established prior to 
their cancer diagnosis. The reason for these changing dietary habits seen in cancer 
survivors is unknown. Cancer patients report a change in taste and smell during 
their cancer therapy but the role this plays on dietary habits during and after cancer 
treatment is not clear. This chapter summarises the literature on taste and smell 
changes during and after cancer therapy. This chapter also summarises the 
evidence for the association of taste and smell changes and food intake and 
whether taste and smell changes are seen in cancer survivors. The findings of this 
chapter have been accepted for publication in Current Pharmaceutical Design 
 
7.1 Introduction 
 
Smell, taste and food intake are tightly intertwined (265, 266). Flavour perception is 
not solely related to taste but is also mediated by olfactory receptors when 
mastication of food occurs (267, 268). The sensory properties of foods can influence 
                                               
5
 This chapter has been accepted for publication in the following peer reviewed journal: 
Cohen J, Wakefield CE, Laing DJ. Review of taste disorders resulting from cancer and 
chemotherapy. Current Pharmaceutical Benefits 
JC undertook the review, JC & CW contributed to data analysis and JC, CW & DL 
contributed to manuscript development 
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both the selection and amount consumed of that food (269). An alteration in taste or 
smell function can lead to a change in a person’s quality of life as well as altering 
food intake and nutritional status (270). In the general population, those with a 
chemosensory dysfunction that occurred after birth may have one of three reactions 
regarding food. They may increase their food intake to compensate for the lack of 
food flavour, decrease their food intake because of the lack of enjoyment of the food 
(271, 272) or continue to eat their normal diet. For many people suffering with 
chemosensory disorders the aetiology is idiopathic (273). Other causes of 
chemosensory disorders include sinus diseases, upper respiratory infection and 
head trauma (273). Chemosensory loss is an under-recognized issue in the general 
population, and there are conflicting data regarding prevalence of smell or taste loss 
(273-279) 
 
Radiotherapy, used as a treatment modality for cancer treatment, is another well 
recognized cause of chemosensory dysfunction (273, 280). However, for many 
cancer patients, chemotherapy is the primary form of treatment and its short and 
long term effect on chemosensory dysfunction is less well understood.  
Chemotherapy targets rapidly dividing cancer cells (49). Unfortunately, 
chemotherapy cannot distinguish between cancer and non-cancer cells (50, 281), 
resulting in potentially severe short and long term side effects. Non-cancer cells that 
are more likely to be affected by chemotherapy include cells in hair follicles, blood 
and bone marrow,  gastrointestinal tract and the reproductive tract (265), causing 
side-effects such as nausea, vomiting, mucositis and diarrhoea. Taste and smell 
receptor cells also rapidly turn over (282, 283) and the division mechanism has been 
suggested to be sensitive to the effects of chemotherapy (281, 284).  
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Anorexia and poor appetite are commonly described in cancer patients (285). 
Malnutrition is a significant challenge for patients undergoing treatment for cancer, 
and rates may be as high as 80% in adult patients (286) and 50% in paediatric 
patients (46). Malnutrition in cancer patients is associated with increased infections, 
leading to an  increase in mortality (112-114), and this is likely to be independent of 
disease severity (115).  Poor nutrition during cancer treatment  can lead to an 
increased length of hospital stay (111), reduced quality of life, reduced treatment 
tolerance and increased treatment side-effects, potentially leading to poorer 
outcomes (6, 14). Malnutrition also reduces the absorption of chemotherapy drugs 
(116) and may be one explanation of poorer survival outcomes in underweight 
patients (114). In children with cancer, malnutrition can have more significant long 
term effects such as growth stunting (84) and cognitive/developmental delay (83). 
 
An alteration of chemosensory function could also affect a patient whose oral intake 
is already affected by cancer (287). The senses of taste and smell are integral in 
motivating a person’s food preferences (270, 288) and both child and adult cancer 
patients commonly attribute difficulties maintaining food intake to the altered taste 
developed during treatment (127, 265, 289). Altered chemosensory function in 
patients with cancer may also lead to food aversions (266), further changing food 
preferences. Chemosensory dysfunction has been associated with a decreased 
energy and nutrient intake (271), nutrient deficiencies (290) and malnutrition (287). 
A loss in sensory perception can also affect a person’s quality of life (291). 
 
Given the potential medical, behavioural and psychological impact of chemosensory 
dysfunction in adult and child cancer patients, this review aims to provide a 
comprehensive overview of the prevalence of taste and smell disorders in cancer 
patients undergoing chemotherapy.  A narrative review will be conducted in 
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accordance with the published Economic and Social Research Council guidance 
(292). This form of review is generally considered ideal where a broad overview is 
required that synthesises both current empirical evidence and theoretical 
understanding (38). This review will first summarise the potential causes of taste 
and smell dysfunction in cancer patients and discuss the methodology used to 
assess chemosensory dysfunction. The review will then summarise the prevalence 
of taste and smell dysfunction, assessed using both objective and subjective 
measures of assessment, in both patients on treatment and survivors of cancer. The 
review will then summarise the prevalence of taste and smell dysfunction, assessed 
using a variety gustatory and olfactory test, in both patients on treatment and 
survivors of cancer. The review will also summarise the impact that chemosensory 
dysfunction has on quality of life and oral intake and will also review the efficacy of 
interventions to improve chemosensory dysfunction in cancer patients. 
 
7.2 Summary of gustation 
An alteration in taste perception can be categorized as ageusia (reduced taste), 
dysgeusia (altered taste) (293), hypergeusia (increased sensitivity) or hypogeusia 
(decreased sensitivity) (287). Taste sensations have previously been categorized 
into four distinct groups: salty, sour, bitter and sweet. Recent work has also 
identified the taste of umami as a fifth taste quality, said to be a savoury flavour 
(294, 295). Fatty acids may also be a taste quality, though further work is needed to 
confirm this (296).  Taste receptors are located on the papillae on the tongue and 
soft palate.  These receptors regenerate regularly (49) although the time required for 
this in humans has not been firmly established (284, 287). The sense of taste comes 
from the detection of chemicals by the taste receptors. The taste receptors are 
innervated by three separate cranial nerves: 1) facial nerve (CNVII); 2) 
glossopharyngeal nerve (CN IX); 3) vagal nerve (CNX) and when activated, carry 
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the taste information to the cerebral cortex (297, 298).  Recent work suggests that 
taste cells in the gut are sensitive to tastes (295).  
 
7.2.1 Potential causes of gustation abnormalities in cancer patients 
The mechanisms for taste abnormalities in cancer patients remain poorly 
understood.  Damage to the sensory receptor cells is considered a primary cause of 
taste disorders in this population (274). Damage may be caused by a decrease in 
the number of normal receptor cells, changes on the taste receptor surface or an 
interruption in neural coding (274).  The perception of taste sensations in the central 
nervous system may also be altered if chemotherapy agents cross the blood-brain 
barrier (299). Chemotherapy drugs may also interfere or damage sensory neurons, 
altering taste pathways (274). These drugs, including platinum based 
chemotherapy, cyclophosphamide, doxorubicin, 5-FU and methotrexate, are known 
to be associated with taste and smell changes (284). Cancer patients may also 
receive supportive care medicines, such as antibiotics and antihypertensive 
medication that are associated with disorders of taste and smell (300). 
Chemotherapy drugs, antibiotics and analgesics contain bitter tasting compounds 
which can diffuse into the taste, via secretion into the saliva (287) causing a bitter or 
metallic taste (274).  A dry mouth is a common side effect from cancer therapy and 
can alter taste perception (301).  Poor oral hygiene, gastrointestinal reflux and 
infections have also been associated with taste changes in cancer patients (290). 
 
7.2.2 Assessment of gustatory function 
Most methods used to assess gustatory function, either assess patients’ detection 
thresholds, their recognition thresholds (274), or their identification ability (275). 
Recognition thresholds provide a measure of taste sensitivity and identification 
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ability, while detection thresholds do not include the classification of a basic taste 
(302).  Electrogustometry is a measure of taste sensitivity. This method uses a mild 
anodal current on the tongue, (303) which causes a metallic taste (304). Detection 
of the taste is through direct stimulation of the gustatory nerve (304). A downside of 
this method is that it does not measure the ability of a person to identify tastants 
(305). 
 
Taste strips, which use filter paper containing different concentrations of four tastes 
(salty, sour, bitter and sweet), have been used to assess gustatory function in local 
regions of the tongue (268). Gustatory function with these tastes has also been 
measured using whole mouth tests which involve liquid solutions or tablets at 
different concentrations of the four tastants (57).  A version of the whole mouth 
method  for children, using 10ml solutions and four concentrations of the above four 
tastants,  has produced normative data from  hundreds of  children aged nine to 
twelve years (276, 277, 306).  Tests for the detection of the taste of umami have 
only been established in recent years, with some work using discs of filter paper 
impregnated with monosodium glutamate (MSG) (307). 
 
7.3 Summary of Olfaction 
 
 
The nasal cavity contains olfactory receptors that are activated when odorant 
molecules bind to them (291). Olfactory receptors are located on  the dendrites of 
olfactory neurons, leading to a direct conduit to the cortex and subcortex (308) via 
cranial nerve I (265). Olfactory neurons are able to regenerate (265), and the 
regeneration time is dependent on the extent and type of damage to the mitotic 
basal cells and olfactory epithelium (284). A reduction in olfactory function can be 
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categorized as anosmia (inability to smell); hyposmia (reduced sensitivity); 
hyperosmia (increased sensitivity) or dysosmia (distorted perception) (273). 
 
7.3.1 Potential causes of olfaction abnormalities in cancer patients?  
The causes of smell dysfunction in the general population may include: 1) traumatic 
olfactory loss; 2) viral-induced olfactory loss; 3) exposure to toxic agents (265); 4) 
age; and 5) chronic rhinosinusitis(307).  For cancer patients, olfactory dysfunction is 
likely related to chemotherapy destroying the rapidly dividing olfactory basal cells in 
the olfactory epithelium (281), (300). Chemotherapy may also cause patients to 
become sensitive to odours, (265) causing food aversions and a loss of appetite 
(281). This may be caused by the compounds in the chemotherapy drugs diffusing 
from the nasal capillaries to the olfactory receptors (308). Changes in smell 
sensitivity in cancer patients may also relate to pseudo hallucinations of odours that 
others cannot sense (309). Cancer patients may also report an increase in 
sensitivity to smells, though the aetiology remains unknown (309). 
 
7.3.2 Objective measures of olfaction  
The most common tests of olfactory function measure odour identification ability, 
odour detection or odour recognition thresholds (275, 276, 306, 310, 311). Odour 
identification testing is performed by assessing a person’s identification of common 
odours (275, 306, 311). The original method developed to produce normative data 
for odour identification was the University of Pennsylvania Smell Identification Test 
(UPSIT). This method uses 40 common odourants which are microencapsulated, 
requiring study participants to “scratch and sniff” the odour (267). A four point forced 
choice method is used to determine the odour presented (267). A short version of 
the UPSIT is The Brief Smell Identification Test (312). Both are available 
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commercially. Another commercially available method for measuring olfaction is the 
German “Sniffin sticks” test which uses smell containing felt tip pens, allowing the 
odour to be presented in a uniform way. Once the odour is presented to the 
participant, the identification of the odour is achieved using a forced choice method 
(311).  
 
Another test is the Connecticut Chemosensory Clinical Research Center test which  
measures both threshold and odour identification, with the odour presented to one 
nostril at a time (313). n-Butyl alcohol is used as the  stimulus in the odour threshold 
component of the test. For odour identification, 10 common odourants are presented 
to the participant and identification is done with the aid of a list of 20 examples 
(313). There are a number of other tests available that measure odour 
discrimination, memory, and suprathreshold, odour intensity and pleasantness 
perception (314, 315), but little if any normative data are available from these and 
the reliability of the data from these tests varies (315). As such, comparisons of 
prevalence of odour dysfunction between studies using different methods need to be 
interpreted with caution. 
 
The above methods to detect odor dysfunction were not developed for use with 
children. One study recently used ‘sniffin’ sticks and UPSIT tests with children, 
however, the scores were generally lower than considered acceptable for validating 
a general or specific olfactory dysfunction (316). A 16 odor identification test which 
was developed for use with children aged over five years, at Sydney Children’s 
Hospital in Australia (275, 276, 306) has been used with hundreds of children at 
schools and in the Sydney Children’s Hospital to produce normative data. This 
method involves participants sniffing opaque bottles containing the odorant. 
Identification is with a three picture - three word forced choice task (306, 317). 
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7.4 Prevalence of taste and smell alterations in cancer patients  
 
 
Ten studies have assessed taste function in cancer patients (Table 7-1). Eight 
studies reported decreased taste sensitivity (n=407) (109, 271, 318-323) and one 
study reported no effect on taste function (n=12) (324). Two studies found both 
increased sensitivity and decreased sensitivity to specific tastes. Nishjima et al, 
2013 reported an increased sensitivity to sweet, salty and sour tastes and 
decreased taste sensitivity to bitter (325), while Caputo and colleagues reported 
increased sensitivity to bitter but decreased sensitivity to salty and sweet (326). 
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Table 7-1 Summary of studies assessing taste function in cancer patients 
Hyperguesia                    
(increased  sensitivity) 
No effect Hypoguesia                               
(decreased sensitivity) 
 
Nishjima 2013 (filter -
paper strips : sweet, 
sour, salty) 
Caputo 2012 
(wholemouth: bitter) 
Steinbach 2012 (taste 
strips) 
Berteretche 2004 
(electrogustometry) 
Nishjima 2013 (filter paper: 
bitter) 
Steinbach 2010 (taste strips: 
bitter) 
Sanchez-Lara 2010 (whole 
mouth: sweet, bitter) 
Caputo 2012 (whole mouth: 
salty, sweet) 
Strasser 2008 (whole mouth: 
4% bitter, 33% sour, 35% salty, 
4% sweet (% with a higher 
detection threshold) 
Steinbach 2009 (taste strips: 
salty, sour, bitter, sweet) 
Oversen 1991 
(electrogustometry) 
Cohen 2012 (whole mouth; 
40% of participants) 
Skolin 2006 (whole mouth: 
bitter) 
 
 
Several objective methods have been used to assess taste and smell function in 
cancer patients (Table 7-3). Two studies that assessed taste sensitivity using 
electrogustometry found higher detection thresholds in cancer patients than in 
control groups (318, 320). Use of whole mouth methods to assess taste detection 
found higher sweet (271) and salty scores (326) compared with controls. 
Interestingly, Caputo et al, (2012) (326) found lower detection bitter scores 
compared with controls, whereas Sanchez-Lara and colleagues (2010) (271) 
reported the opposite. Reasons for this discrepancy in these results are unknown as 
both studies used similar participant groups and testing methods. Strasser and 
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colleagues (2008) (323) assessed the taste detection of 41 cancer patients and 
found a low prevalence of bitter and sweet dysfunction (4%), but higher rates of sour 
and salty dysfunction (33% and 35% respectively. Two studies have used taste test 
strips to assess taste function. In one study of 12 patients with ovarian cancer, no 
significant decrease in taste function during their chemotherapy treatment was found 
(322). However, a study of 87 breast and gynaecological cancer patients found that 
their taste function decreased significantly after chemotherapy infusion (322). Two 
studies assessed taste detection and recognition in paediatric cancer patients. One 
study of children undergoing a bone marrow transplant (BMT) reported that 40% of 
the patients experienced a taste dysfunction (319). Taste function appeared to 
resolve within two months post-transplant. The second study assessed 10 paediatric 
cancer patients during chemotherapy treatment and found higher thresholds for 
bitter taste than controls (109). 
 
A total of seven studies assessed olfactory function in cancer patients undergoing 
chemotherapy with conflicting results (Table 7-3). One study reported decreased 
odour detection (n=87) (321) and another reported no effect on odour detection (n= 
15) (327). The results for odour identification were mixed, with four studies reporting 
decreased identification (n= 130) (319, 321, 324, 328), one study reporting an 
increase in identification (n= 69) and three studies reporting no effect (n= 46) (322). 
Two studies assessed odour sensitivity with one study finding a decreased odour 
threshold (n= 87) (321) and two studies finding no effect (n= 120) (320, 322). 
 
The majority of studies (Table 7-2) assessing olfactory function in cancer patients 
used “Sniffin sticks”. Yakirevitch et al, 2005 reported a prevalence of olfactory 
dysfunction of 5% in patients with solid tumours (328). Two of these studies found a 
statistically significant decrease in olfactory function compared with controls after 
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chemotherapy infusion (321, 324). These findings were not repeated when the 
olfactory function of 69 breast cancer patients were compared with normative data 
and no difference in odour threshold was found (322). Olfactory function assessed 
using the European Test of Olfactory Capabilities also found no difference in odour 
detection and identification between 15 bronchial cancer patients and 15 healthy 
controls (327). The only study assessing olfactory function in paediatric BMT 
patients reported a prevalence of dysfunction of 30%, with symptoms resolving 
within two months (319). 
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Table 7-1 Summary of findings of taste and smell dysfunction  
Author, year N (age range) Cancer Type  Chemotherapy Measures Findings 
 
Joussain et al, 2013 
(327) 
15 cancer patients  
(63.46 ± 6.16 yrs)                                 
15 control (65.9 ± 
4.93 yrs) 
Bronchial Cisplatin European Test of 
Olfactory Capabilities 
(ETOC) 
No difference in  odour 
detection (p> 0.05) and 
identification (p>0.05 
between patients and 
controls 
Berteretche et al, 
2004 (318) 
110 cancer patients 
(58.5±11 yrs)                                         
170 controls 
(60.5±11.6 yrs) 
Not specified Alkylating agents, 
antimetabolites, 
Antispindle agents, 
Intercalating agents, other 
Electrogustometric 
detection threshold 
Cancer patients had 
significantly higher taste 
detection thresholds than 
controls (p=0.02) 
Steinbach et al, 2012 
(324) 
12 (56.5 ± 9.8 yrs) Ovarian  Carboplatinum (plus taxol) Smell: “Sniffin Stick”; 
Taste: Taste strips 
 
Cancer patients had a 
significant decrease in 
olfactory identification (p = 
0.019) after  chemotherapy; 
olfactory function had 
recovered after 3 months 
 
 No significant decrease in 
taste function after 
chemotherapy 
     
Nishijima et al, 2013 
(325) 
23 (58.0± 11.5 yrs) 
 
 
Gynecological Taxane, carboplatin Subjective assessment 
using the Common 
Terminology Criteria for 
48% self-reported taste 
disturbances                                
Electrogustometry:     
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Adverse Events 
Electrogustometry; Filter 
paper disc testing 
Decreased taste sensitivity 
in the chorda tympani nerve 
field.  Increased taste 
sensitivity  in the greater 
petrosal nerve field 
Filter paper testing: 
Increased taste sensitivity  
for sweet, salty, and sour & 
decrease taste sensitivity 
for bitter  
Steinbach et al, 2010 
(322) 
69 (52.4±10.4 yrs) Breast  NS# Taste strips; “Sniffin 
Sticks” 
Smell  
Compared with normative 
data, no significant 
difference in odour 
threshold, but better scores 
for odour identification and 
odour discrimination. 
Taste 
A significantly decreased 
taste sensitivity  value 
compared with controls for 
sour only 
 
Sánchez-Lara et al, 
2010 (271) 
30 cancer patients 
(56.0 ± 15 yrs) 
30 controls (49.4 ± 
11yrs) 
Breast, lung, 
prostate, 
multiple 
myeloma and 
lymphoma 
NS Whole mouth method 
using solutions (sweet, 
bitter and umami) 
Cancer patients had a 
higher sweet detection 
(p=0.03)  and bitter 
recognition thresholds 
(p=0.04) than controls 
Caputo et al, 2012 
(326) 
29 cancer patients 
(50.1± 11.7 yrs) 
Breast, uterus, 
prostate and 
NS Whole mouth detection 
method using single 
Cancer patients had higher 
detection scores for salty, 
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44 controls (49.5 ± 
16.3 yrs 
head and neck 
cancer 
concentration of bitter, 
salty, sour and sweet. 
sweet,  (p< 0.05)and lower  
bitter detection scores than 
controls (p< 0.05) 
Strasser et al, 2008 
(323) 
41 cancer patients Breast, prostate, 
lung and other 
Docetaxel 
Paclitaxel 
Self-reported taste (VAS 
*scale) 
Whole mouth detection  
for salty, sour, sweet 
and bitter at a single 
concentration 
85% self-reported taste 
alterations 
After chemotherapy, a 
number of patients had 
higher detection thresholds: 
4% bitter; 33% sour; 35% 
salty; 4% sweet.  
Steinbach et al, 2009 
(321) 
87 (53.5 ± 10.5 yrs) Breast and 
gynaecological 
CMP: 
(Cyclophosphamide, 
methotrexate, fluorouracil) 
Anthracycline 
Anthracycline & taxane 
Platinum 
 
“Sniffin sticks”; Taste 
strips (sweet, sour, salty 
& bitter) 
Higher detection thresholds 
after chemotherapy infusion 
A decrease in the smell 
threshold, discrimination 
and identification score  
after chemotherapy infusion 
Yakirevitch et al, 
2005 (328) 
21 (mean: 53.6yrs) Solid tumours Cisplatin “Sniffin Sticks” Only 5% of patients had 
decreased smell 
identification after 
chemotherapy infusion  
Ovesen et al, 1991 
(320) 
51 cancer patients 
(mean: 64 yrs)   
29 controls (mean: 
62yrs) 
Lung, ovarian, 
breast 
Lung cancer: Cisplatin, 
vindesine, etoposide, 
vincristine, doxorubicin, 
tenoposide, 
cyclophosphamide, 
CCNU, and 
hexamethylamine, or 
monotherapy with 
tenoposide or etoposide 
Electrogustometric 
detection threshold 
Olfactory detection 
threshold 
Higher electrical taste 
threshold in cancer patients 
than controls ( P< 0.001) 
No difference in smell 
thresholds between the 
cancer and control group 
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Ovarian:  Carboplatin, 
cisplatin, and etoposide or 
with cyclophosphamide, 
Adriamycin (doxorubicin), 
and 5-flu-orouracil  
Breast:  
cyclophosphamide, 
epirubicin, and 5-
fluorouracil or 
monotherapy epirubicin 
Cohen et al, 2012 
(319) 
10 (mean: 12.5yrs) Bone marrow 
transplant 
patients 
NS 16 odour identification 
test 
Taste detection and 
identification test (bitter, 
salty, sweet, sour) 
40% of cancer patients had  
a taste dysfunction 
30% of cancer patients had 
a smell dysfunction 
 
Skolin et al, 2006 
(109) 
10 cancer patients 
(mean: 14.5yrs) 
10 controls 
Leukaemia, solid 
tumour, 
lymphoma, 
central nervous 
system tumour 
NS Taste recognition 
thresholds (bitter, salty, 
sour and sweet). 
Patients had higher  
thresholds for bitter 
taste than controls. 
Patients had more taste 
recognition errors 
compared with control 
* VAS: Visual Analogue Scale; #NS: Not specified 
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7.5 Assessment of taste and smell dysfunction in cancer patients  
 
Table 4 shows the results of eight studies that assessed taste and smell function. 
Unfortunately, there are no validated methods for assessing self-reported taste and 
smell function (302). Fifty percent of the studies used a 16-item taste and smell 
questionnaire which measures self-reported taste and smell alteration (329-332). 
One study indicated that 60% of general cancer patients had taste and/or smell 
alterations (n=192) (330), while others reported that 69% of  lung cancer patients 
(n= 89), 86% of lung, gastrointestinal, breast and prostate cancer patients (n= 
66)(331) and 75% of lung, breast, gastrointestinal and general patients (n= 
518)(333) experienced taste and smell alterations. Self-reported smell changes 
alone was reported in 3% of general cancer patients (n= 192), 5% of lung, 
gastrointestinal, breast and prostate cancer patients (n=66) and 10% of breast, 
gastrointestinal and gynaecological cancer patients (n=518). 
 
Using a two item scale, two studies assessed taste function in breast and 
gynaecological patients (n= 109)(299) and lung, colorectal and pancreatic cancer 
patients (n= 197) (334) and found approximately 70% of patients surveyed reported 
changes in taste. Patients receiving Irinotecan appeared to have a higher report of 
taste changes than those receiving Gemcitabine and a platinum containing 
chemotherapy (334). The results were in contrast to another study of breast and 
gynaecological cancer patients, with less taste changes occurring for those 
receiving gemcitabine (299).  In another breast cancer study (n=45), 84% of 
patients complained of taste alterations (335). A total of 68% of colon, breast, lung, 
lymphoma and  ovarian cancer patients reported taste changes assessed via a 41-
item taste change questionnaire (284).  
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Table 7-3 Summary of studies assessing olfactory function in cancer patients 
 Decreased No effect Increased 
 
Odour detection Steinbach 2009 
(sniffin sticks) 
Joussain 2013 
(ETOC)* 
 
Odour identification Steinbach 2012 
(sniffin sticks) 
Steinbach 2009 
(sniffin sticks) 
Yakrevitch 2005 
(sniffin sticks: 5% of 
participants)  
Cohen 2012 (odor 
identification: 30% of 
participants) 
Joussain 2013 
(ETOC)* 
Yakrevitch 2005 
(sniffin sticks: 95% of 
participants) 
Cohen 2012 (odor 
identification: 70% of 
participants) 
Steinbach 2010 
(sniffin sticks) 
Odour threshold Steinbach 2009 
(sniffin sticks) 
Steinbach 2010 
(sniffin sticks) 
Oversen 1991 
(detection threshold 
method) 
 
* ETOC: European test of olfactory capabilities 
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Table 7-2  Summary of findings of taste and smell alteration  
 
Author, year N (age) Cancer Type, age range Measures Findings 
 
Brisbois et al, 2011(330) 192 (64.3 ±12.4 yrs) 
 
Lung, breast, genitourinary, 
gastrointestinal, neuroendocrine 
system , hematological 
conditions 
Taste and smell survey 60 % taste and smell 
alteration 
    26% taste only 
    3% smell only 
 
McGreevey et al, 2014 
(332) 
89 (69± 9 yrs) Lung cancer Taste and smell survey 69% taste and  smell 
alteration 
Hutton et al, 2007 (331) 66 (65.4 ± 12.4 yrs) Lung , gastrointestinal, breast & 
prostate  
 
Taste and smell survey 86%  taste and smell 
alteration 
    52% taste and smell 
    30% taste only 
    5% smell only 
 
Jensen et al, 2008 (335) 45 cancer patients 
(mean age: 45yrs) 
 
Breast cancer Subjective assessment 
using standardized 
questions of perceived 
taste disturbances 
84% self-reported taste 
changes                                     
 
Bernhardson et al, 2008 
(333) 
518 (58.71 ±  
10.77yrs) 
Breast, gastrointestinal, 
gynecological and other 
Taste and smell survey 75% taste and smell 
alteration                                
10% smell only                   
35% taste only 
Gamper et al, 2012 (299) 109 (61.0 ±12.8) Breast  and gynecological Taste alteration scale 71% taste alteration   
Zabernigg et al, 2010 197 (65.2 ±10.4) Lung, pancreatic and colorectal Taste alteration scale 70 % taste alteration 
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(334) 
Wickham et al, 1999 (336) 284 (58 ± 15 yrs) Colon, breast, lung, lymphoma, 
ovarian 
41-item taste change 
questionnaire 
 
68% taste alteration 
QoL: Quality of life
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7.6 Chemosensory dysfunction in cancer survivors 
 
Taste and smell receptors in cancer patients are said to regenerate within  a finite 
time with some studies indicating a time-scale of 10-30 days (281, 284). For this 
reason, researchers hypothesize that chemosensory dysfunction should not affect 
patients once they have recovered from their cancer therapy.  Steinbach et al, 
(2009) (321) assessed chemosensory function in 87 breast and gynaecological 
cancer patients before, during and after their chemotherapy. This study reported 
olfactory and gustatory function returned to normal three months after completion of 
therapy (321). In a study of 12 patients with ovarian cancer, olfactory function 
returned to normal after three months from completion of chemotherapy (324).  Two 
other studies assessed paediatric haematopoietic stem cell transplant (HSCT) 
patients after treatment completion and found chemosensory function normalized 
after two months (319, 337).   
 
Much of the work assessing taste and smell function in adult cancer survivors has 
focused on patients who had undergone HSCT using self-report measures. In an 
assessment of 50 haematological cancer patients, 20% of the patients reported 
taste or smell changes 100 days post-HSCT (293).  In contrast, Mattson et al, 
(1992) found that taste and smell dysfunction continued  up to one year after HSCT 
(338).  
 
7.7 Chemosensory dysfunction and effect on oral intake in cancer patients 
 
Food aversions can occur if an unpleasant experience occurs in conjunction with 
food ingestion (271). Studies exploring the influence of taste changes and food 
intake during chemotherapy remain inconclusive (339). However, some evidence 
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suggests that there is an association between chemosensory dysfunction and 
changes in oral intake in cancer patients. For example, in an assessment of 192 
advanced cancer patients, those with a self-reported change in taste function 
consumed 20-25% fewer calories per day, had greater weight loss and had a poorer 
quality of life than those who reported no taste and smell alteration (330). A similar 
trend was seen in lung cancer patients, with those reporting taste and smell 
alterations having decreasing energy intake (332). Furthermore, Sanchez-Lara et al, 
(2010) (271) found that in a group of 30 adult cancer patients, those with a higher 
sweet detection threshold or a higher bitter recognition threshold had a lower energy 
and nutrient intake (271). One assessment of 42 cancer patients reported an 
association between those with self-reported taste changes and decreased appetite 
(340). Taste and smell alterations were also associated with a decreased appetite in 
breast and gynaecological cancer patients (299) and lung, colorectal and pancreatic 
cancer patients (334). Importantly, when assessed separately, taste and smell 
dysfunction is associated with a decreasing energy intake (331). 
 
Not all patients however, report that taste and smell changes influence their intake. 
A qualitative study of  21 adult cancer patients with chemosensory loss showed that 
for several of the patients interviewed, their oral intake did not change as a result of 
this dysfunction (341). Bernhardson et al, (2009) (309) compared patients who had 
self-reported smell dysfunction alone, with those who reported both a taste and 
smell dysfunction. Those with a smell dysfunction alone appeared to have fewer 
difficulties with weight loss, appetite and oral intake. This study provides some early 
data that taste and smell dysfunction in combination may be a stronger driver of the 
dietary intake of cancer patients, than smell dysfunction alone. Since the flavor of 
food is comprised of smell and taste stimuli, this finding is not surprising. 
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7.8 Chemosensory changes and quality of life 
 
For many cancer patients, taste changes can affect their quality of life (274, 336). In 
a study of 45 breast cancer patients, 10% of those with a self-reported taste 
dysfunction indicated that this was their most distressing oral symptom (335). 
Another study involving 314 cancer patients with self-reported taste and smell 
alteration, found that over 50% reported high distress as a result of their 
chemosensory symptoms. Almost 30% of this group also reported that it impacted 
their daily life (342). In a study of 284 cancer patients, 40% reported that taste 
changes were moderately distressing and 18.6% reported that their taste changes 
affected their lives (336). A similar finding was seen in a cohort of breast and 
gynaecological cancer patients, with those with a self-reported chemosensory 
dysfunction being more likely to report a depressed mood (333). Taste and smell 
dysfunction may be associated with fatigue in breast and gynaecological cancer 
patients (299) and lung, pancreatic and colorectal cancer patients (334). Taste 
alterations during chemotherapy can also affect activities of daily living such as 
grocery shopping, cooking meals and socializing with friends (340).  
 
7.9 Intervention studies and strategies to improve/ prevent taste and smell 
dysfunction 
 
There are few therapeutic options for the treatment of chemosensory dysfunction 
(298). Although zinc deficiency may be associated with taste disorders (343), there 
is little evidence to suggest that zinc supplementation improves taste function for 
people with taste disorders in the general population (344). As regards to cancer 
patients, a double-blind, placebo controlled randomized controlled trial of 58 patients 
found that zinc supplementation did not prevent taste and smell dysfunction (345).  
Glutamine, a branched-chain amino acid, is thought to play a role in the prevention 
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of chemotherapy-induced neurotoxicity (346). However, a randomized controlled 
trial of glutamine in 52 patients undergoing cancer treatment, found no impact on the 
incidence of taste disorders in an adult cancer population (323).  
 
Encouragingly, the canniboid, delta-9-tetrahydrocannabinol (THC) may be effective 
in improving appetite and oral intake in cancer patients (347). Brisbois et al, (2011) 
assessed the effect of THC on taste and smell, appetite and food intake in 46 
patients with cancer in a randomized controlled trial (24 controls) (294) and found 
that compared with placebo, THC patients exhibited significantly improved 
chemosensory perception, appetite, food intake and quality of life (294).  In another 
approach, miraculin, a protein in a West African fruit, was tested for its ability to 
mask unpleasant flavors in a cross-over trial. Although the sample size was small 
and the trial was not blinded, there was some suggestion that consumption of this 
protein improved the taste of food for all participants while undergoing 
chemotherapy. For some participants, this improvement in taste translated to an 
improvement in oral intake (348). Further testing is required to confirm these results. 
 
Patients use multiple strategies to manage chemosensory dysfunction and to 
improve oral intake. In a qualitative study of 12 patients with taste and smell 
alteration, patients described several strategies, including: 1) Trial and error to 
determine tolerable foods; 2) Having a selection of quick and easy foods available to 
consume; 3) Limiting social interactions; and 4) Working through the symptoms 
(349). It appears that strategies to cope with chemosensory dysfunction, such as the 
use of herbs and spices and avoidance of cooking smells, are not very effective 
(342). In a qualitative study of 21 patients with cancer, participants were unable to 
report any strategies that could alleviate their taste and smell changes (350). When 
cancer patients were provided with an educational intervention on strategies to 
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manage taste changes, only 16% of participants felt that the intervention helped “a 
lot” (340). There is only one study providing data suggesting that a nutritional 
intervention can improve intake. In that study, a combination of flavour enhancers in 
food and nutritional education was used with 107 adult cancer patients (54 
intervention: 53 control)(351). The intervention group received 13 bottles of food 
flavour enhancers in combination with food preparation information. The intervention 
group had  improved nutritional status and physical functioning compared with 
controls, though there was no difference in macronutrient intake or quality of life 
between the two groups (351). 
 
 
7.10  Discussion 
 
This review summarizes studies that have assessed taste and smell dysfunction in 
cancer patients undergoing chemotherapy. Overall there was some suggestion of 
lower taste sensitivity in adult and child cancer patients in 80% of the studies 
reviewed.  The results were not as clear for studies that assessed olfactory function. 
Nevertheless, there appeared to be a higher incidence of odor identification 
dysfunction in patients with cancer undergoing chemotherapy when compared with 
the general population. Overall, the results for changes in odor detection and 
identification for patients with cancer were inconclusive. Eight studies assessed 
taste and smell function using self-reported measures. The incidence of taste and 
smell function, assessed by such imprecise methods ranged from 60% in general 
cancer patients (330) to 86% in lung, gastrointestinal, breast and prostate cancer 
patients (331).   
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There were methodological limitations in the studies in this review. For example, 
there was little consistency in the assessment methods used, making cross-study 
comparisons difficult. Of the included studies, four different methods were used to 
assess taste function: 1) whole mouth testing; 2) filter paper discs; 3) taste strips 
and 4) electrogustometry. Similarly, four methods were used to assess odor 
function: 1) “Sniffin sticks”; 2) ETOC; 3) odor identification; and 4) odor detection. In 
addition, a variety of self-report tools were used that  did not compare results with a 
control group.  Our review concurs with that of Gamper et al, 2012 and Bolton and 
Keast, 2012, who were unable to make firm conclusions regarding the occurrence of 
chemosensory dysfunction in cancer patients due to methodological limitations in 
many of the studies (302, 339). 
 
Very few studies have assessed the prevalence of chemosensory dysfunction in 
paediatric cancer patients undergoing chemotherapy.   The limited studies suggest 
that taste and smell dysfunction is prevalent during chemotherapy treatment and 
BMT. There is a dearth of literature assessing the association of taste and smell 
dysfunction with appetite, oral intake and QoL in childhood cancer patients. A recent 
systematic review of symptom experiences of children and adolescents with cancer 
reported nausea and vomiting to be one of the most commonly identified symptoms 
(10). Taste and smell alterations were not a key symptom identified by paediatric 
patients in the review. The varying cognitive abilities of children of differing ages 
makes it difficult to standardize chemosensory testing  (276). What remains unclear 
from the systematic review of cancer symptoms is whether it is difficult for children 
to articulate taste and smell alterations. Recent work has shown that many cancer 
patients have poor dietary habits after cancer treatment, especially those who have 
survived a diagnosis of childhood cancer (202, 352). There remains a dearth of 
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literature regarding taste and smell function in survivors of childhood cancer and 
whether this is contributing factor the survivor’s poor nutritional intake. 
 
Overall, this review provides evidence that chemosensory dysfunction may be 
associated with a poor appetite, potentially leading to a poor nutritional intake and 
weight loss. The data were predominantly derived from self-reports of taste 
alterations and appetite by patients. The senses of taste and smell are an integral 
part of the experience of eating, but only represent part of the sensations 
experienced (349).  A person’s dietary habits and food intake are driven by their 
enjoyment of the food (353). It may be that severe chemosensory dysfunction 
reduces food enjoyment leading to reduced oral intake (331, 336). The tests used to 
assess chemosensory function are not necessarily in line with the patient’s 
experience of eating (333). Food texture, temperature (349), touch and emotional 
state of mind (354) may be just as important as taste and smell for driving a patient’s 
food intake and preferences (344). Most studies of chemosensory function in cancer 
patients assess taste and smell in isolation. Other factors contributing to food intake 
and food preferences in cancer treatment have not been assessed.  
 
Despite the conflicting evidence for changes in the senses of smell and taste, this 
review also provides evidence for a relationship between chemosensory dysfunction 
and its effect on quality of life in patients undergoing treatment for cancer.  Self-
perceived taste alterations appear to affect mood and can increase fatigue (299, 
333, 334).  Taste alterations are also associated with a higher level of distress for 
cancer patients (309, 335), leading to changes in their daily activity (284, 309). 
Unfortunately, despite these important effects, this review demonstrated that the 
available chemosensory interventions are largely ineffective. It may be that 
interventions are ineffective because they aim to improve perceived taste or smell of 
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food, but have not considered flavour or texture. Given that taste and smell changes 
are often unique to each individual cancer patient, it may be that future interventions 
might be more effective if tailored to the needs of individual patients, rather than 
offering a generalized intervention to all affected patients. 
 
7.11 Conclusion 
 
This review summarizes the available evidence for the role of taste and smell 
dysfunction and on the food intake, appetite and quality of life of patients undergoing 
chemotherapy treatment for cancer.  Both adult and child cancer patients should be 
counselled about the potential impact that taste and smell dysfunction could have on 
their appetite and oral intake during their cancer therapy. Further work is required to 
ascertain the taste and smell function of both adult and child survivors of cancer. 
 
7.11.1 Implication 
 
This chapter summarised the available literature on taste and smell changes during 
and after chemotherapy treatment for both adult and child cancer patients. There 
appears to be a high incidence of self-reported taste and smell alterations occurring 
during chemotherapy treatment. It also appears that taste and smell changes are 
altering the dietary intake of cancer patients. There is some suggestion that taste 
and smell changes may persist well after the cancer therapy is completed in adult 
cancer patients. The next chapter is a study on the taste and smell function in a 
cohort of survivors of childhood cancer. 
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8 TASTE AND SMELL DYSFUNCTION IN CHILDHOOD CANCER SURVIVORS6 
 
Chapter 7 identified that taste and smell dysfunction is seen in cancer patients 
undergoing chemotherapy treatment. Taste and smell alteration was shown to be 
associated with an increase in distress, a reduction in appetite and may be 
contributing towards poor nutritional status in cancer patients. There is also some 
suggestion that taste and smell alteration may continue to be an issue well after 
cancer therapy has been completed. This chapter describes the findings from a 
study assessing taste and smell function in a cohort of survivors of childhood 
cancer. This study was published in Appetite. 
 
8.1 Introduction 
 
One potential side-effect of cancer therapy is reduced or altered taste and smell 
function (265). Both taste and smell receptor cells rapidly turn over and are 
produced from dividing basal cells (282, 283). The division mechanism is sensitive 
to the effects of chemotherapy and/or radiotherapy (284). The senses of taste and 
smell are integral in motivating a person’s food preferences (270, 288) and both 
child and adult cancer patients commonly attribute difficulties maintaining food 
intake to the altered taste developed during treatment (127, 265, 289). Altered taste 
                                               
6
 This chapter has been published in the following peer reviewed journal: 
Cohen J, Laing DG, Wilkes FJ, Chan A, Gabriel M, Cohn RJ. Taste and smell dysfunction in 
childhood cancer survivors. Appetite. 2014;75;135-40 
JC & RC designed the study, JC & AC undertook data collection, JC, DL & AC contributed to 
data analysis, FW provided statistical support and JC, DL, FW & RC contributed to 
manuscript development 
The key findings have been peer reviewed and presented by JC at ANZCHOG ASM, 2014. 
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in cancer patients has also been associated with decreased energy and nutrient 
intake (271), potentially leading to nutrient deficiencies (290). 
 
Although the taste and smell receptor cells are replaced regularly over several 
weeks and longer, cancer therapy can potentially lead to long term taste and smell 
receptor damage. This occurs due to an alteration in the structure of the receptors or 
a decrease in the number of normal receptor cells (290). Long-term taste and smell 
dysfunction has been documented in the adult oncology population (182, 355). 
Patients who have received radiation therapy for head and neck cancer and those 
who have undergone a Hematopoietic Stem Cell Transplant (HSCT) demonstrate 
taste dysfunction, after their cancer treatment, up to seven and three years 
respectively. (287, 355)  
 
Survivors of childhood cancer have been shown to have poor dietary habits (16, 17, 
202) and preferences for high fat foods (153).  In the general population, those with 
a documented taste or smell dysfunction can alter their food intake, either by 
compensating for the lack of flavour in foods with an increase in intake, or 
decreasing their intake due to a lack of enjoyment of the food (271, 331). Taste 
dysfunction has also been associated with obesity in both adults and children (356, 
357) in the general population. The taste and smell function of childhood cancer 
survivors (CCS) has not been previously assessed. If CCS are found to have a taste 
or smell dysfunction this may be one factor influencing their food preferences and 
dietary intake. The aim of this study was to assess smell and taste function in this 
population and to determine whether this influences food preferences which could in 
turn influence their dietary intake. To this end, it was hypothesised that the CCS 
level of taste and smell functioning would be related to food liking scores. 
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8.2 Methods 
 
8.2.1 Study participants 
Participants were CCS who were at least 5 years since cancer treatment completion 
and who attended the long-term follow-up clinics for a their yearly review, at Sydney 
Children’s Hospital, Randwick and the Children’s Hospital Westmead, Australia, 
between July and September 2011. Participants were excluded from participation if 
they were under the age of 12 years, did not speak English or were pregnant. 
Participants were also excluded if they had known problems with swallowing as the 
testing required participants to swallow a small amount of the tasting solutions. The 
study protocol was approved by The Royal Alexandra Hospital for Children Ethics 
Committee (Approval No. 11/CHW/24) and informed consent was obtained from all 
participants 
 
8.2.2 Demographics 
Demographic information collected from the medical records of participants 
included, age, sex, cancer diagnosis, type of treatment received, time since 
treatment completion and current medications. 
 
8.2.3 Taste identification 
Taste function was assessed by the ability to identify four different tastes – sweet, 
sour, salty and bitter across five different concentrations, and five samples of water. 
Each participant was familiarised with the test procedure by sipping a few millilitres 
of a moderate strength solution each child was familiarized with the test by being 
asked to sip a solution (2–3 ml of a single sample) that was moderately sweet 
(sucrose, 0.36 M; Sigma, Sydney, Australia), salty (sodium chloride, 0.18 M; BDH, 
Sydney, Australia), sour (citric acid, 0.009 M; BDH) and bitter (quinine 
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hydrochloride, 0.0001 M; Aldrich, Sydney, Australia), respectively, and water 
(Nobles Ultra Pure Water, Sydney, Australia). Test tastant concentrations were 
prepared by dissolving analytical grade sucrose (0.05, 0.08, 0.12, 0.20, 0.32 M, 
Sigma, Sydney, Australia) citric acid (0.0038, 0.0062, 0.0100, 0.0159, 0.0256M 
BDH, Sydney, Australia), sodium chloride (0.07, 0.11, 0.18, 0.28, 0.46 BDH) and 
quinine hydrochloride (0.00009, 0.00016, 0.00026, 0.00041, 0.00065M, Aldrich, 
Sydney, Australia) in purified drinking water (Nobles Ultra Pure Water, Sydney).  For 
each of the 25 samples, participants were presented with a small amount of tastant 
solution and then asked to select one of three labelled photographs which best 
described the taste they had sampled. The photographs were a pictorial 
representation of the tastant. The photographs also contained the name of the three 
tastants represented e.g. sweet, sour, salty, bitter or water. The assessor read out 
all three names to the participant (276) before they made their choice. The 25 
tastants were presented to each participant in a random order with a 20-30 second 
break between the assessment of each tastant. Participants were advised to rinse 
their mouth with pure water between each sample.  
 
For each tastant, participants who identified less than four out of the five 
concentrations for each individual tastant were considered to have impairment in 
their ability to detect that taste (276). This criteria was established from normative 
data for children (n=232)  and adults (n= 56) older than five years, using the same 
test procedure (276). The same criteria for taste impairment has been used with 
participants with cystic fibrosis (317), chronic kidney disease (358) and healthy 
school children (306). 
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8.2.4 Smell identification 
Smell function was assessed by determining the ability of participants to identify 16 
common odorants including Dettol™ (a common antiseptic product based on 
chloroxylenol), sour, baby powder, fishy, grassy, paint, flowers, strawberry, cheesy, 
petrol, spicy, onion, Vicks VapoRub™ (odour of mentholated topical cream), minty, 
orange and chocolate. The 16 odorants were diluted to a total volume of 20ml with 
odourless dipropylene glycol (Fluka 99% pure) and placed in individual opaque 
squeeze bottles which each participant was shown how to squeeze and sniff from 
the bottle (276). The participants were then presented with three labelled 
photographs and asked to pick the one most representative of the smell they had 
just been presented. The photographs were a pictorial representation of the odorant 
combined with the name of the odorant. The test was developed not only for adults 
but for use with children from five years of age (276). It was developed with children 
five to nine years old (n=232) and adults (n=56).  Early data indicated that children 
from nine years of age performed similarly to adults (277). In addition, it has been 
shown to have a test-retest reliability of 0.98 (306) indicating a high level of 
reliability. A score of less than 13 out of a possible 16 (e.g. more than four smells 
incorrectly identified) was defined as an olfactory impairment (276).  
 
8.2.5 Quality of Life (QoL) 
The Functional Assessment of Anorexia/Cachexia Treatment QoL scale (FAACT) 
was used for participants greater than 18 years of age and the Pediatric Functional 
Assessment of Anorexia Cachexia (Peds-FAACT) used for participants less than 18 
years of age. These tools are validated in this population to measure health related 
quality of life (359, 360)  and contain an additional items section on issues relating to 
anorexia/cachexia. This tool was used as a subjective measure of the severity of 
food-related symptoms such as taste change and poor appetite. 
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8.2.6 Food liking 
A 94-item food liking questionnaire was used to elicit participant’s food preferences 
(361, 362). The questionnaire required participants to rate their attitudes towards a 
range of common foods on a scale of 0 to 5, with 0 = not having tried a food, 1 = 
hating a food, up to 5 = loving the food. The responses were then sorted according 
to 10 food groups; meat/fish, vegetarian foods other than vegetables, bakery goods, 
breakfast foods, convenience foods/takeaways, dairy foods, fruit, snacks, green 
vegetables/salad and other vegetables. The mean liking scores for each of the 10 
categories were calculated. The higher the mean score, the more likely the food 
group was “liked”.  This data was then analysed to illustrate trends in participant’s 
food likes. 
 
8.2.7 Statistical analysis 
Statistical analyses were performed using IBM SPSS version 19 (IBM Corp., 
Armonk, New York). Previous research in clinical and non-clinical populations using 
the same taste and smell tests utilised here indicate that the majority of people 
score towards the high-functioning end of the scale on both of these tests (306, 317, 
319). Since the underlying distribution of these smell and taste tests are non-normal, 
and the comparisons between treatment groups involved small and uneven group 
sizes, non-parametric statistics were considered the most appropriate method of 
analyses for the current data (363). Differences and associations were considered 
significant at p<.05 (2-tailed). Bonferroni corrections were applied to alpha for all 
subsequent post-hoc tests to reduce the chance of type I error (363). The specific 
analyses used to examine each of the variables are described in the respective 
results sections. Where Bonferroni corrections have been applied, the relevant 
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adjusted alpha level is indicated alongside the reported results and significance 
values. 
8.3 Results 
 
8.3.1 Demographics 
Fifty-five childhood cancer survivors were approached to participate in the study of 
which 51 (93%) were recruited. The mean age of the participants was 19.69 (±7.09) 
years and a mean of 12.4 (±6.87) years had passed since completion of their 
treatment (Table 8-1). 
Table 8-1 Demographics of childhood cancer survivors 
 
Characteristic  
 
Sex (male:female) 24:27  
Age at assessment,  
              Mean (SD)(range): Years 
 
19.69 (7.09)(12-40) 
Age at diagnosis,  
              Mean (SD)(range): Years 
 
5.27 (4.05)(0-17) 
Time since treatment completion 
              Mean (SD)(range): Years 
 
12.40 (6.87)(5-38) 
Cancer diagnosis (n) 
 
 
ALL* 18  
AML** 1  
Neuroblastoma 4  
Wilms’ tumour 4  
Rhabdomyosarcma 3  
Lymphoma 4  
Medulloblastoma 
Ewing’s Sarcoma 
Osteosarcoma 
Other 
2  
2 
3 
10 
Treatment (n) 
               Chemotherapy 
               Chemotherapy + Radiotherapy 
                    Cranial Radiotherapy 
                    Abdominal Radiotherapy 
                    Head and Neck Radiotherapy 
 
27  
17 
6 
2 
1 
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                    Other sites 
                    HCST# 
                    Total Body Irradiation 
                                  
8 
7 
4 
* ALL: Acute Lymphoblastic Leukaemia ** AML: Acute Myeloid Leukaemia # HSCT: 
Haematopoietic stem cell transplant (HSCT) 
 
8.3.2 Taste 
Taste dysfunction was found in 14 of the 51 participants (27.5%). Of those with a 
taste dysfunction, five (9.8%), eight (15.7%), four (7.8%) and six (11.8%) had a 
sweet, sour, salty or bitter dysfunction, respectively. Seven participants had a 
dysfunction involving one tastant only, five had a dysfunction involving two tastants 
and two had a dysfunction involving three tastants. No patient had a dysfunction 
involving all four tastants.  A Friedman’s ANOVA test indicated the total scores for 
sweet (4.47 ± 0.67), sour (4.45 ± 0.86), salty (4.61 ± 0.70), bitter (4.47 ± 0.92) and 
water (4.45 ± 1.12) were not significantly different (p=0.490).  
 
A series of Spearman’s correlation tests found no significant relationship between 
taste scores and the age at diagnosis (rho= -0.078; p= 0.585) or years since 
treatment completion (rho= -0.101; p=0.481). When these variables were correlated 
with individual tastant scores there was a significant negative correlation between 
age and bitter score (rho= -.357; p = 0.01) suggesting that as age increased 
participants were less able to identify a bitter taste. No other significant results were 
found. When the participants were separated into three treatment types 
(chemotherapy (n=27), chemotherapy + radiotherapy (n=17), HSCT (n=7)) a 
Kruskall-Wallis test indicated that there were no significant differences in total taste 
scores between the treatment types. It should be noted that the power to find 
differences between treatment types was limited by small group sizes, for analyses 
between the three treatment types the power ranged between 0.18 and 0.34. 
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8.3.3 Smell 
Of the 51 participants, six participants (11.8%) were identified as having some 
degree of a smell dysfunction. Two (3.9%) identified only nine of the 16 odors and 
were classified as hyposmic (i.e. significant loss of smell function). Four of the 
participants were slightly hyposmic with scores of 11 and 12 out of 16 respectively. 
Sour and flower odorants were the least identified odorants while Vicks VapoRub™, 
minty and paint were identified by all the participants (Figure 9.1). 
 
 
Figure 8-1 Percentage of participants who correctly identified each odorant 
 
A series of Spearman’s correlation tests found no significant relationship between 
smell scores and age of participants (rho=-0.223; p=0.116), time since treatment 
completion (rho=-0.178; p=0.211), or age at diagnosis (rho= -0.165; p=0.248). A 
comparison of the smell scores between the three treatment groups (chemotherapy 
(n=27), chemotherapy + radiotherapy (n=17), HSCT (n=7)) using a Kruskall-Wallis 
test found a significant difference (p=0.013). Post-hoc Mann-Whitney tests indicated 
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the odour identification scores for the chemotherapy-only group were significantly 
higher than for the HSCT group [p=0.004; Bonferroni adjusted α= 0.0167]. Again, it 
should be noted that the small group sizes limited power to find significant 
differences between treatment types (power ranged 0.18 to 0.34). Of the six 
participants with hyposmia, four of these received a HSCT transplant of which two 
received total body irradiation (TBI) as part of their treatment. No other significant 
differences were found when comparing the treatment groups.  
 
8.3.4 Food liking 
The final mean score for each food category was out of five with the higher the 
score, the more likely the food was “liked” (Figure 9.2). The data showed that the 
most “liked” foods were non-dairy liquids (4.0), followed by takeaway (3.84) and 
snacks (3.8). The least “liked” food groups were the salads and greens (3) followed 
by breakfast cereal (3.03), vegetarian food (3.14) and then vegetables (3.3).  
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Figure 8-2 Mean liking scores for each food category  
 
Spearman’s correlations indicated a significant negative correlation between smell 
score and liking for snacks (rho=-0.294, p =0.036). Thus, as the smell score 
decreased the liking for snacks increased. In contrast, a significant positive 
correlation was found between smell score and salad/greens, (rho=0.404, p=0.003), 
suggesting that as the smell score increased liking of salad/greens also increased. 
Mann-Whitney tests comparing the food liking scores between those with and 
without a smell dysfunction found significantly higher mean food liking scores 
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(possible score out of five) for those without a smell dysfunction for dairy foods (2.90 
vs. 3.56; p=0.027), fruit (2.14 vs. 3.92; p= 0.001) and salad/greens (1.61 vs. 3.19; 
p= 0.0001). No significant differences or correlations were found between the food 
groupings and the taste scores. The treatment group numbers were small; therefore 
results should be interpreted with caution. The results of this study indicate that the 
differences in food liking for those with and without a smell dysfunction along with 
the above significant correlations provide partial support for the hypothesis that 
smell function is related to CCS food liking. 
8.3.5 Quality of life  
Results from the additional concerns section of the QoL tool indicated that the 
participants had no significant food related concerns (Table 8-2).  
 
Table 8-2 Mean score for questions in additional concerns section of the 
Functional Assessment of Anorexia/Cachexia Treatment QoL scale  
 
FAACT Question Mean ± SD* Range 
 
I have a good appetite 2.80 ± 1.34 0-4 
The amount I eat is sufficient to meet my 
needs 
2.92 ± 1.13 0-4 
I am worried about my weight 1.33 ± 1.43 0-4 
Most food tastes unpleasant to me 0.35 ± 0.86 0-3 
I am concerned about how thin I look 0.37 ± 0.78 0-3 
My interest in food drops as soon as I try 
to eat 
0.29 ± 0.74 0-4 
I have difficulty eating rich or “heavy” 
foods 
0.35 ± 0.93 0-4 
My family or friends are pressuring me to 
eat 
0.33 ± 0.83 0-4 
I have been vomiting 0.12 ± 0.39 0-2 
When I eat, I seem to get full quickly 0.80 ± 1.32 0-4 
I have pain in my stomach area 0.29 ± 0.65 0-2 
My general health is improving 2.80 ± 1.39 0-4 
* Possible values: 0 = Not at all; 1 = A little bit; 2 = somewhat; 3 = Quite a bit; 4 = 
very much 
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For example, the mean score for the section on “food tasting bad” was rated low. 
Correlation tests showed there were no significant relationships between smell and 
taste function (total scores) and any food-related QoL measure.  Mann-Whitney 
tests comparing the individual QoL domains between those with a taste dysfunction 
and those who did not, found a significantly higher QoL score for those with a taste 
dysfunction in response to “My general health is improving” (3.46 vs. 2.29 p=0.016). 
There were no QoL associations found when comparing those with and without a 
smell dysfunction. 
 
8.4 Discussion 
 
The results of this study in CCS demonstrate that 27.5% (n=14) had some degree of 
taste dysfunction and 4% (n=2) had a significant smell dysfunction. There was an 
absence of relationships between taste, food liking and QoL and the modest 
relationship between smell dysfunction and liking for healthy foods.  
 
The prevalence of a taste dysfunction in adult oncology patients during 
chemotherapy has been reported to be as high as 40% (271) using objective 
measures or 86% using subjective measures such as self-report (331). In the 
paediatric oncology population, prevalence rates of a taste dysfunction do not exist 
though it has been reported to be an issue during cancer therapy (127, 337). A taste 
dysfunction during the more intensive paediatric HSCT has been reported to be 
around 40% (319).  
 
The findings in this study show a high prevalence of some degree of taste 
dysfunction in survivors of childhood cancer. Some studies have suggested that 
taste dysfunction continues well after treatment completion (182, 355) but this is the 
first study to assess this in a cohort of survivors of childhood cancer.  There are 
 
194 
 
wide variations in the prevalence rates of taste dysfunction in the general 
population. Taste disorders have been reported to range from 0.85% [34] to 20% 
[35]. The prevalence rates have been found using a wide variety of methodology for 
taste assessment and make it difficult to adequately compare findings. A relevant 
comparison of our prevalence rate of a taste dysfunction of 27% (n=14) in the CCS, 
is with a group of healthy, nine to 12 year old Australian children (n=432).  The 
group of healthy Australian children exhibited a taste loss prevalence of 10% using 
the same taste test as used with the CCS and with the same criterion for defining 
taste loss (277).  
 
Accordingly, the prevalence of taste loss of CCS is higher than the general 
population and is a potential undesirable outcome as a result of the cancer itself or 
the treatment received. The mechanism(s) for taste loss in the present group of 
cancer patients is unknown. Possible explanations include a reduction in the number 
of taste and smell receptors as a result of the cytotoxic effects of treatment; changes 
in the rate of turnover of receptor cells, changes induced in the structure of 
receptors affecting the delivery of taste and smell molecules to taste and smell 
receptors, or abnormalities in the reestablishment of synaptic connections at the end 
of cancer treatment (270). 
 
The incidence of smell dysfunction in the present study (3.9%; (n=2)) is slightly 
higher than the a 1.9% found using the present 16-odour identification test with a 
cohort of nine to 12 year old Australian children (277). Although the numbers are 
small in this study there is the suggestion that the smell dysfunction can be 
influenced by the type of treatment received. Four of the six participants who had a 
smell dysfunction underwent a HSCT of whom two received TBI. This may reflect 
greater and more lasting damage to the olfactory system with the more intensive 
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treatment.  Further work investigating taste function may be warranted with this 
group.   
 
The results from this study indicate childhood cancer survivors appear to  
“like” less healthy food groups such as flavoured beverages, takeaway and snacks 
over healthier food groups such as vegetables and salad. These results are 
consistent with previous research findings with childhood cancer survivors who 
displayed unhealthy eating habits, such as a poor vegetable intake and a high fat 
and sugar intake (16, 17, 202). Despite these findings there did not appear to be any 
association with food likes and taste function. In partial support of the hypothesis, 
there did appear to be some association with a smell dysfunction and a reduced 
liking of dairy, fruit and salad/greens.  Further work is needed to confirm whether 
taste or smell dysfunction is affecting CCS’s food choices. 
 
Whilst taste and smell function does not appear to have a key role in the long term 
food likes of CCS, research suggests that treatment for malignancies may still have 
an influence on food preferences through the development of food aversions. It has 
been reported that the likelihood of an individual selecting a food for a second time 
is related to their prior experiences (364). This may be relevant to the development 
of food aversions in the setting of cancer treatment as taste and smell alterations 
during the period of the disease and subsequent treatments coupled with symptoms 
of nausea and vomiting may have resulted in negative experiences during feeding 
(290, 339).  The effect of food aversions may be even more pronounced in those 
receiving treatment for cancer at very young ages as food preferences are thought 
to be largely established through experiences with food in the first 3 years of life 
(218) 
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The results from the QoL tool indicate that this cohort have an acceptable QoL as 
demonstrated by the ratings of participants which corresponded to low levels of 
concern about weight and appetite.  Participants did not report that “food tasted bad” 
despite 27.5% (n=14) of this cohort displaying some form of taste dysfunction. 
Furthermore, there was no association found between QoL scores and taste and 
smell scores. Previous studies suggest that QoL is influenced by perceived level of 
olfactory dysfunction rather than actual degree of dysfunction (365, 366).  It may be 
that a similar phenomenon occurs with taste dysfunction.  
 
8.5 Conclusion 
 
It is concluded that a degree of taste dysfunction occurs in pediatric long term 
cancer survivors although no relationships were found between taste function and 
food likes, and taste function and Qol. Future work should compare taste and smell 
function of childhood cancer patients and survivors with appropriate healthy 
controls. It does not appear that a smell dysfunction were as prevalent though the 
incidence may be slightly higher than the general population.   It is known that CCS  
have undesirable food habits therefore larger prospective longitudinal studies are 
needed to further understand the reasons for these poor dietary habits. Further work 
is also needed to assess whether taste dysfunction plays a role in these dietary 
habits. 
 
8.5.1 Implications 
The final study in the thesis provides evidence that taste and smell dysfunction is an 
issue is survivors of childhood cancer. This study provides one piece of the puzzle in 
determining the aetiology behind the permanent changes seen in the dietary habits 
of survivors of childhood cancer. The next chapter is the final chapter in this thesis. 
 
197 
 
Chapter 9 provides a summary of the findings from this thesis and provides 
recommendations that have implications for both clinical practice and for future 
research.
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9 DISCUSSION 
Over the last 50 years survival rates for children with cancer have improved. For the 
majority of patients, childhood cancer is no longer considered an acute disease with 
high short term morbidity and mortality, but a chronic disease with the potential for 
long term poor outcomes. The goals of the medical treatment for paediatric cancer 
patients is to maximise cure rates while trying to prevent the risk of long term 
deleterious effects of cancer therapy. Nutritional support is an important part of the 
management of paediatric oncology patients. The goal of nutritional therapy has 
been to prevent under-nutrition, ensuring adequate growth and development. 
Results from this thesis are providing the first evidence that the nutritional 
management of paediatric cancer patients needs to change. It needs to follow the 
goals of the medical treatment particularly with regard to preventing long term 
deleterious effects from the cancer therapy period. Childhood cancer survivors have 
inadequate nutrient intake early after treatment completion and it appears that 
young childhood cancer survivors’ dietary habits do not return to what they were 
pre-diagnosis, often to their detriment.  Poor nutritional intakes and obesity are 
emerging as longer term problems. Clinicians may need to alter the aims of the 
nutritional management of cancer patients being mindful that any decisions made 
during cancer therapy may affect the nutritional intake of patients’ long term. At 
present there are no effective evidence-based interventions available that aim to 
improve the nutritional intake of survivors of childhood cancer. 
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9.1 Summary of findings 
 
This thesis has confirmed the central hypothesis that the nutritional management 
decisions made during treatment for childhood cancer are primarily about the short 
term goal of promoting an adequate energy intake to prevent under nutrition. The 
research undertaken was grounded in clinical practice, using an in depth case study 
of a specialist paediatric oncology clinic in Sydney, Australia. A number of separate 
but related investigations took place to address specific questions (and related sub-
hypotheses) and highlight the way forward for improved practice. The first part of the 
thesis aimed to identify and articulate the problem of childhood nutrition in the 
cancer acute care and survival (Figure 9-1).   
 
 
 
Figure 9-1 Schema of hierarchy of studies used within the context of research 
in practice 
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9.1.1 Confirming the problem 
The first part of the thesis examined the hypothesis that there is a significant 
nutrition related problem in childhood cancer survivors. The first study (Chapter 3) 
showed that young childhood cancer survivors did appear to have a poor dietary 
intake, similar to that seen in the literature for adult survivors of childhood cancer. 
Fifty-four percent of young childhood cancer survivors were consuming above their 
estimated energy requirements. Fifty, 32 and 44 percent of children did not meet 
requirements for folate, calcium, and iron respectively. There was a significant trend 
for increasing BMI percentiles from diagnosis to time of assessment (56.29 vs. 
67.17, P = 0.01).  Results from the child feeding questionnaire showed that parents 
were more likely to monitor and use a restrictive form of parenting to control their 
child's food intake rather than pressure their child to eat (P = 0.001). This study 
indicated the extent and nature of the nutritional problem in this clinical group.  
 
The results from chapter 4 showed that the majority of parents of childhood cancer 
survivors found their child’s nutritional intake changed dramatically during the active 
treatment phase. This result was not unexpected as poor dietary intake during 
treatment has been well document in the literature. Of concern was that some of the 
dietary habits established during treatment appeared to continue once treatment 
had been completed. Three main themes emerged regarding parental perceptions 
of young childhood cancer survivors’ current intake as compared with their pre-
diagnosis eating habits: (1) decreased fruit and vegetable intake, (2) increased 
consumption of "junk food," and (3) increased portion sizes. The eating habits seen 
in the young cancer survivors were substantively different to that described by 
parents of the control group. 
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Many parents also appeared to shift their concerns about their child’s weight. Prior 
to their child’s cancer illness most of the parents reported their child’s weight had not 
been a concern. During treatment their focus had been prevention of weight loss but 
on completion of treatment their focus shifted towards concern about their child 
being overweight. Although most of the children who participated in the study were 
not yet considered overweight, their rising BMIs indicated that the parents’ concern 
was justified. The dietary habits and higher than recommended energy intake, would 
likely be one of the contributing factors in young cancer survivor’s rising BMIs.  This, 
in turn, will be putting them at greater risk of long term cancer side effects such as 
metabolic syndrome, cardiovascular disease and obesity. This second study 
qualified the nature of the problem in terms of the social context in which the 
nutritional intakes become a major concern. 
 
9.1.2 Examining practice 
The second part of this thesis hypothesised that clinicians may not be accounting for 
the potential long-term impact of nutrition decisions on survivors of childhood 
cancer, specifically related to actual feeding practices during and following treatment 
completion. 
 
 The first study in this section  (Chapter 5) involved a systematic review that 
delivered a total of three studies on nutritional interventions of all childhood cancer 
survivors, both adult and child. The studies were heterogeneous in regards to the 
methods of the interventions and a meta-analysis was unable to be performed. One 
study found an improvement in calcium intake and calcium supplementation in an 
intervention in adult survivors of childhood cancer aimed at osteoporosis prevention. 
The second study found that a single group intervention improved the self-reported 
improvement in health food intake, though there was no improvement in self-
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reported junk food intake.  Overall the quality of these studies was poor, there was 
no focus on improving dietary intake and none of the studies focused on young 
cancer survivors early after treatment completion. The results indicated a need to 
research practice in more detail. 
 
Research done by our research team has shown that parents are using many 
negative feeding practices to ensure their child consumes adequate food to prevent 
under nutrition during their cancer therapy. This study also indicated that a 
significant part of these negative practices involved threatening their child with 
enteral tube feeding (known as instrumental feeding) if they consuming an adequate 
oral intake. Long term child feeding practices and food preferences are established 
when children are young and parent practices such as instrumental feeding, have 
been associated with poor dietary intake in adults in the non-cancer population. As 
demonstrated in the introductory review for the thesis (chapter 2), under-nutrition is 
a significant issue during cancer therapy and nutritional supplementation in the form 
of enteral tube feeding is an important part of this management.  
 
The second study in this section (Chapter 6) found there appeared to be common 
perceptions of the purposes and impact of ETF among patients, parents and 
healthcare workers. Both positive (good nutrition, weight gain and decreased 
anxiety) and negative (physical appearance, invasive insertion procedure and 
comfort) aspects of EN were discussed. There were some discordant perceptions 
regarding the timing and type of information provided on the use of ETF, as well as 
the decision making process used. Decision making in the healthcare setting is 
complex and information provision alone does not necessarily help with timely and 
appropriate decisions for families. This research found that by standardizing and 
improving the methods used for the commencement of ETF, family distress 
surrounding the use of ETF with paediatric oncology patients may be reduced. 
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9.1.3 Exploring the impact of taste and smell 
The final section of this thesis hypothesised that taste and smell may be implicated 
in the problem of developing healthy eating habits in childhood cancer survivors. 
The first study in this section (Chapter 7) w found self-reported taste and smell 
alterations are prevalent in upwards of 86% of cancer patients. There was also 
some evidence for decreased taste sensitivity in cancer patients when assessed 
using objective tests. In some patients, taste and smell alterations continued well 
after their cancer treatment had been completed. Taste and smell alterations in 
patients with cancer appeared to increase their distress, reduce appetite and 
contribute towards a poor nutritional status. 
   
In light of this review the second study in this section, and the final study in the 
thesis, found that survivors of childhood cancer do have a greater incidence of taste 
and smell changes, compared to the general population. Twenty-seven percent of 
survivors of childhood cancer had some form of smell dysfunction. This was 
considerably higher than the 10% of smell dysfunction reported in the literature for 
the general population, using similar methods of assessment. The incidence of smell 
dysfunction was 10% of the cancer survivors studied which again is higher than the 
one to two percent smell dysfunction reported in the general population. The child 
cancer survivors' appeared to "like" the less healthy food groups such as flavoured 
beverages, takeaway and snacks over healthier food groups such as vegetables 
and salad. No correlation was found between those with a taste dysfunction and 
their food "likes". Thus it appears that taste and smell may contribute substantially to 
the problem of assuring adequate nutrition in childhood cancer and survival, and 
further research is warranted in this area. 
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9.2 Limitations  
 
As stated earlier, this thesis is presented as a case study of clinical practice in a 
defined setting. The data collected for these studies, focused on a specialist 
paediatric oncology site in Sydney, Australia With the exception of study 8 which 
recruited participants across two paediatric oncology units within Sydney, Australia, 
all the data were collected from this site. The demographics of the participants in 
this thesis may not be representative of the childhood cancer population within 
Australia and internationally, especially those from developing countries.  Further 
case studies, such as the one conducted here would add to this knowledge. In 
addition the studies conducted in the thesis can be repeated with a wider 
demographic representation of childhood cancer patients.  
 
 From a methods perspective, the response rate for both the dietary intake study 
and the enteral feeding study were low. This may relate to the use of mail-out 
surveys to recruit the participants or due to the burden of using three-day food 
diaries to collect dietary intake data (367). Since the completion of the dietary intake 
study, a food frequency questionnaire (FFQ), the  Australian Child and Adolescent 
Eating Survey (ACAES), has been validated for use among Australian children and 
adults (368). There is a lower responder burden associated with the  FFQ has 
compared with food records (367) and its use in future studies may improve 
response rates. The ACAES provides a measure of both nutrient intake and food 
variety scores. Food variety scores are positively associated with good health 
outcomes (369). This is advantageous for determining which food groups may need 
targeting in future interventions (369). Recent literature has shown that multiple 24-
hour recalls may be more accurate in determining energy intake than FFQs in 
survivors of childhood cancer. For future interventions, in which weight loss and 
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subsequently energy intake, is the primary outcome, 24 hour recalls could be used 
as a measure of dietary intake.  
 
The empirical component of the thesis involved discrete primary data collection and 
analysis (Chapters 3, 4, and 8) which employed a cross-sectional study design. As 
discussed in chapter one, a cross-sectional study limits the ability to determine a 
causal relationship (370) . Using a cross-sectional methodology does provide an 
assessment of the prevalence of the outcome and information for the generation of 
hypothesis on causal relationships (33). The results from the cross-sectional studies 
in this thesis have provided evidence of the need for a focus on the nutritional intake 
of childhood cancer survivors early off treatment. It has also provided targets for 
intervention in this patient cohort. Future studies could assess the changing dietary 
patterns during treatment and into survival using a prospective longitudinal study 
design. This will also provide the researchers with the opportunity to assess the 
mechanism involved with this permanent change in dietary habits. 
 
9.3 Conclusions 
 
As childhood cancer is no longer an acute condition with poor outcomes and high 
morbidity and mortality, it should be treated as a chronic condition. The results from 
my research confirm my hypothesis that dietary habits of childhood cancer patients 
developed during cancer therapy are continuing once treatment has completed. In 
addition, the poor dietary intake seen in adult survivors of childhood cancer is likely 
manifesting itself early after treatment completion. There now needs to be greater 
awareness of the link between the nutrition decisions made during the cancer 
therapy and how they may be affecting the child’s nutritional intake well after cancer 
therapy is completed. At the very least, nutritional interventions to improve the 
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dietary habits of survivors of childhood cancer need to be initiated soon after 
treatment completion. Ideally a focus on long-term healthy dietary habits may need 
to occur during cancer therapy. 
 
 
9.4 Implications for clinical practice 
This research was grounded in changing clinical practice. The following 
recommendations are for dietitians and clinicians working with childhood cancer 
patients: 
 
9.4.1 Models of care 
The current standard of dietetic care in paediatric oncology is to provide funding for 
a dietitian to see patients during the acute phase of cancer therapy. This thesis 
highlights the need for the health service to recognise that paediatric oncology no 
longer just about treating disease but is about health protection. Paediatric oncology 
centres should be considering enhancing funding models for the provision of long-
term dietetic follow-up as part of standard care. Medical conditions such as cystic 
fibrosis and type I diabetes are considered chronic conditions and their care model 
provides significant funding for a dietitian to review and manage patients on a 
regular basis. Cancer centres may need to utilise the same model of care as other 
such chronic paediatric diseases, providing regular nutritional assessment and 
follow-up to paediatric cancer patients once treatment is complete. 
 
The referral criteria for nutritional interventions may need to be altered. The current 
model is reactive, where referrals are made to a deititian once weight loss or a 
reduction in oral intake is seen in the patient. This model is used because the 
current funding model is not adequate to allow all patients to be assessed early in 
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their cancer journey. This thesis provides early evidence that the poor dietary habits 
and parenting practices seen during treatment are continuing once therapy is 
completed. This has implications for survivors who are at a high risk of early-onset 
chronic health conditions. The dietetics model should be changed to a proactive 
model in which all patients are counselled on good nutritional practices early on in 
their cancer journey.  
 
9.4.2 Dietetic practice  
As the prevention or treatment of under-nutrition has been the focus of the dietary 
management of childhood cancer patients, recommendations for nutritional support 
have been based on increasing the energy intake of a patient’s diet. This has been 
to the detriment of good nutritional practices. The mantra of “eat whatever you like” 
has been recited among both dietitians and clinicians for many years. In light of the 
shift towards childhood cancer being considered a chronic disease, these practices 
need to also change. Dietitians should no longer focus on improving a patient’s 
energy intake in isolation. Parents and carers should be counselled on the use of 
healthy high energy diets in combination with maintaining intake as close to the 
dietary guidelines as possible.  
 
Dietitians could consider providing education and counselling to parents and 
patients on using positive feeding practices to encourage their child to consume an 
adequate intake during their child’s cancer treatment. The constant pressure to get a 
child to consume an adequate intake may be causing long term issues with food 
aversions. Parents should avoid using the threat of the insertion of a nasogastric 
tube to get their child to eat. Parents and clinicians need to view nasogastric tube 
insertion as part of standard practice of care rather than something that is used as a 
last resort. The practice of prophylactic nasogastric tube insertion may reduce 
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parental stress surrounding their child’s food intake, thereby potentially avoiding 
these negative feeding practices. If a child has a nasogastric tube in to ensure an 
adequate nutritional status is maintained throughout treatment then parents may feel 
more comfortable encouraging a healthy diet when their child does eat. Constant 
exposure to a greater food variety on treatment has the potential to improve the 
dietary habits of childhood cancer patients once their treatment is complete.   
 
9.4.3 Food service 
At present, the meals and snacks provided to the patients in the hospital 
environment, do not necessarily reflect good nutritional practices. Many of the foods 
are heavily processed, the vegetables are inedible, and the mid-meal snacks 
provided include items such as chocolate and sweet biscuits, high sugar yoghurts 
and flavoured milks and high sugar muffins. In light of the results from the thesis, a 
review of the food service system in paediatric oncology units is required. The foods 
provided to the patients, especially mid-meal snacks should complement the 
education regarding healthy high energy foods. The snacks should be low in 
saturated fat and sugar but high in energy and provide other nutritional benefits. The 
paediatric oncology unit currently provides patients and families with fruit for 
consumption, and could consider providing vegetables as well. This may encourage 
families to cook healthier meals to provide to their child when an inpatient. Funding 
for a nutrition assistant could also allow cooking demonstrations on the wards to 
also encourage childhood cancer patients to have a positive relationship with food. 
 
Commercially prepared oral nutritional supplements and some of the supplements 
used for enteral tube feeding may not represent good nutritional practices. Many of 
the oral supplements are very high in sugar to help with palatability, but if used as a 
sole source of nutrition, are likely increasing the patient’s intake of sugar above that 
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recommended in the dietary guidelines. The use of commercially prepared 
supplements is an important part of dietetic practice to provide the patient with 
additional energy and nutrients. To enable a continuation with the practice of using a 
healthy high energy diet to prevent weight loss, the nutritional supplements should 
reflect this. The paediatric oncology unit could provide blenders and high energy 
healthy drink recipes for the parents to make for their children while they are an 
inpatient.  Use of healthy high energy drinks provides an opportunity for the patient 
to consume a greater amount of fruit and vegetables in an easy to consume format. 
 
Although consumption of non-processed food is preferable, supplying freshly 
cooked meals and snacks to patients in the hospital may not be practical. Parents 
have a limited capacity to cook meals due to the time constraints involved with 
looking after a sick child as well as a lack of resources available in the hospital to 
cook for their child. Many patients also find it difficult to consume hot meals due to a 
hypersensitivity to smells. Many families rely on highly processed packaged food to 
ensure their child consumes an adequate energy intake though these foods don’t 
usually provide any other nutrients. Clinicians and dietitians could partner with the 
food industry to develop more appropriate snacks which are not only high in energy 
and palatable but be based on fruit and vegetables as a way to reinforce this 
concept of healthy high energy. 
 
9.4.4 Dietetic education 
Childhood cancer is not the only paediatric condition in which improvements in 
treatment have meant that diseases which were once associated with early mortality 
are now considered chronic disease. Clinicians who work with paediatric patients 
with conditions such as Cystic Fibrosis, renal disease and HIV are also finding their 
patients are at a higher risk of chronic disease, such as cardiovascular disease, than 
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their peers. Dietitians are also becoming aware of the importance of promoting good 
nutritional practices (not just high energy) in young patients with these conditions 
and are starting to change their practice accordingly. Clinical based nutrition 
research should not only focus on nutrient intake but food variety and dietetic 
education given to the patient should reflect this. 
 
 
 The education of dietetic students must also start to reflect this change in dietetic 
practice. Many students are still being educated on the use of commercially 
prepared snacks and supplements as well as sugar-sweetened beverages as the 
first line of dietetic practice. Although these will still remain an important part of 
dietetic practice they should not be considered the first option in dietetic practice. 
Dietetic students should be educated in providing and trialling food based 
recommendations with their patients first, before the use of commercially snacks 
and supplements. 
 
 
9.5 Directions of future research 
 
A number of research questions have been proposed as a result of this thesis and 
have provided a focus for nutritional interventions for young cancer survivors early 
after treatment completion. Our research team has commenced the development of 
an intervention (ReBoot-kids) which aims to improve fruit and vegetable intake and 
reduce non-core food intake in young cancer survivors early after their treatment 
completion. The aim of this study is to determine whether dietary habits of childhood 
cancer survivors can be improved early after treatment completion. The long-term 
aim is reducing the incidence of chronic health conditions in adult survivors of 
childhood cancer. 
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The prevention of poor dietary habits in childhood cancer patients should ideally be 
a focus during treatment. To reflect the recommendations from this thesis on the 
importance of focusing on healthy high energy diet education, a need assessment 
will be undertaken with parents and carers on the paediatric oncology ward, to 
clarify their views on the current dietetic care model.  There is a dearth of research 
assessing the dietary intake of cancer patients during treatment as focus has been 
on energy intake alone. An assessment of the nutritional intake of childhood cancer 
patients should also be undertaken to provide targets for interventions on treatment. 
The results of this research will be used to design education materials reflecting the 
use of a healthy high energy diet, and to improve the food service model. 
 
The thesis has also provided a focus for an intervention for improving the 
information provision regarding nutritional support options during cancer therapy. 
Results from this thesis as well as previous work completed at our centre show that 
uptake of nutritional support such as ETF can be delayed. Parents are using poor 
feeding practices such as forcing their child to eat to prevent their need for ETF. 
These feeding practices also have the potential to cause long-term oral aversions 
and poor dietary habits after treatment completion. Research has begun on 
developing and pilot testing a decision aid for use with childhood cancer patients 
regarding decisions on nutrition supplementation. The aim is to provide adequate 
education to parents about the benefits and risks of all nutrition support options in a 
timely manner. The long-term goal is to ensure parents are adequately informed 
about their child’s nutrition choices. This may reduce the poor parent feeding 
practices seen in this patient cohort thereby preventing poor dietary habits from 
developing during and after cancer therapy.  
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The results from this thesis will inform a longitudinal study assessing the change in 
childhood cancer patient’s dietary habits during their cancer therapy and beyond. 
The longitudinal study will focus on assessing nutrient intake, food variety and 
dietary habits of childhood cancer patients. This study will also assess potential 
predictors and of the changing dietary habits and intake. Such predictors will 
include: 
• Taste and smell changes 
• Parental feeding practices 
• Development of learned aversions 
• Lack of repeated exposure  
• Change in appetite regulation 
 
The longitudinal study will aim to confirm the hypothesis generated from this thesis 
that the dietary habits of childhood cancer patients permanently change as a result 
of their cancer therapy. A secondary aim will be to determine the aetiology and 
predictors of the change in dietary habits. The results from the longitudinal study will 
then drive future dietary interventions for children while on cancer therapy with the 
long-term aim to reduce their risk of long-term metabolic conditions associated with 
survivors of childhood cancer.  
 
I hope that results from this thesis combined with future research on dietary habits 
and dietary practice will ensure that survivors of childhood cancer will have a QoL 
equal, if not better than their peers. 
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APPENDIX A – CHILD FEEDING QUESTIONNAIRE 
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APPENDIX B – 3 DAY FOOD DIARY 
 
 
Parental Attitudes to Nutrition Study 
3-day food diary 
 
Instructions 
1. Pick three days to keep your child’s food diary-one of these days should be 1 weekend and 2 weekdays 
2. Do not change your child’s eating habits during this time 
3. Record everything your child eats and drinks over those three days 
4. Please be as accurate as possible including brands, amounts (weighed if possible) and how it was cooked. 
5. Please indicate if the food is made at home or is bought at a store 
6. Try and include individual ingredients i.e. a ham sandwich is 2 slices white bread & 2 slices of primo ham & 1 tsp margarine 
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Example 
Meal Time Food Item Serving Size Extras (salt, mayo etc 
Breakfast 6.15am Rice bubbles ½ cup  
Breakfast 6.15am Shape milk ½ cup 2 tsp sugar 
Recess 10.30am UncleTobys muesli bar 1 bar  
Recess 10.30am Orange Juice-freshly 
squeezed 
200ml  
Lunch 12.10pm White bread 2 slices  
Lunch 12.10pm Tomato 4 slices  
Lunch 12.10pm Cheese 1 Kraft cheese slice  
Lunch 12.10pm Lettuce 1 leaf cos lettuce 2 tsp margarine 
Afternoon Tea 3.30pm Apple-Granny Smith 1 small  
Afternoon tea  3.30pm Chips-salt & vinegar 25g packet  
Dinner 6.30pm Lamb chop-grilled 2 x 60g 2 tsp tomato sauce 
Dinner 6.30pm Broccoli-boiled 3 rosettes (30g)  
Dinner 6.30pm Carrots-steamed ¼ cup  
Dinner 6.30pm Chips-fried-McCain ½ cup  
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Name:_______________________________________  Day of Week:__________________________________  
Date:________________ 
 
Meal Time Food Item Serving Size 
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APPENDIX C – ETHICS APPROVAL LETTER (CHAPTER 3 & 4) 
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APPENDIX D – SEARCH STRATEGY FOR COCHRANE CENTRAL REGISTER OF 
CONTROLLED TRIALS (CENTRAL) 
1. For Population the following text words were used: 
(infant OR infan* OR newborn OR newborn* OR new-born* OR baby OR baby* OR babies 
OR neonat* OR child OR child* OR schoolchild* OR schoolchild OR school child OR school 
child* OR kid OR kids OR toddler* OR adolescent OR adoles* OR teen* OR boy* OR girl* 
OR minors OR minors* OR underag* OR under ag* OR juvenil* OR youth* OR kindergar* 
OR puberty OR puber* OR pubescen* OR prepubescen* OR prepuberty* OR pediatrics OR 
pediatric* OR paediatric* OR peadiatric* OR schools OR nursery school* OR preschool* OR 
pre school* OR primary school* OR secondary school* OR elementary school* OR 
elementary school OR high school* OR highschool* OR school age OR schoolage OR 
school age* OR schoolage* OR infancy OR young adult OR young adults OR young adult*) 
AND (post treatment OR off treatment OR treatment complet* OR treatment termin* OR 
follow up OR follow-up OR followup OR survivor OR survivors OR Long-Term Survivors OR 
Long Term Survivors OR Long-Term survivor OR survivo* OR surviving) 
2. For Nutrition the following text words were used: 
patient education OR practice guideline OR practice guidelines OR dietary guideline OR 
dietary guidelines OR practice guideline* OR dietary guideline* OR diet OR diets OR diet* 
OR diets* OR dietetic OR dietetics OR diet therapy OR health diet OR healthy food OR 
health promoting behaviour OR health promoting behaviour OR (diet* AND intervent*) OR 
(diet* AND advic*) OR diet* AND counsel* OR (diet* AND therap*) OR (diet* AND 
treatment*) OR (diet* AND educat*) OR (nutriti* AND intervent*) OR (nutriti* AND advice*) 
OR (nutriti* AND counsel*) OR (nutriti* AND therap*) OR (nutriti* AND treatment*) OR 
(nutriti* AND educat*) OR (nutriti* AND support) OR supportive therapy 
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3. For Outcome the following text words were used: 
food OR foods OR food* OR foods* OR food intake OR eating OR ingestion OR nutrition OR 
nutrition* OR (health* AND diet*) OR (health* AND food*) OR energy intake OR caloric 
intake OR kilojoule OR kilojoules OR calorie OR calori* OR caloric restriction OR vitamin OR 
vitamins OR vitamin* OR minerals OR minerals* OR mineral OR mineral* OR micro-nutrient 
OR micro-nutrients OR macro-nutrient OR macro-nutrients OR nutrient OR nutrients OR 
calcium OR folate OR folic acid OR iron OR ferric OR ferrous OR protein OR proteins OR fat 
intake OR fat reduced OR dietary fat restriction OR low fat OR low calorie OR low energy 
OR reduced energy OR calorie controlled OR fatty foods OR high fat OR fruit OR fruits OR 
vegetable OR vegetables OR dietary composition OR carbohydrate intake OR 
obesity OR obese OR adiposity OR body weight OR overweight OR body mass index OR 
BMI OR body mass OR body fat distribution OR body composition OR “bioelectrical 
impedance analysis” OR health behavior OR health behaviors OR health behaviour OR 
health behaviours OR health behaviour* OR health behaviour* OR health promotion OR 
behaviour change OR behavior change OR behaviour change* OR behavior change* OR 
health behaviour change OR health behavior change OR helath behaviour change* OR 
health behavior change* OR life style OR life style* OR weight gain OR weight gains OR 
weight gain* OR body weight OR weight loss OR weight change OR weight changes OR 
weight change* OR overnutrition OR overeating OR hyperphagia OR Metabolic syndrome 
OR Waist hip ratio OR Waist height ratio OR Skinfold thickness OR Skinfold thicknesses OR 
Skinfold thickness* OR DEXA OR Diabetes OR type 2 diabetes OR glucose metabolism OR 
insulin metabolism OR insulin resistance OR hyperinsulinemia OR hyperinsulinaemia OR 
cardiomyopathy OR myocardial Infarction OR fat metabolism OR cardiovascular risk factor 
OR cardiovascular risk factors OR cardiovascular risk factor* OR cardiovascular disease OR 
cardiovascular diseases OR blood pressure OR hypertension OR blood lipid OR blood lipids 
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OR blood lipid* OR hyperlipidemia OR hyperlipidaemia OR dyslipidemia OR dyslipidaemia 
OR cholesterol metabolism OR hypercholesterolemia OR osteoporosis OR bone mineral 
density OR dual energy x-ray absorptiometry OR malnutrition OR undernutrition OR 
Nutritional Deficiency OR Nutritional Deficiencies OR ideal body weight OR body image OR 
eating disorder OR eating disorders OR eating disorder* OR disordered eating OR fussy 
eating OR food refusal OR quality of life OR QoL 
4. For Cancer the following text words were used: 
cancer OR oncology OR oncolog* OR neoplasms OR neoplas* OR carcinoma OR carcinom* 
OR tumor OR tumour OR tumor* OR tumour* OR cancer* OR malignan* OR 
hematooncological OR hemato oncological OR hemato-oncological OR hematologic 
neoplasms OR hematolo* OR bone marrow transplantation OR bone marrow transplant* OR 
leukemia OR leukaemia OR lymphoma 
The search was performed in title, abstract or keywords 
Final search 1 and 2 and 3 and 4 
[* = zero to many characters] 
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APPENDIX E – SEARCH STRATEGY FOR MEDLINE (PUBMED) 
1. For Population the following MeSH headings and text words were used: 
(infant OR infan* OR newborn OR newborn* OR new-born* OR baby OR baby* OR babies 
OR neonat* OR perinat* OR postnat* OR child OR child* OR schoolchild* OR schoolchild 
OR school child OR school child* OR kid OR kids OR toddler* OR adolescent OR adoles* 
OR teen* OR boy* OR girl* OR minors OR minors* OR underag* OR under ag* OR juvenil* 
OR youth* OR kindergar* OR puberty OR puber* OR pubescen* OR prepubescen* OR 
prepuberty* OR pediatrics OR pediatric* OR paediatric* OR peadiatric* OR schools OR 
nursery school* OR preschool* OR pre school* OR primary school* OR secondary school* 
OR elementary school* OR elementary school OR high school* OR highschool* OR school 
age OR schoolage OR school age* OR schoolage* OR infancy OR schools, nursery OR 
infant, newborn OR young adult[mh] OR adult[mh] OR young adult) 
AND (post treatment OR off treatment OR treatment complet* OR treatment termin* OR 
follow up OR follow-up OR followup OR survivor OR survivors OR Long-Term Survivors OR 
Long Term Survivors OR Long-Term survivor OR Survivor, Long-Term OR Survivors, Long-
Term OR survivo* OR surviving) 
2. For Nutrition the following MeSH headings and text words were used: 
patient education OR practice guideline OR practice guidelines OR dietary guideline OR 
dietary guidelines OR practice guideline* OR dietary guideline* OR diet OR diets OR diet* 
OR diets* OR dietetic OR dietetics OR diet therapy OR health diet OR healthy food OR 
health promoting behaviour OR health promoting behaviour OR (diet* AND intervent*) OR 
(diet* AND advic*) OR diet* AND counsel* OR (diet* AND therap*) OR (diet* AND 
treatment*) OR (diet* AND educat*) OR (nutriti* AND intervent*) OR (nutriti* AND advice*) 
OR (nutriti* AND counsel*) OR (nutriti* AND therap*) OR (nutriti* AND treatment*) OR 
(nutriti* AND educat*) OR (nutriti* AND support) OR supportive therapy 
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3. For Outcome the following MeSH headings and text words were used: 
food OR foods OR food* OR foods* OR food intake OR eating OR ingestion OR nutrition OR 
nutrition* OR (health* AND diet*) OR (health* AND food*) OR energy intake OR caloric 
intake OR kilojoule OR kilojoules OR calorie OR calori* OR caloric restriction OR vitamin OR 
vitamins OR vitamin* OR minerals OR minerals* OR mineral OR mineral* OR micro-nutrient 
OR micro-nutrients OR macro-nutrient OR macro-nutrients OR nutrient OR nutrients OR 
calcium OR folate OR folic acid OR iron OR ferric OR ferrous OR protein OR proteins OR fat 
intake OR fat reduced OR dietary fat restriction OR low fat OR low calorie OR low energy 
OR reduced energy OR calorie controlled OR fatty foods OR high fat OR fruit OR fruits OR 
vegetable OR vegetables OR dietary composition OR carbohydrate intake OR 
obesity OR obese OR adiposity OR body weight OR overweight OR body mass index OR 
BMI OR body mass OR body fat distribution OR body composition OR “bioelectrical 
impedance analysis” OR  health behavior OR health behaviors OR health behaviour OR 
health behaviours OR health behaviour* OR health behaviour* OR health promotion OR 
behaviour change OR behavior change OR behaviour change* OR behavior change* OR 
health behaviour change OR health behavior change OR health behaviour change* OR 
health behavior change* OR life style OR life style* OR weight gain OR weight gains OR 
weight gain* OR body weight OR weight loss OR weight change OR weight changes OR 
weight change* OR overnutrition OR overeating OR hyperphagia OR Metabolic syndrome 
OR Waist hip ratio OR Waist height ratio OR Skinfold thickness OR Skinfold thicknesses OR 
Skinfold thickness* OR DEXA OR Diabetes OR type 2 diabetes OR glucose metabolism OR 
insulin metabolism OR insulin resistance OR hyperinsulinemia OR hyperinsulinaemia OR 
cardiomyopathy OR myocardial Infarction OR fat metabolism OR cardiovascular risk factor 
OR cardiovascular risk factors OR cardiovascular risk factor* OR cardiovascular disease OR 
cardiovascular diseases OR blood pressure OR hypertension OR blood lipid OR blood lipids 
OR blood lipid* OR hyperlipidemia OR hyperlipidaemia OR dyslipidemia OR dyslipidaemia 
OR cholesterol metabolism OR hypercholesterolemia OR osteoporosis OR bone mineral 
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density OR dual energy x-ray absorptiometry OR malnutrition OR undernutrition OR 
Nutritional Deficiency OR Nutritional Deficiencies OR ideal body weight OR body image OR 
eating disorder OR eating disorders OR eating disorder* OR disordered eating OR fussy 
eating OR food refusal OR quality of life OR QoL 
4. For Cancer the following MeSH headings and text words were used: 
cancer OR oncology OR oncolog* OR neoplasms OR neoplas* OR carcinoma OR carcinom* 
OR tumor OR tumour OR tumor* OR tumour* OR cancer* OR malignan* OR 
hematooncological OR hemato oncological OR hemato-oncological OR hematologic 
neoplasms OR hematolo* OR bone marrow transplantation OR bone marrow transplant* OR 
leukemia OR leukaemia OR lymphoma 
5. For RCTs and CCTs the following MeSH headings and text words were used: 
(randomized controlled trial[pt]) OR (controlled clinical trial[pt]) OR (randomized[tiab]) OR 
(placebo[tiab]) OR (drug therapy[sh]) OR (randomly[tiab]) OR (trial[tiab]) OR (groups[tiab])) 
AND (humans[mh] 
Final search 1 and 2 and 3 and 4 and 5 
[pt = publication type; tiab = title, abstract; sh = subheading; mh = MeSH term; * = zero to 
many characters; RCT = randomized controlled trial; CCT = controlled clinical trial] 
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APPENDIX F – SEARCH STRATEGY FOR EMBASE (OVID) 
1. For Popuation the following Emtree terms and text words were used: 
1. infant/ or infancy/ or newborn/ or baby/ or child/ or preschool child/ or school child/ 
2. adolescent/ or juvenile/ or boy/ or girl/ or puberty/ or prepuberty/ or pediatrics/ 
3. primary school/ or high school/ or kindergarten/ or nursery school/ or school/ 
4. or/1-3 
5. (infant$ or newborn$ or (new adj born$) or baby or baby$ or babies or neonate$ or 
perinat$ or postnat$).mp. 
6. (child$ or (school adj child$) or schoolchild$ or (school adj age$) or schoolage$ or (pre adj 
school$) or preschool$).mp. 
7. (kid or kids or toddler$ or adoles$ or teen$ or boy$ or girl$).mp. 
8. (minors$ or (under adj ag$) or underage$ or juvenil$ or youth$ or young adult or young 
adults or young adult$).mp. 
9. (puber$ or pubescen$ or prepubescen$ or prepubert$).mp. 
10. (pediatric$ or paediatric$ or peadiatric$).mp. 
11. (school or schools or (high adj school$) or highschool$ or (primary adj school$) or 
(nursery adj school$) or (elementary adj school) or (secondary adj school$) or 
kindergar$).mp. 
12. or/5-11 
13. 4 or 12 
AND 
1. (survivor or survivors or (long adj term survivor) or (long adj term survivors) or 
survivo$).mp. 
2. survivor/ or cancer survivor/ 
3. survivi$.mp. 
4. (post treatment or off treatment).mp. 
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5. (treatment complet* or treatment termin*).mp. 
6. (follow up or followup or follow-up).mp. or exp follow up/ 
7. or/1-6 
2. For Nutrition the following Emtree terms and text words were used: 
1. patient education.mp. or exp patient education/ 
2. (practice guideline or practice guidelines or practice guideline$).mp. 
3. exp practice guideline/ 
4. (dietary guideline or dietary guidelines or dietary guideline$).mp. 
5. exp DIET/ or diet.mp. 
6. (diets or diet$ or diets$ or dietetic or dietetics).mp. 
7. diet therapy.mp. or exp diet therapy/ 
8. (health diet or healthy food).mp. or exp health food/ 
9. exp health behavior/ 
10. (health promoting behaviour or health promoting behavior).mp. 
11. (diet$ and intervent$).mp. 
12. (diet$ and advic$).mp. 
13. (diet$ and counsel$).mp. 
14. (diet$ and therap$).mp. 
15. (diet$ and treatment$).mp. 
16. (diet$ and educat$).mp. 
17. (nutriti$ and intervent$).mp. 
18. (nutriti$ and advice$).mp. 
19. (nutriti$ and counsel$).mp. 
20. (nutriti$ and therap$).mp. 
21. (nutriti$ and treatment$).mp. 
22. (nutriti$ and educat$).mp. 
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23. (nutriti$ and support).mp. 
24. supportive therapy.mp. 
25. or/1-24 
3. For Outcome the following Emtree terms and text words were used: 
1. (food or foods or food* or foods* or food intake).mp. 
2. exp FOOD INTAKE/ or exp FOOD/ 
3. eating.mp. or exp EATING/ 
4. ingestion.mp. or exp INGESTION/ 
5. exp NUTRITION/ 
6. (nutrition or nutrition$).mp. 
7. (health$ and diet$).mp. 
8. (health$ and food$).mp. 
9. (energy intake or carbohydrate intake or caloric intake).mp. or exp caloric intake/ 
10. (kilojoule or kilojoules or calorie or calori$ or caloric restriction).mp. 
11. vitamin/ 
12. (vitamin or vitamins or vitamin$).mp. 
13. exp MINERAL/ 
14. (minerals or minerals$ or mineral or mineral$).mp. 
15. exp trace element/ 
16. (micro-nutrient or micro-nutrients).mp. 
17. exp MACRONUTRIENT/ 
18. (macro-nutrient or macro-nutrients or nutrient or nutrients).mp. 
19. (calcium or 7440-70-2).mp. 
20. (folate or folic acid or 59-30-3).mp. 
21. (iron or 7439-89-6 or ferric or ferrous).mp. 
22. protein/ 
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23. (protein or proteins).mp. 
24. exp low fat diet/ 
25. (fat reduced or dietary fat restriction or low fat or fat intake).mp. 
26. (low calorie or low energy or reduced energy or calorie controlled).mp. 
27. (fatty foods or high fat).mp. 
28. (fruit or fruits or vegetable or vegetables).mp. 
29. exp dietary intake/ or dietary composition.mp. 
30. exp OBESITY/ 
31. (obesity or obese).mp. 
32. adiposity.mp. 
33. body weight.mp. or exp body weight/ 
34. overweight.mp. 
35. exp body mass/ 
36. (body mass index or BMI or body mass).mp. 
37. body fat distribution.mp. or exp body fat distribution/ 
38. bioelectrical impedance analysis.mp. 
39. body composition.mp. or exp body composition/ 
40. exp health behavior/ 
41. (health behavior or health behaviors or health behaviour or health behaviours or health 
behaviour$ or health behaviour$).mp. 
42. health/ 
43. (health knowledge or health attitude$).mp. 
44. health promotion.mp. or exp health promotion/ 
45. exp behavior change/ 
46. (behaviour change or behavior change or behaviour change$ or behavior change$ or 
health behaviour change or health behavior change or health behaviour change$ or health 
behavior change$).mp. 
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47. exp lifestyle/ 
48. (life style or life style$ or lifestyle or lifestyle$).mp. 
49. (weight gain or weight gains or weight gain$).mp. 
50. exp weight gain/ 
51. exp weight reduction/ 
52. (weight loss or weight change or weight changes or weight change$).mp. 
53. exp OVERNUTRITION/ 
54. exp HYPERPHAGIA/ 
55. (overnutrition or overeating or hyperphagia).mp. 
56. Metabolic syndrome.mp. or metabolic syntrome X/ 
57. Waist hip ratio.mp. or exp waist hip ratio/ 
58. Waist height ratio.mp. 
59. exp skinfold thickness/ 
60. (Skinfold thickness or Skinfold thicknesses or Skinfold thickness$).mp. 
61. DEXA.mp. or exp dual energy X ray absorptiometry/ 
62. (Diabetes or type 2 diabetes).mp. or exp diabetes mellitus/ 
63. glucose metabolism.mp. or exp glucose metabolism/ 
64. insulin metabolism.mp. or exp insulin metabolism/ 
65. exp hyperinsulinemia/ or (hyperinsulinemia or hyperinsulinaemia).mp. 
66. exp CARDIOMYOPATHY/ or cardiomyopathy.mp. 
67. myocardial Infarction.mp. or exp heart infarction/ 
68. fat metabolism.mp. or exp lipid metabolism/ 
69. exp cardiovascular risk/ 
70. (cardiovascular risk factor or cardiovascular risk factors or cardiovascular risk 
factor$).mp. 
71. exp cardiovascular disease/ or (cardiovascular disease or cardiovascular diseases).mp. 
72. blood pressure.mp. or exp blood pressure/ 
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73. exp hypertension/ or hypertension.mp. 
74. exp lipid blood level/ 
75. (blood lipid or blood lipids or blood lipid$).mp. 
76. cholesterol metabolism.mp. or exp cholesterol metabolism/ 
77. exp hypercholesterolemia/ or hypercholesterolemia.mp. 
78. exp hyperlipidemia/ or (hyperlipidemia or hyperlipidaemia).mp. 
79. exp dyslipidemia/ or (dyslipidemia or dyslipidaemia).mp. 
80. osteoporosis/co, dt, rt, si, th [Complication, Drug Therapy, Radiotherapy, Side Effect, 
Therapy] 
81. Osteoporosis.mp. 
82. bone mineral density.mp. or exp bone density/ 
83. malnutrition.mp. or exp MALNUTRITION/ 
84. undernutrition.mp. 
85. exp nutritional deficiency/ 
86. (Nutritional Deficiency or Nutritional Deficiencies).mp. 
87. ideal body weight.mp. or exp body weight/ 
88. body image.mp. or exp body image/ 
89. exp eating disorder/ 
90. (eating disorder or eating disorders or eating disorder$ or disordered eating or fussy 
eating).mp. 
91. exp food refusal/ or food refusal.mp. 
92. exp "quality of life"/ or (quality of life or QoL).mp. 
93. or/1-92 
4. For Cancer the following Emtree terms and text words were used: 
1. (cancer or cancers or cancer$).mp. 
2. (oncology or oncolog$).mp. or exp oncology/ 
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3. (neoplasm or neoplasms or neoplasm$).mp. or exp neoplasm/ 
4. (carcinoma or carcinom$).mp. or exp carcinoma/ 
5. (tumor or tumour or tumor$ or tumour$ or tumors or tumours).mp. or exp tumor/ 
6. (malignan$ or malignant).mp. 
7. (hematooncological or hemato oncological or hemato-oncological or hematologic 
neoplasms or hematolo$).mp. or exp hematologic malignancy/ 
8. (leukemia or leukaemia).mp. or exp LEUKEMIA/ 
9. lymphoma.mp. or exp LYMPHOMA/ 
10. or/1-9 
5. For RCTs and CCTs the following Emtree terms and text words were used: 
1. Randomized Controlled Trial/ 
2. Controlled Clinical Trial/ 
3. randomized.ti,ab. 
4. placebo.ti,ab. 
5. randomly.ti,ab. 
6. trial.ti,ab. 
7. groups.ti,ab. 
8. drug therapy.sh. 
9. or/1-8 
10. Human/ 
11. 9 and 10 
Final search 1 AND 2 AND 3 AND 4 AND 5 
[mp = title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name; sh = subject heading; ti,ab = title or abstract; / = 
Emtree term; $= zero to many characters; co = complication; dt = drug therapy; rt = 
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radiotherapy; si = side effect; th = therapy; RCT = randomized controlled trial; CCT = 
controlled clinical trial] 
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APPENDIX G – ETHICS APPROVAL LETTER FOR CHAPTER 6 
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APPENDIX H – ETHICS APPROVAL LETTER FOR CHAPTER 8 
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APPENDIX I – FOOD LIKING QUESTIONNAIRE 
 
FOOD PREFERENCE QUESTIONNAIRE 
Please indicate how much you like each food by ticking in the appropriate box 
IF YOU HAVE NEVER TRIED A FOOD, TICK THE 1
ST
 BOX ONLY 
 
 
 
 
Never 
tried  it 
 
I hate 
it 
 
I don’t 
like it 
 
It’s 
OK 
 
I quite 
like it 
 
 
I love it 
 
Beef 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Beefburger, hamburger 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Lamb 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Pork 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Chicken 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Turkey 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Veal 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Ham 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Sausages / Frankfurts 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Liver 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Pate 
 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Liver sausage /Liverwurst 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Bacon 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Mortadella / Devon / Salami 
 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Fish: fried in batter or breadcrumbs 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
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Never 
tried  it 
 
I hate 
it 
 
I don’t 
like it 
 
It’s 
OK 
 
I quite 
like it 
 
 
I love 
it  
 
Fish: plain, white (Snapper, Bream, Flounder) 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
High fat fish (Mullet, Gemfish, Herring) 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Tuna / Salmon - tinned 
 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Baked beans 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Lentils, chickpeas etc 
 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Tofu 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Soya meat eg Nutolene,  
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
TVP (textured vegetable protein) 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Vegeburger, Vegesausage eg Sanitarium 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Nuts, eg peanuts,  nut dishes 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Eggs: boiled, poached 
 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Eggs: scrambled 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Eggs: fried 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Lasagne 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
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Never 
tried  it 
 
I hate 
it 
 
I  
don’t 
like it 
 
It’s 
OK 
 
I quite 
like it 
 
 
I love 
it  
 
Spaghetti Bolognaise 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Meat pies / Party Pies 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Pizza 
 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Quiche 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Sausage rolls 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Shepherd’s pie 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Bread, Bread Rolls  
 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Lavash / Lebanese bread / Pitta bread 
    
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Saos/ Water crackers 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Ryvita / Vita Weats/ Salada etc 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Savoury snacks eg Ritz / Jatz/ Shapes 
 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Cheese (processed)  
 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Cheese (hard), eg cheddar 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Cheese (soft), eg cottage cheese, Ricotta 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Cheese: (cream) eg Philadelphia 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
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Never 
tried  it 
 
I hate 
it 
 
I 
don’t 
like it 
 
It’s 
OK 
 
I 
quite 
like it 
 
 
I love 
it  
 
Cheese (soft): eg Brie, camembert 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Bran cereals: e.g. All Bran 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Muesli:  
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Porridge  
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Rice or corn cereal, eg Cornflakes, Rice 
Bubbles 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Sugared cereal, eg Frosties,  
Coco Pops, Froot Loops  
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Wheat cereal, eg Weetbix, Shredded Wheat 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Potatoes: boiled, mashed or jacket 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Potatoes: chips 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Potatoes: roast, fried 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Broccoli 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Cabbage, Bok Choy 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Carrots 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Cauliflower 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Egg Plant  
 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Pumpkin 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
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Never 
tried  it 
 
I hate 
it 
 
I don’t 
like it 
 
It’s 
OK 
 
I quite 
like it 
 
 
I love 
it  
 
Green beans 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Leeks 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Zucchini 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Mushrooms 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Onions 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Parsnips 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Peas 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Salad greens, eg lettuce 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Capsicum 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Tomatoes 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Brussel Sprouts 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Cucumber 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Olives 
 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Celery 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Spinach 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
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Yams 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
  
Never 
tried  it 
 
I hate 
it 
 
I don’t 
like it 
 
It’s 
OK 
 
I quite 
like it 
 
 
I love 
it  
 
Pumpkin 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Sweetcorn 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Avocado  
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Apricots 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Apples 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Bananas 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Oranges 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Mandarins 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Grapes 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Melon – Honeydew / Cantaloupe Watermelon 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Peaches, Nectarines 
 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Pears 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Plums 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Kiwi Fruit   
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Dried fruit eg Sultana, Prune, Apricot 
 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Cherrys 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
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Never 
tried  it 
 
I hate 
it 
 
I don’t 
like it 
 
It’s 
OK 
 
I quite 
like it 
 
 
I love 
it  
 
Strawberries 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Mango 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Pineapple 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Tinned fruit eg two fruits, fruit salad 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Soup: vegetable or meat-based  
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Milk (skimmed) 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Milk (semi-skimmed) 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Milk (full fat) 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Soft drinks eg  Coca Cola, Fanta, Lemonade 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Fruit juice:  
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Cordial 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Butter 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Margarine 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Cream 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Biscuits: plain, eg Morning Coffee, Milk 
Arrowroot  
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
292 
 
 
 
 
 
 
Never 
tried  it 
 
I hate 
it 
 
I don’t 
like it 
 
It’s 
OK 
 
I quite 
like it 
 
 
I love 
it  
Biscuits sweet eg cream biscuits, Monte Carlo,    
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Biscuits: chocolate 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Cakes 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Pavlova, Cheese cake 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Buns/pastries, eg scones, Danish pastries 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Fruit pie / tarts / crumbles 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Sponge pudding 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Ice cream 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Ice blocks  
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Custard 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Blancmange   
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Dairy desserts, eg mousse 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Yogurt, Fruche 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Doughnuts , Krispy Creams 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Packet chips / Twisties / Burger Rings 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Jam / Honey 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
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Never 
tried  it 
 
I hate 
it 
 
I don’t 
like it 
 
It’s 
OK 
 
I quite 
like it 
 
 
I love 
it  
 
Chocolate 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Lollies eg boiled  / jelly 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Lollies eg mints 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Lollies: toffee, fudge 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Sauces: BBQ, Tomato, Soy, HP, Teryaki etc 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Sauces: Salad Dressing, Mayonnaise 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Sauces: warm, savoury eg gravy 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Rice 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Pasta 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Peanut Butter 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Vegemite 
 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Dried peas, beans  or lentils 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Baked beans 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Tinned spaghetti 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
 
 
 
 
Thank you very much for helping us with our research. 
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